10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-35064

IMPERIAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Florida	30-0663473
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

701 Park of Commerce Boulevard — Suite 301

Boca Raton, Florida 33487

(Address of principal executive offices, including zip code)

(561) 995-4200

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ¨    No  x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of January 15, 2013, the Registrant had 21,206,121 shares of common stock outstanding.

IMPERIAL HOLDINGS, INC.

FORM 10-Q REPORT FOR THE QUARTER ENDED SEPTEMBER 30, 2012

TABLE OF CONTENTS

	Page No.
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)		4
Consolidated and Combined Balance Sheets as of September 30, 2012 and December 31, 2011		4
Consolidated and Combined Statements of Operations for the three months and nine months ended September 30, 2012 and 2011		5
Consolidated and Combined Statement of Comprehensive Income (Loss) for the three months and nine months ended September 30, 2012 and 2011		6
Consolidated and Combined Statement of Stockholders’ Equity for the nine months ended September  30, 2012		7
Consolidated and Combined Statements of Cash Flows for the nine months ended September  30, 2012 and 2011		8
Condensed Notes to Consolidated and Combined Financial Statements		9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		42
Item 3. Quantitative and Qualitative Disclosures About Market Risk		69
Item 4. Controls and Procedures		71
PART II — OTHER INFORMATION
Item 1. Legal Proceedings		73
Item 1A. Risk Factors		74
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		75
Item 3. Defaults Upon Senior Securities		75
Item 4. Mine Safety Disclosures		75
Item 5. Other Information		75
Item 6. Exhibits		75

2

“Forward-Looking” Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond the Company’s control. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Unless otherwise required by law, the Company disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this report.

Factors that could cause our actual results to differ materially from those indicated in our forward-looking statements include, but are not limited to, the following:

• our results of operations;

• continuing costs associated with the USAO investigation, SEC investigation, derivative actions, the class action lawsuits and similar matters;

• adverse developments, including financial ones, associated with the USAO investigation, SEC investigation, derivative actions or class action lawsuits or similar matters;

• our inability to obtain financing on favorable terms or at all;

• our ability to continue to make premium payments on the life insurance policies that we own;

• obligations that may be undertaken by the Company to settle derivative actions or class action lawsuits;

• loss of business due to negative press from the USAO investigation, SEC investigation, Non-Prosecution Agreement, class action lawsuits or otherwise;

• costs in excess of our directors’ & officers’ insurance coverage;

• refusal by our directors’ and officers’ insurance carriers to reimburse us for claims submitted;

• loss of revenue associated with the termination of our premium finance business;

• further adjustments to the discount rates used to value the life insurance policies that we own;

• inaccurate estimates regarding the likelihood and magnitude of early death benefits related to life insurance policies that we own;

• changes in mortality rates and inaccurate assumptions about life expectancies;

• changes to actuarial life expectancy tables;

• lack of mortalities of insureds of the life insurance policies that we own;

• increased carrier challenges to the validity of our life insurance policies;

• delays in the receipt of death benefits from our portfolio of life insurance policies;

• the effect on our financial condition of any lapse of life insurance policies;

• deterioration of the market for life insurance policies and life settlements;

• our inability to re-sell the life insurance policies we own at favorable prices, if at all;

• adverse developments associated with uncooperative co-trustees;

• loss of the services of any of our executive officers;

• adverse court decisions interpreting insurable interest or the obligation of a life insurance carrier to return premiums upon a successful rescission or contest;

• our inability to continue to grow our businesses;

• changes in laws and regulations applicable to premium finance transactions, life settlements or structured settlements;

• increased competition for the acquisition of structured settlements;

• adverse developments in capital markets;

• disruption of our information technology systems;

• our failure to maintain the security of personally identifiable information pertaining to our customers and counterparties;

• regulation of life settlement transactions as securities;

• our limited operating experience;

• refusal by our lender protection insurer to pay claims;

• deterioration in the credit worthiness of the life insurance companies that issue the policies serving as collateral for our premium finance loans;

• increases in premiums on life insurance policies that we own or finance;

• changes in current tax law regarding the treatment of structured settlements;

• our ability to grow our database of structured settlement holders;

• the effects of United States involvement in hostilities with other countries and large-scale acts of terrorism, or the threat of hostilities or terrorist acts; and

• changes in general economic conditions, including inflation, changes in interest or tax rates and other factors.

All written and oral forward-looking statements attributable to the Company, or persons acting on its behalf, are expressly qualified in their entirety by these cautionary statements. See “Risk Factors” below and in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the U.S. Securities and Exchange Commission on October 5, 2012. You should evaluate all forward-looking statements made in this Form 10-Q in the context of these risks and uncertainties. The Company cautions you that the important factors referenced above may not contain all of the factors that are important to you.

All statements in this Form 10-Q to “Imperial,” “Company,” “we,” “us,” or “our” refer to Imperial Holdings, Inc. and its consolidated subsidiaries unless the context suggests otherwise.

3

Item 1 Financial Statements.

Imperial Holdings, Inc. and Subsidiaries

CONSOLIDATED AND COMBINED BALANCE SHEETS

	September 30,			December 31,
	2012			2011
	(Unaudited)
	(In thousands except share data)
ASSETS
Assets
Cash and cash equivalents	$	16,455		$	16,255
Restricted cash		1,148			691
Certificate of deposit - restricted		—			891
Investment securities available for sale, at estimated fair value		24,173			57,242
Deferred costs, net		123			1,874
Prepaid expenses and other assets		14,634			3,277
Deposits - other		2,078			761
Interest receivable, net		1,356			5,758
Loans receivable, net		5,394			29,376
Structured settlement receivables at estimated fair value, net		2,496			12,376
Structured settlement receivables at cost, net		1,783			1,553
Investment in life settlements, at estimated fair value		102,328			90,917
Fixed assets, net		289			585
Other receivable		2,062			1,043
Total assets	$	174,319		$	222,599
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Accounts payable and accrued expenses	$	11,237		$	16,336
Other liabilities		24,993			4,279
Interest payable		358			5,505
Notes payable		1,222			19,277
Income taxes payable		6,295			6,295
Total liabilities		44,105			51,692
Commitments and contingencies (Note 16)
Stockholders’ Equity
Common stock (par value $0.01 per share 80,000,000 and 80,000,000 authorized; 21,206,121 and 21,202,614 issued and outstanding as of September 30, 2012 and December 31, 2011, respectively)		212			212
Additional paid-in-capital		237,960			237,755
Accumulated other comprehensive (loss)		7			(66	)
Accumulated deficit		(107,965	)		(66,994	)
Total stockholders’ equity		130,214			170,907
Total liabilities and stockholders’ equity	$	174,319		$	222,599

The accompanying notes are an integral part of these financial statements.

4

Imperial Holdings, Inc. and Subsidiaries

CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(in thousands, except per share data)
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		252			2,289			1,856			7,031
Interest and dividends on investment securities available for sale		72			247			332			441
Origination fee income		45			1,753			483			5,858
Realized gain on sale of structured settlements		2,187			2,240			7,796			5,457
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other income		123			155			989			481
Total income		(14,171	)		(1,763	)		11,978			52,308
Expenses
Interest expense		141			1,660			1,219			7,431
Provision for losses on loans receivable		—			3,583			441			3,712
(Gain) loss on loan payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlement write off		140			—			140			—
Amortization of deferred costs		254			1,409			1,751			4,913
Personnel costs		3,595			4,836			12,317			14,158
Marketing costs		1,034			1,754			4,481			4,185
Legal fees		9,328			1,821			22,918			4,187
Professional fees		1,559			1,452			5,272			4,238
Insurance		626			186			1,712			548
Other selling, general and administrative expenses		771			1,652			2,730			4,173
Total expenses		17,309			18,614			52,995			51,472
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Loss per share:
Basic	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Diluted	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Weighted average shares outstanding:
Basic		21,206,121			21,202,614			21,205,622			18,728,435
Diluted		21,206,121			21,202,614			21,205,622			18,728,435

The accompanying notes are an integral part of these financial statements.

5

Imperial Holdings, Inc. and Subsidiaries

CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
	(In thousands)						(In thousands)
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Other comprehensive loss, net of tax:
Unrealized gains (loss) on investment securities available for sale		9			(44	)		73			(44	)
Comprehensive loss	$	(31,466	)	$	(12,594	)	$	(40,898	)	$	(560	)

The accompanying notes are an integral part of these financial statements.

6

Imperial Holdings, Inc.

CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

For the Nine Months Ended September 30, 2012

					Additional		Retained Earnings			Accumulated Other
	Common Stock				Paid-in Capital		(Accumulated Deficit)			Comprehensive Income (Loss)			Total
	Shares		Amount
Balance, December 31, 2011		21,202,614	$	212	$	237,755	$	(66,994	)	$	(66	)	$	170,907
Comprehensive loss		—		—		—		(40,971	)		73			(40,898	)
Stock-based compensation		—		—		205		—			—			205
Restricted stock issued		3,507				—		—			—			—
Balance, September 30, 2012		21,206,121	$	212	$	237,960	$	(107,965	)	$	7		$	130,214

The accompanying notes are an integral part of these financial statements.

7

Imperial Holdings, Inc. and Subsidiaries

CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the Nine Months Ended
	September 30,
	2012			2011
	(In thousands)
Cash flows from operating activities
Net loss	$	(40,971	)	$	(516	)
Adjustments to reconcile net loss to net cash used in operating activites:
Depreciation and amortization		325			457
Amoritzation of premiums and accretion of discounts on available for sale securities		845			823
Provision for doubtful accounts		—			575
Provision for losses on loans receivable		441			3,712
Stock-based compensation		205			1,464
Loss on loan payoffs and settlements, net		14			3,927
Loss on write-off of life settlment		140			—
Origination fee income		(483	)		(5,858	)
Unrealized change in fair value of life settlements		8,401			(14,811	)
Unrealized change in fair value of structured settlements		(1,587	)		(2,145	)
Gain on forgiveness of debt		—			(4,880	)
Interest income on loans		(1,856	)		(7,031	)
Amortization of deferred costs		1,751			4,913
Accretion of discount on debenture payable		—			233
Gain on sale of life settlements		(291	)		(5	)
Gain on sale and prepayment of investment securities available for sale		(80	)		(51	)
Change in assets and liabilities:
Certificate of deposit—restricted		895			(125	)
Deposits—other		(1,317	)		(61	)
Restricted cash		(457	)		—
Agency fees receivable		—			165
Structured settlement receivables		11,481			(354	)
Prepaid expenses and other assets		(11,302	)		(2,205	)
Deferred costs		—			2,755
Other receivables		(1,022	)		—
Accounts payable and accrued expenses		(5,100	)		(599	)
Other liabilities		20,715			(6,299	)
Interest receiavble		221			(558	)
Income tax liability		—			1,352
Deferred income taxes		(46	)		—
Interest payable		(5,147	)		(4,183	)
Net cash used in operating activities		(24,225	)		(29,305	)
Cash flows from investing activities
Purchase of fixed assets, net of disposals		(21	)		(265	)
Purchase of investment securities available for sale		(35,492	)		(121,818	)
Proceeds from sale and prepayments of investment securities available for sale		67,915			44,700
Premiums paid on investments in life settlements		(20,106	)		(9,863	)
Deposits on purchases of life settlements (life insurance policies)		—			(965	)
Purchases of investments in life settlements		(130	)		(48,057	)
Proceeds from sale of investments in life settlements		5,626			—
Proceeds from loan payoffs		24,687			39,166
Originations of loans receivable		—			(18,711	)
Net cash provided by (used in) investing activities		42,479			(115,813	)
Cash flows from financing activities
Proceeds from initial public offering		—			174,233
Repayment of borrowings under credit facilities		(18,054	)		(27,378	)
Borrowings under credit facilities		—			234
Borrowings from affiliates		—			2,645
Net cash (used in) provided by financing activities		(18,054	)		149,734
Net increase in cash and cash equivalents		200			4,616
Cash and cash equivalents, at beginning of the period		16,255			14,224
Cash and cash equivalents, at end of the period	$	16,455		$	18,840
Supplemental disclosures of cash flow information:
Cash paid for interest during the period	$	6,353		$	11,314
Supplemental disclosures of non-cash financing activities:
Conversion of debt to common stock	$	—		$	35,158
Supplemental disclosures of non-cash investing activities:
Investment in life settlements acquired in foreclosure	$	5,050		$	2,098

The accompanying notes are an integral part of these financial statements.

8

Imperial Holdings, Inc. and Subsidiaries

CONDENSED NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2012

(1) Description of Business

Imperial Holdings, Inc. (“Imperial,” the “Company,” “we” or “us”) was formed pursuant to an operating agreement dated December 15, 2006 between IFS Holdings, Inc., IMEX Settlement Corporation, Premium Funding, Inc. and Red Oak Finance, LLC. The Company, operating through its subsidiaries, is a specialty finance company with its corporate office in Boca Raton, Florida. The Company operates in two reportable business segments: life finance (formerly referred to as premium finance) and structured settlements. In the life finance business, the Company earns revenue/income from interest charged on loans, loan origination fees, agency fees from referring agents, servicing income, changes in the fair value of life settlements the Company acquires and receipt of death benefits with respect to matured life insurance policies it owns. In the structured settlement business, the Company purchases structured settlements at a discounted rate and sells such assets to third parties.

In February 2011, the Company completed the sale of 17,602,614 shares of common stock in its initial public offering at a price of $10.75 per share. The Company received net proceeds of approximately $174.2 million after deducting the underwriting discounts and commissions and its offering expenses.

Imperial Holdings, Inc. succeeded to the business of Imperial Holdings, LLC and its assets and liabilities pursuant to the corporate conversion of Imperial Holdings, LLC effective February 3, 2011.

On September 27, 2011, a search warrant was executed at the Company’s headquarters and the Company was informed that it was being investigated by the U.S. Attorney’s Office for the District of New Hampshire (the “USAO Investigation”). At that time, the Company was also informed that its chief executive officer and then chairman, president and chief operating officer, former general counsel, two vice presidents, three life finance sales executives and a funding manager were also considered “targets” of the USAO Investigation. The USAO Investigation focused on the Company’s premium finance loan business. On September 28, 2011, the Company’s board of directors formed a special committee, comprised of all of the Company’s independent directors, to conduct an independent investigation in connection with the USAO Investigation. In December 2011, the U.S. Attorney’s Office for the District of New Hampshire (the “USAO”) confirmed that Mr. Antony Mitchell, our chief executive officer, was no longer a target of the USAO investigation.

On February 17, 2012, the Company received a subpoena issued by the staff of the U.S. Securities and Exchange Commission (the “SEC”) seeking documents from 2007 through the present, generally related to the Company’s premium finance business and corresponding financial reporting. The SEC is investigating whether any violations of federal securities laws have occurred and the Company has been cooperating with the SEC regarding this matter. The Company is unable to predict what action, if any, might be taken in the future by the SEC or its staff as a result of the matters that are the subject of the subpoena or what impact, if any, the cost of responding to the subpoena might have on the Company’s financial position, results of operations, or cash flows. The Company has not established any provision for losses in respect of this matter or in respect of the class action lawsuits and derivative actions related to the USAO Investigation. See Notes 16 and 18 for more information regarding these matters.

On April 30, 2012, the Company entered into a Non-Prosecution Agreement (the “Non-Prosecution Agreement”) with the USAO, which agreed not to prosecute the Company for its involvement in the making of misrepresentations on life insurance applications in connection with its premium finance business or any potential securities fraud claims related to its premium finance business. In the Non-Prosecution Agreement, the USAO and the Company agreed among other things, that the following facts are true and correct: (i) at all relevant times (x) certain insurance companies required that the prospective insured applying for a life insurance policy, and sometimes the agent, disclose information relating to premium financing on applications for life insurance policies, and (y) the questions typically required the prospective insured to disclose if he or she intended to seek premium financing in connection with the policy and sometimes required the agent to disclose if he or she was aware of any such intent on the part of the applicant; (ii) in connection with a portion of the Company’s retail operation known as “retail non-seminar” that began in December 2006 and was discontinued in January 2009, Imperial had a practice of disclosing on applications that the prospective insured was seeking premium financing when the life insurance company allowed premium financing from Imperial; however, in certain circumstances, Imperial internal life agents facilitated and/or made misrepresentations on applications that the prospective insured was not seeking premium financing when the insurance carrier was likely to deny the policy on the basis of premium financing; and (iii) to the extent that external agents, brokers and insureds caused other misrepresentations to be made in life insurance applications in connection with the retail non-seminar business, Imperial failed to appropriately tailor controls to prevent potential fraudulent practices in that business. As of September 30, 2012, the Company had 12 policies in its portfolio that once served as collateral for premium finance loans derived through the retail non-seminar business.

9

In connection with the Non-Prosecution Agreement, Imperial voluntarily agreed to terminate its premium finance business, which accounted for approximately 58.2% of its revenues in the year ended December 31, 2011, and terminated certain senior sales staff associated with the premium finance business. Additionally, the Company paid the United States Government $8.0 million, and agreed to cooperate fully with the USAO’s ongoing investigation and to refrain from and self-report any criminal conduct. The Non-Prosecution Agreement has a term of three years, but after two years the Company may petition the USAO to forego the final year of the Non-Prosecution Agreement, if we otherwise comply with all of our obligations under the Non-Prosecution Agreement. Should the USAO conclude that Imperial has not abided by its obligations under the Non-Prosecution Agreement, the USAO could choose to terminate the Non-Prosecution Agreement, resume its investigation of the Company, or bring charges against Imperial.

On August 2, 2012, the Board of Directors of the Company appointed Andrew Dakos, Phillip Goldstein and Gerald Hellerman to serve as directors of the Company in connection with a settlement (the “Settlement”) with Opportunity Partners L.P. (“Opportunity”). The Settlement resulted in Opportunity withdrawing its demand for a special meeting of shareholders, which it had submitted to the Company on May 23, 2012 and agreeing to dismiss its lawsuit to compel an annual meeting of shareholders. In connection with the Settlement, Walter Higgins and A. Penn Wyrough resigned from the Board of Directors. On August 14, 2012, Antony Mitchell, the Company’s chief executive officer, resigned as Chairman of the Board (though he continues to serve as a director and the Company’s chief executive officer) and Mr. Goldstein was elected Chairman.

Life Finance

Our life finance segment is comprised of our premium finance loan and life settlements businesses. The Company historically provided premium finance loans for individual life insurance policies and, commencing in 2011, began using its life settlement provider licenses to purchase life insurance policies. As described above, the Company voluntarily terminated its premium finance business in connection with the Non-Prosecution Agreement with the USAO. We had effectively suspended originating premium finance loans, however, as of the end of the third quarter of 2011.

Structured Settlements

Washington Square Financial, LLC, a wholly owned subsidiary of the Company, purchases structured settlements from individuals. Structured settlements refer to a contract between a plaintiff and defendant, whereby the plaintiff agrees to settle a lawsuit (usually a personal injury, product liability or medical malpractice claim) in exchange for periodic payments over time. A defendant’s payment obligation with respect to a structured settlement is usually assumed by a casualty insurance company. This payment obligation is then satisfied by the casualty insurer through the purchase of an annuity from a highly rated life insurance company, thereby providing a high credit quality stream of payments to the plaintiff.

Recipients of structured settlements are permitted to sell their deferred payment streams to a structured settlement purchaser pursuant to state statutes that require certain disclosures, notice to the obligors and state court approval. Through such sales, the Company purchases a certain number of fixed, scheduled future settlement payments on a discounted basis in exchange for a single lump sum payment.

(2) Principles of Consolidation and Basis of Presentation

The accompanying unaudited consolidated and combined financial statements include the accounts of the Company, all of its wholly-owned subsidiaries and its special purpose entities, with the exception of Imperial Settlements Financing 2010, LLC (“ISF 2010”), an unconsolidated special purpose entity (see Note 10). The special purpose entities have been created to fulfill specific objectives. Also included in the consolidated and combined financial statements is Imperial Life Financing, LLC which is owned by two stockholders of the Company and is combined with the Company for reporting purposes. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited consolidated and combined financial statements have been prepared in conformity with the rules and regulations of the SEC for Form 10-Q and therefore do not include certain information, accounting policies, and footnote disclosures information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with generally accepted accounting principles. However, all adjustments (consisting of normal recurring accruals), which, in the opinion of management, are necessary for a fair presentation of the financial statements, have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. These interim financial statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in Imperial’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

10

Gain on Maturities of Life Settlements with Subrogation Rights, net

Every credit facility entered into by subsidiaries of the Company between December 2007 and December 2010 to finance the premium finance lending business required lender protection insurance for each loan originated under such credit facility. Generally, when the Company exercises its right to foreclose on collateral the Company’s lender protection insurer has the right to direct control or take beneficial ownership of the life insurance policy, subject to the terms and conditions of the lender protection insurance policy, including notice and timing requirements. Otherwise, the lender protection insurer maintains its salvage collection and subrogation rights. The lender protection insurer’s salvage collection and subrogation rights generally provide a remedy by which the insurer can seek to recover an amount equal to but not greater than the amount of the lender protection claim paid plus premiums paid by it, expenses and interest thereon.

In those instances where the Company has foreclosed on the collateral, the lender protection insurer has maintained its salvage collection and subrogation rights, and has been covering the cost of the ongoing premiums needed to maintain these life insurance policies. However, the lender protection insurer may elect at any time to discontinue the payment of premiums which would result in lapse of the policies if the Company does not otherwise pay the premiums. The Company views these policies as having uncertain value because the lender protection insurer controls what happens to the policy from a payment of premium standpoint, and the amount of the lender protection insurer’s salvage collection and subrogation claim rights on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. For these reasons, these policies are considered contingent assets and not included in the amount of life settlements on the accompanying consolidated and combined balance sheet.

The Company accounts for the maturities of life settlements with subrogation rights, net of subrogation expenses as contingent gains in accordance with Accounting Standards Codification (ASC) 450, Contingencies and recognizes the revenue from the maturities of these policies when all contingencies are resolved.

Use of Estimates

The preparation of these consolidated and combined financial statements, in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and such differences could be material. Significant estimates made by management include the loan impairment valuation, allowance for doubtful accounts, income taxes, valuation of securities available for sale, valuation of structured settlements and the valuation of investments in life settlements.

Change in Accounting Estimate

The Company has elected to account for the life settlement policies it acquired using the fair value method. The fair value of life settlement policies is determined on a discounted cash flow basis, incorporating current life expectancy, expected premiums and discount rate assumptions (see Note 12). During the first quarter of 2011, the Company made revisions to the application of its valuation technique and assumptions used to measure fair value of the life settlement policies it acquired. The Company accounted for this change in accounting estimate prospectively in accordance with ASC 250-10-45-17, Change in Accounting Estimate, resulting in recognition of a pretax gain of $3.0 million recorded in unrealized change in fair value of life settlements in the accompanying consolidated and combined statement of operations for the nine months ended September 30, 2011.

The Company’s decision to revise its fair value calculations used to value all life insurance policies on hand at December 31, 2010 was driven by two factors. Firstly, with consideration to the wind-down of the lender protection insurance coverage (LPIC) program, which ended on December 31, 2010, the value of the collateral serving the Company’s new lending activity is no longer determined primarily by the limit of liability provided by the LPIC coverage. Instead, the value of the collateral was based solely on the Company’s valuation model. Secondly, as a result of the Company’s initial public offering in February, 2011 and the new capital structure provided by it, the Company planned to build and retain a large and diversified pool of life policies.

As discussed above, the Company uses a discounted cash flow model to calculate the fair value of its life insurance policy portfolio. That model is based on three principal factors: life expectancy, expected premiums and the discount rate. As discussed in Note 12, the Company began receiving updated life expectancy reports on the insureds represented in the Company’s portfolio of life insurance policies. As a result, the calculation of the life expectancy and discount rate inputs have changed. While the Company is endeavoring to obtain updated life expectancy reports for all of its policies, at September 30, 2012, the Company had only received updated life expectancies for 64 of the 212 policies in its portfolio. Since September 30, 2012, however, the Company received additional updated life expectancies on 79 more policies. All updated reports that were obtained have been blended and inputted in the Company’s fair value model at September 30, 2012, which drove a decline of $30.3 million in the fair market value of the Company’s portfolio of life insurance policies. This decline was partially offset by premium payments, accretion due to the passage of time, and other changes to the Company’s fair value model, which resulted in a net unrealized change in fair value of approximately $17.5 million during the quarter ended September 30, 2012. See Note 18 – Subsequent Event

(3) Recent Accounting Pronouncements

There are no recent accounting pronouncements issued by the Financial Accounting Standards Board (FAS) (including its Emerging Issues Task Force), and the SEC that are believed to have a material impact on the Company’s present or future financial statements.

11

(4) Earnings Per Share

As of February 3, 2011, the Company had 3,600,000 shares of common stock outstanding. The impact of the Company’s corporate conversion has been applied on a retrospective basis to January 1, 2011 to determine earnings per share for the nine months ended September 30, 2011.

As of September 30, 2011, there were 21,202,614 issued and outstanding shares.

Basic net income per share is computed by dividing the net earnings attributable to common shareholders by the weighted average number of common shares outstanding during the period.

Diluted earnings per share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding, increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Conversion or exercise of the potential common shares is not reflected in diluted earnings per share, unless the effect is dilutive. The dilutive effect, if any, of outstanding common share equivalents is reflected in diluted earnings per share by application of the treasury stock method, as applicable. In determining whether outstanding stock options, restricted stock, and common stock warrants should be considered for their dilutive effect, the average market price of the common stock for the period has to exceed the exercise price of the outstanding common share equivalent.

The following tables reconcile actual basic and diluted earnings per share for the three months and nine months ended September 30, 2012 and 2011 (in thousands except share and per share data).

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2012			2011			2012			2011
Basic (loss) earnings per share:
Numerator:
Net loss available to common stockholders	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Denominator:
Weighted average common shares outstanding		21,206,121			21,202,614			21,205,622			18,728,435
Basic loss per share	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Diluted earnings per share:
Numerator:
Net loss available to common stockholders	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Denominator:
Diluted weighted average shares outstanding		21,206,121			21,202,614			21,205,622			18,728,435
Diluted loss per share(1)(2)	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)

(1) The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the three months and nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

(2) The computation of diluted EPS did not include 488,499 options and 4,240,521 warrants for the three months and nine months ended September 30, 2012, as the effect of their inclusion would have been anti-dilutive.

Pro Forma Earnings Per Share

The pro forma earnings per share for the nine months ended September 30, 2011, gives effect to (i) the consummation of the corporate conversion, pursuant to which all outstanding common and preferred limited liability company units (including all accrued, but unpaid dividends thereon) and all principal and accrued interest outstanding under our promissory note in favor of IMPEX Enterprises, Ltd. were converted into 2,300,273 shares of our common stock; (ii) the issuance of 27,000 shares of common stock to two of our employees pursuant to the terms of each of their respective phantom stock agreements; and (iii) the issuance and conversion of a $30.0 million debenture into 1,272,727 shares of our common stock as if these events had been completed by January 2011.

12

Unaudited pro forma net income attributable to common stockholders per share is computed using the weighted-average number of common shares outstanding, including the pro forma effect of (i) to (iii) above, as if such conversion occurred at January 1, 2011. The pro forma net loss reflects a reduction of interest expense of $178,000, net of tax for the nine months ended September 30, 2011 due to the conversion of a promissory note in favor of IMPEX Enterprises, Ltd. into shares of our common stock, which occurred prior to the closing of our initial public offering, and the conversion of our promissory note in favor of Branch Office of Skarbonka Sp. z o.o into a $30.0 million debenture, and the conversion of that $30.0 million debenture into shares of our common stock, which occurred immediately prior to the closing of our public offering.

The following tables reconcile pro forma basic and diluted earnings per share for the nine months ended September 30, 2011 (in thousands except share and per share data).

	For the Nine Months
	Ended September 30,
	2011
Basic earnings (loss) per share:
Numerator:
Net loss available to common stockholders(1)(3)	$	(338	)
Denominator:
Weighted average common shares outstanding		18,728,435
Basic loss per share	$	(0.02	)
Diluted earnings per share:
Numerator:
Net loss available to common stockholders(1)(3)	$	(338	)
Denominator:
Diluted weighted average shares outstanding		18,728,435
Diluted loss per share(2)	$	(0.02	)

(1) Reflects a reduction of interest expense of $178,000, net of tax for the nine months ended September 30, 2011 due to the conversion of our promissory note in favor of IMPEX Enterprises, Ltd. into shares of our common stock, which occurred prior to the closing of our initial public offering, and the conversion of our promissory note in favor of Branch Office of Skarbonka Sp. z o.o into a $30.0 million debenture, and the conversion of that $30.0 million debenture into shares of our common stock, which occurred immediately prior to the closing of our initial public offering.

(2) The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

(3) For the pro forma period for the nine months ended September 30, 2011, the results of the Company being treated for the pro forma presentation as a “C” corporation resulted in no impact to the consolidated and combined balance sheet or statement of operations. The primary reasons for this are that the losses produce no current benefit and any net operating losses generated and other deferred assets (net of liabilities) at that time would have been fully reserved due to historical operating losses. The Company, therefore, has not recorded any pro forma tax provision.

(5) Gain on Maturities of Life Settlements with Subrogation Rights, net

In the third quarter of 2011, two individuals covered under policies, which were subject to subrogation claims unexpectedly passed away. The Company collected the death benefit on one of these policies in the amount of $3.5 million during the third quarter of 2011. The other was the result of an accidental death and the $10.0 million face value of the policy was larger than average.

The Company accounted for the maturities of each of these polices as contingent gains in accordance with ASC 450, Contingencies and recognized $3.2 million in death benefits net of subrogation expenses of $312,000 in its consolidated and combined statement of operations for the nine months ended September 30, 2011. In the second quarter of 2012, the Company negotiated a settlement in respect of the larger policy and collected approximately $6.1 million, net of subrogation expenses of $910,000, and has reported a gain in accordance with ASC 450, Contingencies in its consolidated and combined statement of operations for the nine months ended September 30, 2012 as all contingencies were resolved.

13

The Company believes these contingent gains to be unpredictable because the lender protection insurer can discontinue paying the premiums necessary to keep a policy subject to subrogation and salvage claims in force at any time and the amount of the lender protection insurer’s subrogation and salvage claim on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. No expectations for similar gains in the future should be inferred from the events occurring in the third quarter of 2011 and second quarter of 2012.

(6) Investment Securities Available for Sale

The amortized cost and estimated fair values of securities available for sale at September 30, 2012 are as follows (in thousands):

	September 30, 2012
	Amortized		Gross Unrealized		Gross Unrealized			Estimated
Description of Securities	Cost		Gains		Losses			Fair Value
Corporate bonds	$	19,118		39	$	(89	)	$	19,068
Government bonds		4,690		100		—			4,790
Other bonds		312		3		—			315
Total available for sale securities	$	24,120	$	142	$	(89	)	$	24,173

The amortized cost and estimated fair values of securities available for sale at December 31, 2011 are as follows (in thousands):

	December 31, 2011
Description of Securities	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate bonds	$	41,697	$	32	$	(127	)	$	41,602
Government bonds		14,789		39		(9	)		14,819
Other bonds		821		—		—			821
Total available for sale securities	$	57,307	$	71	$	(136	)	$	57,242

The scheduled maturities of securities (in thousands) at September 30 2012, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	September 30, 2012
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	14,628	$	14,655
Due after one year but less than five years		4,802		4,728
Due after five years but less than ten years		4,690		4,790
Total available for sale securities	$	24,120	$	24,173

The scheduled maturities of securities (in thousands) at December 31, 2011, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	December 31, 2011
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	25,904	$	25,892
Due after one year but less than five years		20,243		20,160
Due after five years but less than ten years		11,160		11,190
Total available for sale securities	$	57,307	$	57,242

14

Information pertaining to securities with gross unrealized losses (in thousands) at September 30, 2012, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position is as follows:

	September 30, 2012
	Less than 12 Months		12 Months or More							Total
	Estimated		Unrealized			Estimated		Unrealized		Estimated		Unrealized
Description of Securities	Fair Value		Loss			Fair Value		Loss		Fair Value		Loss
Corporate bonds		7,041		(89	)		—		—		7,041		(89	)
Total available for sale securities	$	7,041	$	(89	)	$	—	$	—	$	7,041	$	(89	)

Information pertaining to securities with gross unrealized losses (in thousands) at December 31, 2011, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position is as follows:

	December 31, 2011
	Less than 12 Months		12 Months or More							Total
Description of Securities	Estimated Fair Value		Unrealized Loss			Estimated Fair Value		Unrealized Loss		Estimated Fair Value		Unrealized Loss
Corporate bonds	$	26,051	$	(127	)	$	—	$	—	$	26,051	$	(127	)
Government bonds		5,927		(9	)		—		—		5,927		(9	)
Total available for sale securities	$	31,978	$	(136	)	$	—	$	—	$	31,978	$	(136	)

Proceeds from sale and prepayment of investment securities available for sale during the nine months ended September 30, 2012 amounted to approximately $67.9 million, resulting in gross realized gains of approximately $80,000.

The Company monitors its investment securities available for sale for other-than-temporary impairment, or OTTI, on an individual security basis considering numerous factors, including the Company’s intent to sell securities in an unrealized loss position, the likelihood that the Company will be required to sell these securities before an anticipated recovery in value, the length of time and extent to which fair value has been less than amortized cost, the historical and implied volatility of the fair value of the security, failure of the issuer of the security to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency and recoveries or additional declines in fair value subsequent to the balance sheet date. The relative significance of each of these factors varies depending on the circumstances related to each security.

None of the securities in unrealized loss positions at September 30, 2012 were determined to be other-than-temporarily impaired. The Company does not intend to sell securities that are in unrealized loss positions and it is not more likely than not that the Company will be required to sell these securities before recovery of the amortized cost basis, which may be at maturity. At September 30, 2012, 6 securities were in unrealized loss positions. The amount of unrealized losses related to all of these securities was considered insignificant, totaling approximately $89,000. None of these securities were in a continuous unrealized loss position for 12 months or longer. No further analysis with respect to these securities was considered necessary.

(7) Loans Receivable

A summary of loans receivables at September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,			December 31,
	2012			2011
Loan principal balance	$	7,673		$	31,264
Loan origination fees, net		1,751			8,307
Loan impairment valuation		(4,030	)		(10,195	)
Loans receivable, net	$	5,394		$	29,376

The Company also had interest receivable, net which consisted of approximately $1.1 million and $5.3 million in accrued and unpaid interest at September 30, 2012 and December 31, 2011, respectively and a related impairment valuation of approximately $1.1 million and $1.9 million, respectively.

15

An analysis of the changes in loans receivable principal balance during the three months and nine months ended September 30, 2012 and 2011 is as follows (in thousands):

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2012			2011			2012			2011
Loan principal balance, beginning	$	12,935		$	51,092		$	31,264		$	76,939
Loan originations		—			2,549			—			18,385
Subsequent year premiums paid, net of reimbursement		—			34			—			326
Loan write-offs		—			(662	)		—			(2,950	)
Loan payoffs		(2,712	)		(8,809	)		(16,037	)		(47,867	)
Loans transferred to investments in life settlements		(2,550	)		(1,012	)		(7,554	)		(1,641	)
Loan principal balance, ending	$	7,673		$	43,192		$	7,673		$	43,192

Loan origination fees include origination fees, which are payable to the Company on the date the loan matures. The loan origination fees are reduced by any direct costs that are directly related to the creation of the loan receivable in accordance with ASC 310-20, Receivables — Nonrefundable Fees and Other Costs, and the net balance is accreted over the life of the loan using the effective interest method. Discounts include purchase discounts, net of accretion, which are attributable to loans that were acquired from affiliated companies under common ownership and control.

In accordance with ASC 310, Receivables, the Company specifically evaluates all loans for impairment based on the fair value of the underlying policies as foreclosure is considered probable. The loans are considered to be collateral dependent as the repayment of the loans is expected to be provided by the underlying policies.

16

An analysis of the loan impairment valuation for the three months ended September 30, 2012 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period	$	5,517		$	1,309		$	6,826
Charge-offs		(1,487	)		(252	)		(1,739	)
Balance at end of period	$	4,030		$	1,057		$	5,087

An analysis of the loan impairment valuation for the three months ended September 30, 2011 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period	$	5,201		$	1,189		$	6,390
Provision for loan losses		3,264			319			3,583
Charge-offs		(963	)		(118	)		(1,081	)
Balance at end of period	$	7,502		$	1,390		$	8,892

An analysis of the loan impairment valuation for the nine months ended September 30, 2012 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period		10,195			1,920			12,115
Provision for loan losses		360			81			441
Charge-offs		(6,525	)		(944	)		(7,469	)
Balance at end of period	$	4,030		$	1,057		$	5,087

An analysis of the loan impairment valuation for the nine months ended September 30, 2011 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period		7,176			1,340			8,516
Provision for loan losses		3,337			375			3,712
Charge-offs		(3,011	)		(325	)		(3,336	)
Balance at end of period	$	7,502		$	1,390		$	8,892

17

An analysis of the allowance for loan losses and recorded investment in loans by loan type for the nine months ended September 30, 2012 is as follows (in thousands):

	Uninsured			Insured
	Loans			Loans			Total
Loan impairment valuation
Balance at beginning of period		7,103			3,092			10,195
Provision for losses	$	—		$	360		$	360
Charge-offs		(3,687	)		(2,838	)		(6,525	)
Ending balance	$	3,416		$	614		$	4,030
Ending balance: individually evaluated for impairment	$	3,416		$	614		$	4,030

All loans were individually evaluated for impairment as of September 30, 2012. There were no loans collectively evaluated for impairment and there were no loans acquired with deteriorated credit quality.

An analysis of the allowance for loan losses and recorded investment in loans by loan type for the nine months ended September 30, 2011 is as follows (in thousands):

	Uninsured			Insured
	Loans			Loans			Total
Loan impairment valuation
Balance at beginning of period	$	869		$	6,307		$	7,176
Provision for loan losses		3,318			19			3,337
Charge-offs		(407	)		(2,604	)		(3,011	)
Ending balance	$	3,780		$	3,722		$	7,502
Ending balance: individually evaluated for impairment	$	3,780		$	3,722		$	7,502

All loans were individually evaluated for impairment as of September 30, 2011. There were no loans collectively evaluated for impairment and there were no loans acquired with deteriorated credit quality. Notwithstanding the foregoing, the provision for losses on loans receivable for uninsured loans has increased for the nine months ended September 30, 2011 as a result of the decline in the estimated fair value of the collateral due to the higher discount rate applied in the fair value model. See Note 12.

An analysis of the credit ratings of life insurance carriers that issued life insurance policies that serve as our loan collateral by loan type at September 30, 2012 is presented in the following table (dollars in thousands):

18

	Uninsured					Insured(1)
S&P Designation	Unpaid Principal Balance		Percent			Unpaid Principal Balance		Percent
AAA	$	—		0.00	%	$	—		0.00	%
AA+		694		11.39	%		—		0.00	%
AA		—		0.00	%		—		0.00	%
AA-		3,550		58.25	%		696		44.10	%
A+		1,242		20.38	%		93		5.87	%
A1		—		0.00	%		—		0.00	%
A		543		8.91	%		101		6.40	%
A-		65		1.07	%		689		43.63	%
Total	$	6,094		100	%	$	1,579		100	%

(1) All of the Company’s insured loans have lender protection coverage with Lexington Insurance Company. As of September 30, 2012, Lexington had a financial strength rating of “A” with a stable outlook by Standard & Poor’s.

An analysis of the credit ratings of life insurance carriers that issued life insurance policies that serve as our loan collateral by loan type at December 31, 2011 is presented in the following table (dollars in thousands):

	Uninsured					Insured(1)
S&P Designation	Unpaid Principal Balance		Percent			Unpaid Principal Balance		Percent
AAA	$	—		0.00	%	$	—		0.00	%
AA+		694		5.08	%		222		1.26	%
AA		—		0.00	%		—		0.00	%
AA-		6,558		48.05	%		9,085		51.57	%
A+		3,060		22.42	%		1,287		7.31	%
A1		—		0.00	%		—		0.00	%
A		3,336		24.44	%		7,022		39.86	%
A-		—		0.00	%		—		0.00	%
Total	$	13,648		100	%	$	17,616		100	%

(1) All of the Company’s insured loans have lender protection coverage with Lexington Insurance Company. As of December 31, 2011, Lexington had a financial strength rating of “A” by Standard & Poor’s.

19

A summary of our investment in impaired loans at September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,		December 31,
	2012		2011
Loan receivable, net	$	5,063	$	17,424
Interest receivable, net		1,068		6,799
Investment in impaired loans	$	6,131	$	24,223

An analysis of impaired loans with and without a related allowance at September 30, 2012 is presented in the following table by loan type (in thousands):

			Unpaid				Average		Interest
	Recorded		Principal		Related		Recorded		Income
	Investment		Balance		Allowance		Investment		Recognized
With no related allowance recorded:
Uninsured Loans	$	—	$	—	$	—	$	—	$	—
Insured Loans		—		—		—		—		—
With an allowance recorded:
Uninsured Loans		4,722		6,074		3,991		7,437		1,612
Insured Loans		1,409		1,374		1,097		7,740		513
Total Impaired Loans	$	6,131	$	7,448	$	5,088	$	15,177	$	2,125

An analysis of impaired loans with and without a related allowance at December 31, 2011 is presented in the following table by loan type (in thousands):

			Unpaid				Average		Interest
	Recorded		Principal		Related		Recorded		Income
	Investment		Balance		Allowance		Investment		Recognized
With no related allowance recorded:
Uninsured Loans	$	—	$	—	$	—	$	—	$	—
Insured Loans		—		—		—		—		—
With an allowance recorded:
Uninsured Loans		10,153		13,628		6,894		6,764		1,684
Insured Loans		14,070		10,391		3,301		24,847		3,195
Total Impaired Loans	$	24,223	$	24,019	$	10,195	$	31,611	$	4,879

The amount of the investment in impaired loans that had an allowance as of September 30, 2012 and December 31, 2011 was $6.1 million and $24.2 million, respectively. The amount of the investment in impaired loans that did not have an allowance was $0 as of September 30, 2012 and December 31, 2011. The average aggregate investment in impaired loans during the periods ended September 30, 2012 and 2011 was approximately $15.2 million and $34.1 million, respectively. The interest recognized on the impaired loans was approximately $166,000 and $1.1 million for the nine months ended September 30, 2012 and 2011, respectively.

An analysis of the unpaid principal balance of past due loans at September 30, 2012 is presented in the following table by loan type (in thousands):

					Greater Than
	30-59 Days		60-89 Days		90 Days		Total
	Past Due		Past Due		Past Due		Past Due
Uninsured Loans	$	—	$	—	$	599	$	599
Insured Loans		—		43		272		315
Total	$	—	$	43	$	871	$	914

20

An analysis of the unpaid principal balance of past due loans at December 31, 2011 is presented in the following table by loan type (in thousands):

	30-59 Days Past Due		60-89 Days Past Due		Greater Than 90 Days Past Due		Total Past Due
Uninsured Loans	$	—	$	—	$	599	$	599
Insured Loans		1,570		—		—		1,570
Total	$	1,570	$	—	$	599	$	2,169

During the nine months ended September 30, 2012 and the year-ended December 31, 2011, the Company originated 0 and 58 loans receivable with a principal balance of approximately $0 and $18.3 million, respectively. Loan interest receivable at September 30, 2012 and December 31, 2011 was approximately $1.1 million and $5.3 million net of impairment of approximately $1.1 million, and $1.9 million, respectively. As of September 30, 2012, there were 31 loans with the average loan balance of approximately $233,000.

The allowance for interest receivable represents interest that is not expected to be collected. At the time the interest income was recognized and at the end of the reporting period in which the interest income was recognized, the interest income was believed to be collectible. The Company continually reassesses whether interest income is collectible in conjunction with its loan impairment analysis. The allowance for interest receivable represents interest that was determined to be uncollectible during a reporting period subsequent to the initial recognition of the interest income. As of September 30, 2012, the loan portfolio consisted of loans with original maturities of 2 to 4 years and variable interest rates at an average interest rate of 12.9%. During the nine months ended September 30, 2012 and 2011, 79 and 131 of our loans were paid off with proceeds of lender protection insurance totaling approximately $24.0 million and $26.3 million, respectively, of which approximately $15.6 million, and $16.8 million was for the principal of the loans and approximately $6.0 million and $4.3 million was for accrued interest, respectively, and accreted origination fees of approximately $6.6 million and $6.7 million, respectively. The Company had an impairment associated with these loans of approximately $4.6 million and $2.3 million, respectively. We recognized a loss of approximately $14,000 and a gain of approximately $736,000 on these transactions, respectively.

During the nine months ended September 30, 2012 and 2011, the Company wrote off 0 and 8 loans, respectively related to the Acorn facility. The principal amount written off was approximately $0 and $2.4 million with accrued interest of approximately $0 and $545,000, and origination receivable of approximately $0 and $381,000, respectively. The Company had an impairment associated with these loans of approximately $0 and $72,000, and incurred a loss on these loans of approximately $0 and $3.3 million, respectively.

(8) Origination Fees

A summary of the balance of origination fees that is included in loans receivable in the consolidated and combined balance sheet as of September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,			December 31,
	2012			2011
Loan origination fees gross	$	2,127		$	10,844
Un-accreted origination fees		(399	)		(2,666	)
Amortized loan origination costs		23			129
	$	1,751		$	8,307

Loan origination fees are fees payable to the Company on the date of loan maturity or repayment. Loan origination costs are deferred costs that are directly related to the creation of the loan receivable.

(9) Stock-Based Compensation

In connection with the Company’s initial public offering, the Company established the Imperial Holdings 2010 Omnibus Incentive Plan (the “Omnibus Plan”). The purpose of the Omnibus Plan is to attract, retain and motivate participating employees and to attract and retain well-qualified individuals to serve as members of the board of directors, consultants and advisors through the use of incentives based upon the value of our common stock. Awards under the Omnibus Plan may consist of incentive awards, stock options, stock appreciation rights, performance shares, performance units, and shares of common stock, restricted stock, restricted stock units or other stock-based awards as determined by the compensation committee. The Omnibus Plan provides that an aggregate of 1,200,000 shares of common stock are reserved for issuance under the Omnibus Plan, subject to adjustment as provided in the Omnibus Plan. The Company recognized approximately $105,000 and $423,000 in stock-based compensation expense relating to stock options it granted under the Omnibus Plan during the three months ended September 30, 2012 and 2011, respectively and $201,000 and $1.2 million during the nine months ended September 30, 2012 and 2011, respectively. The Company incurred additional stock-based compensation expense of approximately $290,000 related to the conversion of two phantom stock agreements it had with two employees into 27,000 shares of common stock in connection with its corporate conversion in the first quarter of 2011

21

and approximately $0 and $9,500 in stock-based compensation relating to restricted stock granted to its board of directors during the three months ended September 30, 2012 and 2011, respectively and $4,000 and $24,000 during the nine months ended September 30, 2012 and 2011, respectively. Prior to our initial public offering, the Company had no equity compensation plan.

Options

As of September 30, 2012, options to purchase 488,499 shares of common stock were outstanding and unexercised under the Omnibus Plan at a weighted average exercise price of $10.75 per share. All of the outstanding options expire seven years after the date of grant and were granted with a strike price at $10.75 which was the offering price of our initial public offering or fair market value (closing price) of the stock on the date of grant and vest over three years.

The Company has used the Black-Scholes model to calculate fair values of options awarded. This model requires assumptions as to expected volatility, dividends, terms, and risk free rates. Assumptions used for the periods covered herein, are outlined in the table below:

	Nine Months Ended September 30, 2011
Expected Volatility	54.18% — 54.23%
Expected Dividend	0%
Expected Term in Years	4.5
Risk Free Rate	2.16% — 2.29%

There were no options granted in the nine months ended September 30, 2012.

The Company commenced its initial public offering of common stock in February 2011. Accordingly, there was no public market for the Company’s common stock prior to this date. Therefore, the Company identified comparable public entities and used the average volatility of those entities to reasonably estimate its expected volatility. The Company does not expect to pay dividends on its common stock for the foreseeable future. Expected term is the period of time over which the options granted are expected to remain outstanding and is based on the simplified method as outlined in the SEC Staff Accounting Bulletin 110. The Company will continue to estimate expected lives based on the simplified method until reliable historical data becomes available. The risk free rate is based on the U.S Treasury yield curve in effect at the time of grant for the appropriate life of each of each option.

The following table presents the activity of the Company’s outstanding stock options of common stock for the nine-month period ended September 30, 2012:

Common Stock Options	Number of Shares			Weighted Average Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Options outstanding, December 31, 2011		627,419		$	10.75		6.11	$	—
Options granted		—			—		—		—
Options exercised		—			—		—		—
Options forfeited		(138,920	)		10.75		—		—
Options expired		—					—		—
Options outstanding, September 30, 2012		488,499		$	10.75			$	—
Exercisable at September 30, 2012		287,988			10.74		5.36	$	—
Unvested at September 30, 2012		200,511		$	10.75		5.36	$	—

22

As of September 30, 2012, all outstanding stock options had an exercise price above the fair market value of the common stock on that date.

The remaining unamortized amounts of approximately $105,000, $336,000 and $21,000 will be expensed during 2012, 2013 and 2014, respectively.

Restricted Stock

3,507 shares of restricted stock granted to our directors under the Omnibus Plan subject to a one year vesting schedule commencing on the date of grant vested during the nine months ended September 30, 2012. The fair value of the vested restricted stock was valued at $38,016 based on the closing price of the Company’s shares on the grant date.

The following table presents the activity of the Company’s unvested restricted common shares for the nine-month period ended September 30, 2012:

Common Unvested Shares	Number of Shares
Outstanding December 31, 2011		3,507
Granted		—
Vested		(3,507	)
Forfeited		—
Outstanding September 30, 2012		—

There were no restricted stock awards granted during the nine months ended September 30, 2012.

(10) Structured Settlements

The balances of the Company’s structured settlements are as follows (in thousands):

	September 30,		December 31,
	2012		2011
Structured settlements — at cost	$	1,783	$	1,553
Structured settlements—at fair value		2,496		12,376
Structured settlements receivable, net	$	4,279	$	13,929

All structured settlements that were acquired subsequent to July 1, 2010 were marked to fair value. Structured settlements that were acquired prior to July 1, 2010 were recorded at cost. During 2011, the Company reacquired certain structured settlements that were originally acquired prior to July 1, 2010 and the Company continued to carry those structured settlements at cost upon reacquisition.

Certain financing arrangements for the Company’s structured settlements are described below:

Life-Contingent Structured Settlement Facility

On December 30, 2011, Washington Square Financial, LLC (“WSF”) entered into a forward purchase and sale agreement (“PSA”) to sell up to $40.0 million of life contingent structured settlement receivables to Compass Settlements LLC (“Compass”). Subject to predetermined eligibility criteria and on-going funding conditions, Compass committed, in increments of $5.0 million, up to $40.0 million to purchase life-contingent structured settlement receivables from WSF. The PSA obligates WSF to sell the life-contingent structured settlement receivables it originates to Compass on an exclusive basis for twenty-four months, subject to Compass maintaining certain purchase commitment levels. Additionally, the Company has agreed to guaranty WSF’s obligation to repurchase any ineligible receivables sold under the PSA and certain other related obligations.

For the nine months ended September 30, 2012, the Company recognized income from the sale of 311 structured settlement transactions under this facility generating income of approximately $1.8 million recorded as gain on sale of structured settlements in the attached financial statements. Of the 311 structured transactions, 107 were previously recorded at the market rate generating income of approximately $1.1 million and the change in value was recorded as an unrealized change in fair value on the financial statements presented for the year ended December 31, 2011 and 55 were previously recorded at the market rate generating income of approximately $565,000 with the change in value recorded as an unrealized change in fair value on the financial statements presented for the two quarters ended June 30, 2012.

The Company also realized income of approximately $147,000 that was recorded as an unrealized change in fair value during the three months ended September 30, 2012 on structured settlements that are intended for sale to Compass.

23

8.39% Fixed Rate Asset Backed Variable Funding Notes

Imperial Settlements Financing 2010, LLC (“ISF 2010”) was formed as an affiliate of the Company to serve as a special purpose financing entity to allow the Company to sell structured settlements and assignable annuities, which are referred to as receivables, to ISF 2010 and ISF 2010 to borrow against certain of its receivables to provide ISF 2010 liquidity. ISF 2010 is a non-consolidated special purpose financing entity. On September 24, 2010, ISF 2010 entered into an arrangement to obtain up to $50 million in financing. Under this arrangement, a subsidiary of Partner Re, Ltd. (the “noteholder”) became the initial holder of ISF 2010’s 8.39% Fixed Rate Asset Backed Variable Funding Note issued under a master trust indenture and related indenture supplement (collectively, the “Indenture”) pursuant to which the noteholder committed to advance ISF 2010 up to $50 million upon the terms and conditions set forth in the Indenture. The note is secured by the receivables that ISF 2010 acquires from the Company from time to time. The note is due and payable on or before January 1, 2057, but principal and interest must be repaid pursuant to a schedule of fixed payments from the receivables that secure the notes. The arrangement generally has a concentration limit of 15% for the providers of the receivables that secure the notes. Wilmington Trust is the collateral trustee. As of September 30, 2012 and December 31, 2011, the balance of the notes outstanding on the special purpose financing entity’s books was $40.4 million and $20.6 million, respectively.

Upon the occurrence of certain events of default under the Indenture, all amounts due under the note are automatically accelerated. The Company’s maximum exposure related to ISF 2010 is limited to 5% of the dollar value of the ISF 2010 transactions, which is held back by ISF 2010 at the time of sale, and is designed to absorb potential losses in collecting the receivables. The obligations of ISF 2010 are non-recourse to the Company. The total funds held back by ISF 2010 as of September 30, 2012 and December 31, 2011 were approximately $2.1 million and $1.0 million and are included in other receivable in the accompanying consolidated balance sheet.

During the nine months ended September 30, 2012 and 2011, the Company sold 500 and 485 non-life contingent, or term certain structured settlements, respectively, 181 and 12 of which were originated in 2011 and 2010, respectively. These sales generated income of approximately of $3.2 million and $129,000, respectively, which was recorded as an unrealized change in fair value of structured settlements in 2011 and 2010, respectively. The Company originated and sold 319 and 307 term certain structured settlement transactions under this facility generating income of approximately $4.2 million and $3.8 million, respectively, which was recorded as a realized gain on sale of structured settlements during the nine months ended September 30, 2012 and 2011, respectively. During the nine months ended September 30, 2011, the Company also had three SPV’s that pledged 38 term certain structured settlement transactions under this facility generating income of approximately $32,000, which was recorded as an unrealized change in the fair value of structured settlements. The Company also realized income of approximately $548,000 and $582,000 that was recorded as an unrealized change in fair value during the nine months ended September 30, 2012 and 2011, respectively, on structured settlements that are intended for sale to ISF 2010. The Company receives 95% of the purchase price in cash from ISF 2010. Of the remaining 5%, which represents the Company’s interest in ISF 2010, 1% is required to be contributed to a cash reserve account held by Wilmington Trust. In addition, the Company also purchased and sold 131 guaranteed structure transactions generating income of $64,000, which was recorded as a realized gain on sale of structured settlements.

When the transfer of the receivables occurs, the Company records the transaction as a sale and removes the asset from its balance sheet. In determining whether the Company is the primary beneficiary of the trust, the Company concluded that it does not control the servicing, which is the activity that most significantly impacts the trust performance. An independent third party is the master servicer and they can only be replaced by the control partner, which is the entity that holds the majority of the outstanding notes. The Company is a back-up servicer, which is not significant to the performance of ISF 2010.

Washington Square Financial 3rd Party Sales

For the nine months ended September 30, 2012, in addition to its intended sales to Compass and ISF 2010, the Company also sold 169 deals to unrelated parties for $2.5 million generating income of $1.8 million recorded as a gain on sale of structured settlements and $134,000 that was previously recorded as an unrealized change in fair value.

During the nine months ended September 30, 2012 and 2011, respectively, the Company recorded income of approximately $188,000 and $107,000, respectively, that was recorded as unrealized change in fair value on structured settlements that are intended for sale to other parties

Total income recognized through accretion of interest income on structured settlement transactions for the nine months ended September 30, 2012 and 2011, respectively, was approximately $243,000 and $318,000, respectively, recognized in interest income in the accompanying consolidated and combined statement of operations. The receivables at September 30, 2012 and December 31, 2011 were approximately $4.3 million and $13.9 million, respectively, net of a discount of approximately $11.1 million and $27.8 million, respectively.

The Company recognized a gain on the sale of approximately $223,000 through the collection of holdback funds during the nine months ended September 30, 2011. The holdback is equal to the aggregate amount of payments due and payable by the annuity holder within 90 days after the date of sale. These amounts are held back in accordance with the purchase agreement and were released upon proof of collections by the Company acting as servicer.

24

(11) Investment in Life Settlements (Life Insurance Policies)

During the nine months ended September 30, 2012 and throughout the year ended December 31, 2011, the Company acquired life insurance policies as a result of certain of the Company’s borrowers defaulting on premium finance loans and relinquishing the underlying policy to the Company in exchange for being released from further obligations under the loan. In 2011, the Company also began acquiring life insurance policies in the secondary and tertiary markets. The Company elected to account for these policies using the fair value method in accordance with ASC 325-30-50 Investments – Other – Investment in Insurance Contracts. Under the fair value method, the Company recognizes the initial investment at the purchase price. For policies that were relinquished in satisfaction of premium finance loans at maturity, this is the loan carrying value and for policies purchased in the secondary or tertiary markets, this is the amount of cash outlay at the time of purchase. At each reporting period, the Company re-measures the investment at fair value in its entirety and recognizes changes in fair value in earnings in the period in which the changes occur. See Note 12.

As of September 30, 2012 and December 31, 2011, the Company owned 212 and 190 policies, respectively, with an aggregate estimated fair value of investments in life settlements of $102.3 million and 90.9 million, respectively.

The weighted average life expectancy calculated based on death benefit of insureds in the policies owned by the Company at September 30, 2012 was 10.5 years. The following table describes the Company’s investment in life settlements as of September 30, 2012 (dollars in thousands):

	Number of
	Life Settlement		Fair		Face
Remaining Life Expectancy (In Years)	Contracts		Value		Value
0 - 1		—	$	—	$	—
1 - 2		—		—		—
2 - 3		1		1,021		2,500
3 - 4		4		2,901		11,450
4 - 5		8		10,655		33,050
Thereafter		199		87,751		1,011,156
Total		212		102,328		1,058,156

The weighted average life expectancy calculated based on death benefit of insureds in the policies owned by the Company at December 31, 2011 was 10.6 years. The following table describes the Company’s investment in life settlements as of December 31, 2011 (in thousands):

Remaining Life Expectancy (In Years)	Number of Life Settlement Contracts		Fair Value		Face Value
0 - 1		—	$	—	$	—
1 - 2		1		3,033		5,000
2 - 3		2		2,484		4,500
3 - 4		4		7,084		20,200
4 - 5		3		2,357		7,950
Thereafter		180		75,959		897,816
Total		190		90,917		935,466

Estimated premiums to be paid for each of the five succeeding fiscal years and thereafter, to keep the life insurance policies in force as of September 30, 2012, are as follows (in thousands):

Remainder of 2012		6,855
2013		27,755
2014		25,226
2015		25,462
2016		25,756
Thereafter		323,609
	$	434,663

25

The amount of $434.7 million noted above represents the estimated total future premium payments required to keep the life insurance policies in force during the life expectancies of all the underlying insured lives and does not give effect to projected receipt of death benefits. The Company has not yet experienced the mortalities of insureds or received the resulting death benefits from our life insurance policies (other than from policies with subrogation rights that are not reported on our balance sheet and that are considered contingent assets). The estimated total future premium payments could increase or decrease significantly to the extent that actual mortalities of insureds differs from the estimated life expectancies.

(12) Fair Value Measurements

The Company carries investments in life settlements (life insurance policies), certain structured settlements, and investment securities available for sale at estimated fair value in the consolidated and combined balance sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified based on the following fair value hierarchy:

Level 1 — Valuation is based on unadjusted quoted prices in active markets for identical assets and liabilities that are accessible at the reporting date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

Level 2 — Valuation is determined from pricing inputs that are other than quoted prices in active markets that are either directly or indirectly observable as of the reporting date. Observable inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 — Valuation is based on inputs that are both significant to the fair value measurement and unobservable. Level 3 inputs include situations where there is little, if any, market activity for the financial instrument. The inputs into the determination of fair value generally require significant management judgment or estimation. Accordingly, the actual exit price for any Level 3 asset, such as the Company’s investments in life insurance policies, may be substantially higher or lower than the reported valuation for such asset.

26

Assets and liabilities measured at fair value on a recurring basis

The balances of the Company’s assets measured at fair value on a recurring basis as of September 30, 2012, are as follows (in thousands):

							Total
	Level 1		Level 2		Level 3		Fair Value
Assets:
Investment in life settlements	$	—	$	—	$	102,328	$	102,328
Structured settlement receivables		—		—		2,496		2,496
Investment securities available for sale		—		24,173		—		24,173
	$	—	$	24,173	$	104,824	$	128,997

The balances of the Company’s assets measured at fair value on a recurring basis as of December 31, 2011, are as follows (in thousands):

	Level 1		Level 2		Level 3		Total Fair Value
Assets:
Investment in life settlements	$	—	$	—	$	90,917	$	90,917
Structured settlement receivables		—		—		12,376		12,376
Investment securities available for sale		—		57,242		—		57,242
	$	—	$	57,242	$	103,293	$	160,535

The Company values its investment in life settlement portfolio in two classes, non-premium financed and premium financed. In considering the categories, it is generally believed that market participants would require a lower risk premium for policies that were non-premium financed, while a higher risk premium would be required for policies that were premium financed.

($ in thousands)			Quantative Information about Level 3 Fair Value Measurements
	Fair Value at 9/30/12		Aggregate death benefit 9/30/12		Valuation Technique (s)	Unobservable Input	Range ( Weighted Average)
Non-premium financed	$	31,464	$	206,450	Discounted cash flow	Discount rate	18.05%
						Life expectancy evaluation	9.3 years
Premium financed		70,864		851,706	Discounted cash flow	Discount rate	20.05% - 30.65%
						Life expectancy evaluation	10.8 years
Investment in life settlements	$	102,328	$	1,058,156	Discounted cash flow	Discount rate	(24.61%)
						Life expectancy evaluation	(10.5 years)
Structured settlements receivables	$	2,496			Discounted cash flow	Facility sales discount rates	7.38% - 19.16%

Following is a description of the methodologies used to estimate the fair values of assets and liabilities measured at fair value on a recurring basis and within the fair value hierarchy.

Investment in life settlements— The Company has elected to account for the life settlement policies it acquires using the fair value method. Due to the inactive market for life settlements, the Company uses a present value technique to estimate the fair value of our investments in life settlements, which is a Level 3 fair value measurement as the significant inputs are unobservable and require significant management judgment or estimation. The Company currently uses a probabilistic method of valuing life insurance policies, which we believe to be the preferred valuation method in the industry. The most significant assumptions which we estimate are the life expectancy of the insured and the discount rate.

27

In determining the life expectancy estimate, we analyze medical reviews from independent secondary market life expectancy providers (each a “LE provider”). Additionally, the Company began procuring updated life expectancy reports and has applied updated life expectancy reports on 143 policies to its fair value model at September 30, 2012, including 79 reports that were produced after the valuation date. The Company recorded a non-cash charge of $20.1 million as unrealized loss on change in fair value of life settlements for the three months ended September 30, 2012. See Note 18 – Subsequent Events. An LE provider reviews the medical records and identifies all medical conditions it feels are relevant to the life expectancy of the insured. Debits and credits are then assigned by the LE provider to the individual’s health based on these medical conditions. The debit or credit that an LE provider assigns to a medical condition is derived from the experience of mortality attributed to this condition in the portfolio of lives that it monitors. The health of the insured is summarized by the LE provider into a life assessment of the individual’s life expectancy expressed both in terms of months and in mortality factor.

The resulting mortality factor represents an indication as to the degree to which the given life can be considered more or less impaired than a standard life having similar characteristics (e.g. gender, age, smoking, etc.). For example, a standard insured (the average life for the given mortality table) would carry a mortality rating of 100%. A similar but impaired life bearing a mortality rating of 200% would be considered to have twice the chance of dying earlier than the standard life. Historically, the Company has procured the majority of its life expectancy reports from two life expectancy report providers and only used AVS life expectancy reports for valuation purposes. Beginning in the quarter ended September 30, 2012, the Company began utilizing life expectancy reports from 21st Services for valuation purposes and began averaging or “blending,” the results of the two life expectancy reports to establish a composite mortality factor. However, when “blending” the AVS and 21st Services life expectancy reports, if the probability of mortality between the reports is greater than 150%, the Company will reduce the higher mortality factor until the difference is 150%.

The probability of mortality for an insured is then calculated by applying the blended life expectancy estimate to a mortality table. The mortality table is created based on the rates of death among groups categorized by gender, age, and smoking status. By measuring how many deaths occur before the start of each year, the table allows for a calculation of the probability of death in a given year for each category of insured people. The probability of mortality for an insured is found by applying the mortality rating from the life expectancy assessment to the probability found in the actuarial table for the insured’s age, sex and smoking status. The Company historically applied an actuarial table developed by a third party. However, as that party has ceased operations, in the quarter ended September 30, 2012, the Company transitioned to a table developed by the U.S. Society of Actuaries known as the 2008 Valuation Basic Table, or the 2008 VBT. However, because the 2008 VBT table does not account for anticipated improvements in mortality in the insured population, the table was modified by outside consultants to reflect these expected mortality improvements. The Company believes that the change in mortality table does not materially impact the valuation of its life insurance policies and that its adoption of a modified 2008 VBT table is consistent with modified tables used by market participants and third party medical underwriters. The Company believes that the change in mortality table does not materially impact the valuation of its life insurance policies and that its adoption of a modified 2008 VBT table is consistent with modified tables used by market participants and third party medical underwriters.

The mortality rating is used to create a range of possible outcomes for the given life and assign a probability that each of the possible outcomes might occur. This probability represents a mathematical curve known as a mortality curve. This curve is then used to generate a series of expected cash flows over the remaining expected lifespan of the insured and the corresponding policy. A discounted present value calculation is then used to determine the price of the policy. If the insured dies earlier than expected, the return will be higher than if the insured dies when expected or later than expected.

The calculation allows for the possibility that if the insured dies earlier than expected, the premiums needed to keep the policy in force will not have to be paid. Conversely, the calculation also considers the possibility that if the insured lives longer than expected, more premium payments will be necessary. Based on these considerations, each possible outcome is assigned a probability and the range of possible outcomes is then used to create a price for the policy.

The Company’s pricing department uses a premium optimizer to reverse engineer a projected payment stream for subsequent year premiums. This is determined based on inputs from the carrier such as the life insurance policy, the in force ledger or illustration and premium history.

The valuation of life insurance policies is performed by our pricing department at the end of each reporting period. During this process, management assesses and determines whether the valuation technique and inputs continues to be appropriate.

Life expectancy sensitivity analysis

As of September 30, 2012 the weighted average life expectancy calculated based on death benefit of the insured was 10.5 years. If all of the insured lives in the Company’s life settlement portfolio live six months shorter or longer than the blended life expectancies provided by these third parties, the change in fair market value would be as follows (dollars in thousands):

28

Life Expectancy Months Adjustment	Value		Change in Value
+6		85,305		(17,023	)
-		102,328		—
-6		120,596		18,268

As noted above, the Company takes an average, or blend, of the two life expectancy reports to derive a composite mortality factor, unless the probability of mortality between the reports is greater than 150%. In such instances and as reflected in the fair market value at September 30, 2012, the Company will cap the higher mortality factor at amount that is 150% above the lower mortality factor, which ultimately reduces the mortality factor inputted into the Company’s fair value model. At September 30, 2012, had the Company not implemented such a cap on affected policies, the fair value of the Company’s portfolio would have increased from the reported amount by $9.2 million.

Discount rate

The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require.

The Company believes that investors in esoteric assets such as life insurance policies typically target yields averaging between 12%—17% for investments of more than a 5 year duration, and had historically used a 15%—17% range of discount rates to value its life insurance policies. In the third quarter of 2011 and in the immediate aftermath of becoming aware of the USAO investigation, the Company substantially increased the discount rates inputted into its fair value model as it believed that the USAO Investigation along with certain unfavorable court decisions unrelated to the Company contributed to a contraction in the marketplace that has continued to reverberate. Since that time, the Company has been re-evaluating its discount rates at the end of every reporting period in order to reflect the estimated discount rates that could reasonably be used in a market transaction involving the Company’s portfolio of life insurance policies. In doing so, the Company relies on management insight, engages third party consultants to corroborate its assessment, engages in discussions with other market participants and potential financing sources and extrapolates the discount rate underlying actual sales of policies.

Although the Company believes that its entry into the Non-Prosecution Agreement had a positive effect on the market generally and for premium financed life insurance policies specifically, the Company believes that, when given the choice to invest in a policy that was associated with the Company’s premium finance business and a similar policy without such an association, all else being equal, an investor would have generally opted to invest in the policy that was not associated with the Company’s premium finance business. However, since entering into the Non-Prosecution Agreement, investors have required less of a risk premium to transact in these policies and the Company expects that, in time, investors will continue to require less of a risk premium to transact in policies associated with its premium finance business

Credit exposure of insurance company

The company considers the financial standing of the issuer of each policy typically, we seek to hold policies issued by insurance companies with investment-grade ratings of at least single-A. At September 30, 2012, the Company had six life insurance policies issued by one carrier that was rated non-investment grade by S&P at September 30, 2012. In order to compensate a market participant for the perceived credit and challenge risks associated with these policies, the Company applied an additional 300 basis point risk premium.

Estimated risk premium

As of September 30, 2012, the Company owned 212 policies with an aggregate investment in life settlements of $102.3 million. Of these 212 policies, 169 were premium financed and are valued using discount rates that range from 20.05% – 30.65%. The remaining 43 policies which are non-premium financed are valued using a discount rate of 18.05%. As of September 30, 2012, the weighted average discount rate calculated based on death benefit used in valuing the policies in our life settlement portfolio was 24.61%.

The extent to which the fair value could vary in the near term has been quantified by evaluating the effect of changes in the weighted average discount rate used to estimate the fair value. If the weighted average discount rate were increased or decreased by ¹/₂ of 1% and the other assumptions used to estimate fair value remained the same, the change in fair market value would be as follows (in thousands):

Market interest rate sensitivity analysis

Weighted Average Rate Calculated Based on Death Benefit	Rate Adjustment			Value		Change in Value
24.11%		-.50	%		104,992		2,663
24.61%		—			102,328		—
25.11%		+.50	%		99,769		(2,560	)

Future changes in the discount rates we use to value life insurance policies could have a material effect on our yield on life settlement transactions, which could have a material adverse effect on our business, financial condition and results of our operations.

29

Structured settlement receivables— All structured settlements that were acquired subsequent to July 1, 2010 were marked to fair value. Structured settlements that were acquired prior to July 1, 2010 were recorded at cost. We make this election because it is our intention to sell these assets within the next twelve months. Structured settlements are purchased at effective yields which are fixed. Purchase discounts are accreted into interest income using the effective-interest method for those structured settlements marked to fair value. As of September 30, 2012, the Company had 70 newly-acquired structured settlements with an estimated fair value of $2.5 million. The average sales discount rate for these newly-acquired structured settlements was 10.8%.

Changes in Fair Value

The following tables provide a roll-forward in the changes in fair value for the nine months ended September 30, 2012, for all assets for which the Company determines fair value using a material level of unobservable (Level 3) inputs (in thousands):

Life Settlements:
Balance, December 31, 2011	$	90,917
Purchase of policies		130
Acquired in foreclosure		5,050
Unrealized change in fair value		(8,401	)
Sale of policies		(5,334	)
Transfers into level 3		—
Transfers out of level 3		—
Premiums paid		20,106
Policies lapsed/written off		(140	)
Balance, September 30, 2012	$	102,328
Changes in fair value included in earnings for the period relating to assets held at September 30, 2012	$	(8,638	)

The Company recorded unrealized change in fair value loss of approximately $17.5 million and $14.1 million during the three months ended September 30, 2012 and 2011, respectively, and a loss in fair value of life settlements of approximately $8.4 million and a gain of approximately $14.8 million for the nine months ended September 30, 2012 and 2011, respectively.

Structured Settlements:
Balance, December 31, 2011	$	12,376
Purchase of contracts		17,115
Unrealized change in fair value		1,588
Sale of contracts		(28,396	)
Collections		(187	)
Transfers into level 3		—
Transfers out of level 3		—
Balance, September 30, 2012	$	2,496
Changes in fair value included in earnings for the period relating to assets held at September 30, 2012	$	429

The following tables provide a roll-forward in the changes in fair value for the nine months ended September 30, 2011, for all assets for which the Company determines fair value using a material level of unobservable (Level 3) inputs (in thousands).

Life Settlements:
Balance, December 31, 2010	$	17,138
Purchase of policies		48,057
Acquired in foreclosure		2,098
Unrealized change in fair value		14,811
Premiums paid		9,863
Transfers into Level 3		—
Transfers out of Level 3		—
Balance, September 30, 2011	$	91,967

30

Changes in fair value included in earnings for the period relating to assets held at September 30, 2011	$	14,811
Structured Settlements:
Balance, December 31, 2010	$	1,446
Purchase of contracts		21,469
Unrealized change in fair value		2,145
Sale of contracts		(20,789	)
Collections		(114	)
Transfers into Level 3		—
Transfers out of Level 3		—
Balance, September 30, 2011		4,157
Changes in fair value included in earnings for the period relating to assets held at September 30, 2011	$	1,151

There were no transfers of financial assets between levels of the fair value hierarchy during the nine months ended September 30, 2012 and 2011.

Assets and liabilities measured at fair value on a non-recurring basis

Following is a description of the methodologies used to estimate the fair values of assets and liabilities measured at fair value on a non-recurring basis, and the level within the fair value hierarchy in which those measurements are typically classified.

The Company’s impaired loans are measured at fair value on a non-recurring basis, as the carrying value is based on the fair value of the underlying collateral. The method used to estimate the fair value of impaired collateral-dependent loans depends on the nature of the collateral. For collateral that has lender protection insurance coverage, the fair value measurement is considered to be Level 2 as the insured value is an observable input and there are no material unobservable inputs. For collateral that does not have lender protection insurance coverage, the fair value measurement is considered to be Level 3 as the estimated fair value is based on a model whose significant inputs are the life expectancy of the insured and the discount rate, which are not observable inputs. As of September 30, 2012 and December 31, 2011, the Company had insured impaired loans with a net carrying value, which includes principal, accrued interest, and accreted origination fees, net of impairment, of approximately $1.4 million and $14.1 million, respectively. As of September 30, 2012 and December 31, 2011, the Company had uninsured impaired loans (Level 3) with a net carrying value of approximately $4.7 million and $10.2 million, respectively. The provision for losses on loans receivable related to impaired loans was approximately zero and $3.6 million for the three months ended September 30, 2012 and 2011, respectively and approximately $449,000 and $3.7 million for the nine months ended September 30, 2012 and 2011, respectively. See Notes 6 and 11.

31

(13) Notes and Debenture Payable

A summary of the principal balances of notes payable included in the consolidated and combined balance sheet as of September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,		December 31,
	2012		2011
Cedar Lane	$	1,222	$	19,104
White Oak, Inc.		—		173
Total	$	1,222	$	19,277

Cedar Lane

On December 2, 2009, Imperial PFC Financing II, LLC was formed to enter into a financing agreement with Cedar Lane Capital, LLC, so that Imperial PFC Financing II, LLC could purchase Imperial Premium Finance notes for cash or a participation interest in the notes. The financing agreement is for a minimum of $5 million to a maximum of $250 million. The agreement is for a term of 28 months from the time of borrowing and the borrowings bear an annual interest rate of 14%, 15% or 16%, depending on the class of lender and are compounded monthly. All of the assets of Imperial PFC Financing II, LLC serve as collateral under this credit facility. The Company is subject to several restrictive covenants under the facility. The restrictive covenants include items such as restrictions on the ability to pay dividends or incur additional indebtedness by Imperial PFC Financing II, LLC. The Company believes it is in compliance at September 30, 2012. The outstanding principal at September 30, 2012 and December 31, 2011 was approximately $1.2 million and $19.1 million, respectively, and accrued interest was approximately $358,000 and $5.4 million, respectively. The Company is required to retain 2% of the principal amount of each loan made to the borrower, for purposes of indemnifying the facility for any breaches of representations, warranties or covenants of the borrower, as well as to fund collection efforts, if required. As of September 30, 2012 and December 31, 2011 the Company’s consolidated financial statements reflected balances of approximately $1.1 million and $691,000 included in restricted cash, respectively. Our lender protection insurer ceased providing us with lender protection insurance under this credit facility on December 31, 2010.

White Oak, Inc.

On February 5, 2009, Imperial Life Financing II, LLC, was formed to enter into a loan agreement with White Oak Global Advisors, LLC, so that Imperial Life Financing II, LLC could purchase Imperial Premium Finance notes in exchange for cash or a participation interest in the notes.

In September 2009, the Imperial Life Financing II, LLC loan agreement was amended to increase the commitment by $12 million to a total commitment of $27 million. All of the assets of Imperial Life Financing II, LLC serve as collateral under this facility. The notes are payable 6-26 months from issuance and the facility matured on March 11, 2012. The outstanding principal at September 30, 2012 and December 31, 2011, was approximately $0 and $172,000, respectively, and accrued interest was approximately $0 and $104,000, respectively. After December 31, 2010, we ceased originating premium finance loans with lender protection insurance. All remaining amounts under this facility were repaid during the three months ended March 31, 2012.

(14) Segment Information

The Company operates in two segments: life finance and structured settlements. The life finance segment provided financing in the form of loans to trusts and individuals for the payment of premiums of life insurance policies until the end of the third quarter of 2011. Beginning in 2011, in this segment, the Company also acquired life insurance policies through policy purchases in the secondary and tertiary markets. The structured settlements segment purchases structured settlements from individuals.

Recipients of structured settlements are permitted to sell their deferred payment streams to a structured settlement purchaser pursuant to state statutes that require certain disclosures, notice to the obligors and state court approval. Through such sales, the Company purchases a certain number of fixed, scheduled future settlement payments on a discounted basis in exchange for a single lump sum payment.

The performance of the segments is evaluated on the segment level by members of the Company’s senior management team. Cash and income taxes generally are managed centrally. Performance of the segments is based on revenue and cost control.

32

Segment results and reconciliation to consolidated net income were as follows (in thousands):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Life finance
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		180			2,145			1,613			6,712
Origination income		45			1,753			483			5,858
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other		16			8			175			182
		(17,018	)		(5,469	)		1,206			43,647
Direct segment expenses
Interest expense		140			1,660			1,215			7,135
Provision for losses on loan receivables		—			3,583			441			3,712
(Gain) loss on loans payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlements write off		140			—			140			—
Amortization of deferred costs		255			1,409			1,752			4,913
Personnel costs		1,099			2,192			4,663			5,121
Marketing		—			—			—			16
Legal fees		1,116			803			2,622			1,456
Professional fees		315			460			1,180			1,359
Insurance		313			—			806			133
Other selling, general and administrative expenses		443			863			1,205			1,390
		3,682			11,231			14,038			29,162
Segment operating (loss) income	$	(20,700	)	$	(16,700	)	$	(12,832	)	$	14,485

33

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Structured settlements
Income
Realized gain on sale of structured settlements	$	2,187		$	2,240		$	7,796		$	5,457
Interest income		72			144			243			319
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Other income		101			50			354			195
		2,769			3,362			9,980			8,116
Direct segment expenses
Personnel costs		2,443			2,959			7,033			6,544
Marketing		1,034			1,754			4,481			4,169
Legal fees		527			455			1,671			1,803
Professional fees		615			199			1,527			930
Insurance		313			67			799			216
Other selling, general and administrative expenses		328			1,467			1,362			1,573
		5,260			6,901			16,873			15,235
Segment operating loss	$	(2,491	)	$	(3,539	)	$	(6,893	)	$	(7,119	)
Consolidated
Segment operating (loss) income		(23,191	)		(20,239	)		(19,725	)		7,366
Unallocated income
Other income		78			344			969			545
Unallocated expenses
Interest expense		—			—			3			296
Personnel costs		53			(315	)		621			2,498
Legal fees		7,685			563			18,625			928
Professional fees		629			793			2,565			2,157
Insurance		—			119			107			199
Other selling, general and administrative expenses		—			(678	)		340			997
		8,367			482			22,261			7,075
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)

34

Segment assets and reconciliation to consolidated total assets were as follows (in thousands):

	September 30,		December 31,
	2012		2011
Direct segment assets
Life finance	$	122,395	$	138,520
Structured settlements		6,876		17,155
		129,271		155,675
Other unallocated assets		45,048		66,924
	$	174,319	$	222,599

(15) Stockholders’ Equity

In January 2011, Imex Settlement Corporation executed an agreement to purchase from the Company 110,000 Series F Preferred Units for an $11.0 million promissory note. The Series F Preferred Units were non-voting and would be redeemed at any time by the Company for an amount equal to the applicable unreturned preferred capital amount allocable to the Series F Preferred Units sought to be redeemed, plus any accrued and unpaid preferred return. The cumulative rate of preferred return was equal to 16.0% of the outstanding units, per annum. The Series F Preferred units and the $11 million promissory note were extinguished as a result of the corporate conversion.

On February 3, 2011, the Company converted from a Florida limited liability company to a Florida corporation at which time the members of Imperial Holdings, LLC became shareholders of Imperial Holdings, Inc. As a limited liability company, the Company was treated as a partnership for United States federal and state income tax purposes and, as such, the Company was not subject to taxation. For all periods subsequent to such conversion, the Company will be subject to corporate-level United States federal and state income taxes.

As part of the corporate conversion, the Company entered into a plan of conversion with its shareholders on January 12, 2011, as amended on February 3, 2011. Pursuant to the plan of conversion, all of the Company’s outstanding common units and Series A, B, C, D and E preferred units and all principal and accrued and unpaid interest outstanding under our promissory note in favor of IMPEX Enterprises, Ltd. were converted into 2,300,273 shares of our common stock. The plan of conversion, which describes the corporate conversion as well as other transactions and agreements by the parties with an interest in the Company’s equity, reflects an agreement among its then shareholders as to the allocation of the shares of common stock to be issued to its shareholders in the corporate conversion. Thus, there is no formula that may be used to describe the conversion of a common unit or a Series A, B, C, D and E preferred unit into common stock.

Immediately after the corporate conversion and prior to the conversion of the Skarbonka debenture and the closing of the Company’s initial public offering on February 11, 2011, the Company’s shareholders consisted of two Florida corporations and one Florida limited liability company. These three shareholders reorganized so that their beneficial owners received the same number of shares of common stock of Imperial Holdings, Inc. issuable to the members of Imperial Holdings, LLC in the corporate conversion.

After the corporate conversion and prior to the closing of the Company’s initial public offering on February 11, 2011, the Company converted two phantom stock agreements it had with two employees into 27,000 shares of common stock and incurred stock compensation of approximately $290,000.

In addition, following the corporate conversion and upon the closing of the Company’s initial public offering on February 11, 2011, three shareholders received ownership of warrants that may be exercised for up to a total of 4,053,333 shares of the Company’s common stock at a weighted average exercise price of $14.51 per share. In connection with the over-allotment option, the same three shareholders received ownership of 187,188 additional warrants. One-third of the warrants will have an exercise price equal to 120% of the price of the common stock sold in this offering, one-third of the warrants will have an exercise price equal to 135% of the price of the common stock sold in this offering, and one-third of the warrants will have an exercise price equal to 150% of the price of the common stock sold in this offering. The warrants will expire 7 years after the date of issuance and the exercisability of the warrant will vest ratably over four years.

On February 11, 2011, the Company closed its initial public offering of 16,666,667 shares of common stock at $10.75 per share. On February 15, 2011 Imperial Holdings, Inc. sold an additional 935,947 shares of common stock. The sale was in connection with the over-allotment option Imperial granted to its underwriters in connection with Imperial’s initial public offering. As a result, the total initial public offering size was 17,602,614 shares. All shares were sold to the public at a price of $10.75. The Company received net proceeds of approximately $174.2 million after deducting the underwriting discounts and commissions and our offering expenses.

35

After giving effect to (i) the corporate conversion, pursuant to which all outstanding common and preferred limited liability company units of Imperial Holdings, LLC (including all accrued and unpaid dividends thereon) and all principal and accrued and unpaid interest outstanding under the Company’s promissory note in favor of IMPEX Enterprises, Ltd. were converted into 2,300,273 shares of the Company’s common stock; (ii) the issuance of 27,000 shares of common stock to two employees pursuant to the terms of each of their respective phantom stock agreements; (iii) the conversion of a $30.0 million debenture into 1,272,727 shares of common stock (iv) the sale of 16,666,667 shares in the Company’s initial public offering, and (v) the sale of 935,947 shares in connection with the over-allotment option granted to the Company’s underwriters, there are 21,202,614 shares of common stock outstanding. Up to an additional 4,240,521 shares of common stock will be issuable upon the exercise of warrants issued to existing members of the Company. Moreover, the Company reserved an aggregate of 1,200,000 shares of common stock under its Omnibus Plan, of which 665,956 options to purchase shares of common stock were granted to existing employees, directors and named executive officers at a weighted average exercise price of $10.75 per share, and an additional 3,507 shares of restricted stock had been granted under the plan subject to vesting. The remaining 530,537 shares of common stock are available for future awards.

(16) Commitments and Contingencies

In accordance with applicable accounting guidance, the Company establishes an accrued liability for litigation and regulatory matters when those matters present loss contingencies that are both probable and estimable. In such cases, there may be an exposure to loss in excess of any amounts accrued. When a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. As a litigation or regulatory matter develops, the Company, in conjunction with any outside counsel handling the matter, evaluates on an ongoing basis whether such matter presents a loss contingency that is probable and estimable. If, at the time of evaluation, the loss contingency related to a litigation or regulatory matter is not both probable and estimable, the matter will continue to be monitored for further developments that would make such loss contingency both probable and estimable. Once the loss contingency related to a litigation or regulatory matter is deemed to be both probable and estimable, the Company will establish an accrued liability with respect to such loss contingency and record a corresponding amount of litigation-related expense. The Company continues to monitor the matter for further developments that could affect the amount of the accrued liability that has been previously established. Excluding expenses of external legal service providers, litigation-related fees of $2.6 million and $12.8 million was recognized for the three months and nine months ended September 30, 2012, respectively. There were no comparable expenses in the respective periods during 2011.

Employment Agreements

In connection with our initial public offering, we entered into employment agreements with certain of our executive officers. The agreement for our chief executive officer provides for substantial payments in the event that the executive terminates his employment with us due to a material change in the geographic location where such officer performs his duties or upon a material diminution of his base salary or responsibilities, with or without cause. For our chief executive officer, payments are equal to three times the sum of base salary and the average of the three years’ annual cash bonus, unless the triggering event occurs during the first three years of his employment agreement, in which case the payments are equal to six times base salary. For our chief executive officer, the agreement provides for bonus incentives based on pre-tax income thresholds.

On April 26, 2012, the Company entered into a Separation Agreement and General Release of Claims (the “Separation Agreement”) with its chief operating officer, Jonathan Neuman. As part of the Separation Agreement, Mr. Neuman resigned as a member of the Company’s board of directors and as an employee of Company. Pursuant to the Separation Agreement, the Company paid Mr. Neuman a separation payment of $1.4 million. The Separation Agreement does not include a covenant by Mr. Neuman to refrain from competing with Imperial, but does contain customary non-disparagement and non-solicitation provisions. The Separation Agreement provides releases by each party and also obligates the Company to continue to indemnify Mr. Neuman for his legal expenses substantially in the same manner contemplated by his employment agreement with the Company.

On February 15, 2012, the Company entered into a retention arrangement with its Chief Financial Officer and Chief Credit Officer, Richard O’Connell, Jr. The arrangement provides that, in the event Mr. O’Connell’s employment is terminated without cause or Mr. O’Connell terminates his employment with the Company for good reason, in each case, prior to December 31, 2013, Mr. O’Connell will be entitled to 24 months’ base salary in addition to any accrued benefits. Additionally, unless Mr. O’Connell’s employment is terminated for cause, Mr. O’Connell will be entitled to a minimum bonus of $250,000 for each of 2012 and 2013, subject to the Company’s Board of Directors’ right to terminate the bonus payment in respect of 2013 prior to January 1, 2013. Except for the provisions relating to severance and other termination benefits, the terms of Mr. O’Connell’s Employment and Severance Agreement entered into with the Company as of November 4, 2010 remain in effect during the term of the retention arrangement and the provisions of the employment agreement relating to severance and other termination benefits will again be in effect following any termination of the retention arrangement if Mr. O’Connell is then employed by the Company.

During the first quarter of 2012, the Company also entered into severance and retention award agreements with certain of its executive officers (other than the CEO and CFO). The agreements generally provide for a minimum guaranteed bonus in each of 2012 and 2013 as well as severance payments equal to two years base salary in the event of termination by the Company without Cause (as defined in the respective agreement) provided the executive executes a general release of claims against the Company.

36

We do not have any general policies regarding the use of employment agreements, but may, from time to time, enter into such a written agreement to reflect the terms and conditions of employment of a particular named executive officer, whether at the time of hire or thereafter.

Subrogation Rights, net

Every credit facility entered into by subsidiaries of the Company between December 2007 and December 2010 to finance the premium finance lending business required lender protection insurance for each loan originated under such credit facility. Generally, when the Company exercises its right to foreclose on collateral, the Company’s lender protection insurer has the right to direct control or take beneficial ownership of the life insurance policy, subject to the terms and conditions of the lender protection insurance policy, including notice and timing requirements. Otherwise, the lender protection insurer maintains its salvage collection and subrogation rights. The lender protection insurer’s salvage collection and subrogation rights generally provide a remedy by which the insurer can seek to recover the amount of the lender protection claim paid plus premiums paid by it, expenses and interest thereon.

In those instances where the Company has foreclosed on the collateral, the lender protection insurer has maintained its salvage collection and subrogation rights and has been covering the cost of the ongoing premiums needed to maintain certain of these life insurance policies. However, the lender protection insurer may elect at any time to discontinue the payment of premiums which would result in lapse of the policies if the Company does not otherwise pay the premiums. The Company views these policies as having uncertain value because the lender protection insurer controls what happens to the policy from a payment of premium standpoint, and the amount of the lender protection insurer’s salvage collection and subrogation claim rights on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. For these reasons, these policies are considered contingent assets and are not included in the amount of life settlements on the accompanying consolidated and combined balance sheet.

The Company accounts for the maturities of life settlements with subrogation rights net of subrogation expenses as contingent gains in accordance with ASC 450, Contingencies and recognizes the revenue from the maturities of these policies when all contingencies are resolved.

The Class Action Litigation

On September 29, 2011, the Company, and certain of its officers and directors were named as defendants in a putative securities class action filed in the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entitled Martin J. Fuller v. Imperial Holdings, Inc. et al. Also named as defendants were the underwriters of the Company’s initial public offering. That complaint asserted claims under Sections 11 and 15 of the Securities Act of 1933, as amended, alleging that the Company should have but failed to disclose in the registration statement for its initial public offering purported wrongful conduct relating to its life finance business which gave rise to the government investigation described above. On October 21, 2011, an amended complaint was filed that asserts claims under Sections 11, 12 and 15 of the Securities Act of 1933, based on similar allegations. On October 25, 2011, defendants removed the case to the United States District Court for the Southern District of Florida.

On October 31, 2011, another putative class action case was filed in the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entitled City of Roseville Employees Retirement System v. Imperial Holdings, et al, naming the same defendants and also bringing claims under Sections 11,12 and 15 of the Securities Act of 1933 based on similar allegations. On November 28, 2011, defendants removed the case to the United States District Court for the Southern District of Florida. The plaintiffs in the Fuller and City of Roseville cases moved to remand their cases back to state court. Those motions were fully briefed and argued, and a decision is pending.

On November 18, 2011, a putative class action case was filed in the United States District Court for the Southern District of Florida, entitled Sauer v. Imperial Holdings, Inc., et al., naming the same defendants and bringing claims under Sections 11 and 15 of the Securities Act based on similar allegations.

On December 14, 2011, another putative class action case filed in United States District Court for the Southern District of Florida, entitled Pondick v. Imperial Holdings, Inc., et al., naming the same defendants and bringing claims under Sections 11, 12, and 15 of the Securities Act based on similar allegations.

On February 24, 2012, the four putative class actions were consolidated and designated: Fuller v. Imperial Holdings et al. in the United States District Court for the Southern District of Florida, and Lead Plaintiffs were appointed. In addition, the underwriters of the Company’s initial public offering have asserted that the Company is required by its Underwriting Agreement to indemnify the underwriters’ expenses and potential liabilities in connection with the litigation. See Note 18 — Subsequent Events.

37

The Insurance Coverage Declaratory Relief Complaint

On June 13, 2012, Catlin Insurance Company (UK) Ltd. (“Catlin”) filed a declaratory relief action against the Company in the United States District Court for the Southern District of Florida. The complaint seeks a determination that there is no coverage under Catlin’s primary Directors, Officers and Company Liability Policy (the “Policy”) issued to the Company for the period February 3, 2011 to February 3, 2012, based on a prior and pending litigation exclusion (the “Exclusion”). Catlin also seeks a determination that it is entitled to reimbursement of the approximately $0.8 million in defense costs and fees advanced to the Company in the first quarter of 2012 under the Policy if it is determined that the Exclusion precludes coverage. The Company recorded a reserve of $0.8 million for the recovery received during the nine months ended September 30, 2012 as other selling, general and administrative expense. $0.6 million of the amount reserved was recorded as other income due to this portion of the recovery relating to 2011 expenses and the remaining $0.2 million was recorded as a reduction of legal expenses for the nine months ended September 30, 2012. As of the filing of this Form 10-Q, the Company has not yet been served with the complaint. See Note 18 — Subsequent Events.

Derivative Claims

On November 16, 2011, the Company’s Board of Directors received a shareholder derivative demand from Harry Rothenberg (the “Rothenberg Demand”), which was referred to the Special Committee of the Company’s Board of Directors consisting of five outside Board Members (the “Special Committee”) for a thorough investigation of the issues, occurrences and facts relating to, connected to, and arising from the USAO Investigation referenced in the Rothenberg Demand. On May 8, 2012, the Company’s Board of Directors received a derivative demand made by another shareholder, Robert Andrzejczyk (the “Andrzejczyk Demand”). The Andrzejczyk Demand, like the Rothenberg Demand was referred to the Special Committee, which determined that it did not contain any allegations that differed materially from those alleged in the Rothenberg Demand. On July 20, 2012, the Company (as nominal defendant) and certain of the Company’s officers, directors, and a former director were named as defendants in a shareholder derivative action filed in the Circuit Court of the 15^th Judicial Circuit in and for Palm Beach County, Florida, entitled Robert Andrzejczyk v. Imperial Holdings, Inc. et al. The complaint alleges, among other things, that the Special Committee’s refusal of the Andrzejczyk Demand was improper. The defendants have not yet been required to respond to the complaint. See Note 18 — Subsequent Events.

SEC Investigation

On February 17, 2012, the Company received a subpoena issued by the staff of the SEC seeking documents from 2007 through the present, generally related to the Company’s premium finance business and corresponding financial reporting. The SEC is investigating whether any violations of federal securities laws have occurred and the Company has been cooperating with the SEC regarding this matter. The Company is unable to predict what action, if any, might be taken in the future by the SEC or its staff as a result of the matters that are the subject of the subpoena or what impact, if any, the cost of responding to the subpoena might have on the Company’s financial position, results of operations, or cash flows. The Company has not established any provision for losses in respect of this matter.

The Florida Litigation

On March 14, 2012, Opportunity Partners L.P. (“Opportunity”) served the Company with a complaint in the Circuit Court of the 15^th Judicial Circuit in and for Palm Beach County, Florida seeking to compel the Company to hold an annual meeting of shareholders as soon as possible and seeking recovery of all costs and expenses, including reasonable attorney’s fees and expenses of experts in connection with the complaint. On March 28, 2012, Opportunity filed a motion to compel an annual meeting of shareholders. The Company filed a motion to dismiss the complaint on April 3, 2012 and an opposition to the motion to compel on May 24, 2012. Following a hearing on June 1, 2012, the Court entered an Order dated June 15, 2012 granting Opportunity’s motion to compel an annual meeting of shareholders and denying the Company’s motion to dismiss. Pursuant to the Court’s Order, the Company was required to hold its annual meeting of shareholders on or before August 20, 2012. In addition, the Court ordered the Company to seek an exemption from the SEC pursuant to SEC Regulation 17 C.F.R. § 200.30-1(e)(18) on or before June 20, 2012 and to update the Court of any adverse response to its application on or before July 18, 2012.

On August 2, 2012, the Board of Directors of the Company appointed Andrew Dakos, Phillip Goldstein and Gerald Hellerman to serve as directors of the Company in connection with a settlement with Opportunity that resulted in Opportunity withdrawing its demand for a special meeting of shareholders, which it had submitted to the Company on May 23, 2012, and agreeing to dismiss its lawsuit to compel an annual meeting of shareholders. In connection with the Settlement, Walter Higgins and A. Penn Wyrough resigned from the Board of Directors. On August 14, 2012, Antony Mitchell, the Company’s chief executive officer, resigned as Chairman of the Board, though he continues to serve as the Company’s chief executive officer as well as a member of the Board of Directors, and Mr. Goldstein was elected Chairman. The committees of the Board of Directors were also reconstituted as follows: Audit: Messrs. Hellerman (chair), Buzen, Crow and Rosenberg; Compensation: Messrs. Dakos (chair), Crow, Goldstein and Hellerman; and Corporate Governance & Nominating Committee: Messrs. Goldstein (chair), Crow, Dakos and Hellerman.

38

Litigation

We are party to various other legal proceedings, which arise in the ordinary course of business. We believe that the resolution of these other proceedings will not, based on information currently available to us, have a material adverse effect on our financial position or results of operations. See Note 18 – Subsequent Events.

Guarantees

Under our Cedar Lane facility where we have guaranteed 5% of the applicable special purpose entity’s obligations, our chief executive officer and then chief operating officer made certain guaranties to lenders for the benefit of the special purpose entities for matters other than financial performance. These guaranties are not unconditional sources of credit support, but are intended to protect the lenders against acts of fraud, willful misconduct or a borrower commencing a bankruptcy filing. To the extent lenders sought recourse against our chief executive officer and former chief operating officer for such non-financial performance reasons, then our indemnification obligations to our chief executive officer and chief operating officer may require us to indemnify them for losses they may incur under these guaranties.

(17) Income Taxes

The Company and its subsidiaries are subject to U.S. federal income tax as well as to income tax in Florida and other states in which it operates.

Except as noted below, our provision for income taxes is estimated to result in an annual effective tax rate of 0.0% in 2012, except as noted below. The 0.0% effective tax rate is a result of our recording of a valuation allowance for those deferred tax assets that are not expected to be recovered in the future. Due to large losses in 2011, the uncertainties that resulted from the USAO Investigation and expectation of taxable losses in the foreseeable future, we may not have sufficient taxable income of the appropriate character in the future to realize any portion of the net deferred tax asset.

Generally, the amount of tax expense or benefit allocated to continuing operations is determined without regard to the tax effects of other categories of income or loss, such as other comprehensive income. However, an exception to the general rule is provided when, in the presence of a valuation allowance against deferred tax assets, there is a pretax loss from continuing operations and pretax income from other categories. In such instances, income from other categories must offset the current loss from operations, the tax benefit of such offset being reflected in continuing operations. For the period ended September 30, 2012 we reduced deferred tax valuation allowance from continuing operations by $46,000 to reflect the future taxable income associated with unrealized gains in accumulated other comprehensive income.

On February 3, 2011, we converted from a Florida limited liability company to a Florida corporation (the “Conversion”). Prior to the Conversion we were treated as a partnership for federal and state income tax purposes. As a partnership our taxable income and losses were attributed to our members, and accordingly, no provision or liability for income taxes was reflected in the accompanying consolidated financial statements for periods prior to the Conversion. As a result of the Conversion, we recorded a one-time deferred tax liability of approximately $4.4 million for the federal and state tax effects of cumulative differences between financial and tax reporting which existed at the time of the conversion. Pursuant to ASC 740 these deferred taxes were recorded in income tax expense for the first quarter of 2011. In the second quarter of 2011, the deferred tax liability was increased by $175,000 to account for changes in the estimated differences at the date of conversion. In addition, following the conversion and prior to the initial public offering, one of the founding members entered into a reorganization that allowed the company to assume the corporate shareholder’s tax attributes. These tax attributes include approximately $11.2 million of net operating loss carryovers (“NOLs”). During the second quarter, we completed an evaluation of this transaction and determined that we were entitled to assume the NOLs of this founding member. Accordingly, in the second quarter we recorded a one-time deferred tax asset of approximately $4.3 million related to these tax attributes and this amount was recorded as an income tax benefit during that period. For the post-conversion period ended September 30, 2011, we used an estimated annual effective tax rate of 38.6% resulting in a tax provision of $1.1 million. For the third quarter ended September 30, 2011 the total provision was $1.4 million.

39

At September 30, 2012, income taxes payable includes an estimated liability for unrecognized tax benefits of $6.3 million that related to the Conversion and was charged to paid-in-capital in the first quarter of 2011.

(18) Subsequent Events

Class Action, Derivative Claims and the Insurance Coverage Declaratory Relief Complaint

On December 18, 2012, attorneys for Imperial signed a Term Sheet for Global Settlement Regarding Imperial Holdings, Inc. Matters (the “Term Sheet”). Also signing the Term Sheet were attorneys representing the plaintiffs in the previously disclosed class action lawsuits and derivative actions instituted against the Company as well attorneys for Imperial’s director and officer liability insurance carriers (“D&O Carriers”), certain individual defendants named in the class actions and the underwriters in Imperial’s initial public offering. The Term Sheet provides the terms upon which each of the parties represented by the signatories would be willing to settle the class action litigation and derivative actions as well as the declaratory relief action filed by Catlin, Imperial’s primary D&O Carrier.

While non-binding and subject to certain contingencies, the Term Sheet provides that each of the parties will endeavor to enter into definitive settlement agreements in respect of the class action litigation, derivative action and insurance coverage declaratory relief complaint, each of which are described in Note 16 above, by January 15, 2013. Although the Company does not expect that the definitive settlement agreements will be executed by January 15, 2013, the Company does expect to continue to work in good faith with the other parties to the Term Sheet to execute settlement agreements as soon as is practicable thereafter.

The terms of the class action settlement include a cash payment of $12.0 million, of which $11.0 million is to be contributed by Imperial’s primary and excess D&O Carriers; the issuance of two million warrants for shares of the Company’s stock with an estimated value of $3.1 million at the date of the signing of the Term Sheet. The value of the warrants will be re-assessed at issuance. The warrants will have a five-year term with an exercise price of $10.75 and will be issued when the settlement proceeds are distributed to the claimants. In addition, the underwriters in Imperial’s initial public offering are to waive their rights to indemnity and contribution by Imperial. The Company established a reserve related to the proposed settlement of $15.1 million, which is included in other liabilities and a receivable for insurance recoverable from the Company’s D&O Carrier of $11.0 million, which is included in prepaid and other assets. The $4.1 million net effect of the settlement is included in legal fees in the statement of operations for the three months ended September 30, 2012.

The derivative actions subject to ratification, would be settled for implementation of certain compliance reforms. The Term Sheet also contemplates payment by Imperial’s primary D&O carrier of $1.5 million for legal fees in respect of the derivative actions and the contribution of $500,000 in Imperial stock.

In addition, the Term Sheet contemplates that Imperial will contribute $500,000 to a trust to cover certain claims under its director and officer liability insurance policies.

The Company established a reserve related to the proposed derivative settlement and insurance trust of $2.5 million, which is included in other liabilities and a receivable for insurance recoverable from the Company’s D&O Carrier of $1.5 million, which is included in prepaid and other assets. The net effect of the settlement of $1.0 million is included in legal fees in the statement of operations for the three months ended September 30, 2012.

The proposed settlement also requires Imperial to advance legal fees to and indemnify certain individuals covered under the policies. The obligation to advance and indemnify on behalf of these individuals, while currently unquantifiable, may be substantial and could have a material adverse effect on the Company’s financial position and results of operations.

Use of Updated Life Expectancies

As stated in Note 12, during the quarter ended September 30, 2012 the Company began receiving updated life expectancy reports on all of the insureds represented in the Company’s portfolio of life insurance policies. While the Company is endeavoring to obtain updated life expectancy reports for all of its policies, at September 30, 2012, the Company had only received updated life expectancies for 64 of the 212 policies in its portfolio. Since September 30, 2012, however, the Company received additional updated life expectancies on 79 more policies. All updated reports that were obtained have been blended and inputted in the Company’s fair value model at September 30, 2012. The Company believes that applying the results of the 79 life expectancy reports produced after the valuation date is appropriate since it provides additional evidence about conditions that existed at the date of the balance sheet. The company recorded a non-cash charge of $20.1 million as unrealized loss on change in fair value of life settlements for the three months ended September 30, 2012.

40

Certain Balance Sheet Items

Cash and Cash Equivalents, inclusive of investment securities available for sale

We estimate that we will need to pay $6.9 million in premiums to keep our current portfolio of life insurance policies in force through 2012 and an additional $27.8 million to keep the portfolio in force through 2013. As of December 31, 2012 we had approximately $20.3 million of cash and cash equivalents, and marketable securities, including $1.1 million of restricted cash. Based on the Company’s current internal forecast, a liquidity shortfall will occur in the second quarter of 2013. Accordingly, to avoid lapsing policies, the Company is actively seeking additional capital to pay premiums by means of debt and/or equity financing. There can be no assurance, however, that the Company will be able to consummate a financing on favorable terms or at all. If the Company cannot obtain necessary financing, it may need to sell the policies that it owns, but there can be no assurance that the Company can consummate any sales or that, if consummated, sales of policies will be at or above their carrying values.

The Company also expects during that, as part of the framework for the settlement embodied by the Term Sheet, it will, among other things, agree to pay $1.0 million of a $12.0 million payment to settle the class action litigation and will agree to contribute $500,000 to a trust to cover certain claims under its director and officer liability insurance policies, which will further stress the Company’s liquidity position. In addition, under the Term Sheet, the Company will undertake to advance legal fees and indemnify certain individuals covered under its director and officer liability insurance policies. The obligation to advance and indemnify on behalf of these individuals, while currently unquantifiable, may be substantial and could have a adverse effect on the Company’s financial position and results of operations.

41

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, and cash flows of our Company as of and for the periods presented below and should be read in conjunction with the financial statements and accompanying notes included with this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors. See “Forward-Looking Statements.”

Overview

We were founded in December 2006 as a Florida limited liability company and in connection with our initial public offering, on February 3, 2011, Imperial Holdings, Inc. succeeded to the business of Imperial Holdings, LLC and its assets and liabilities.

Imperial Holdings, Inc. (the “Company” or “Imperial”) operates in two reportable business segments: life finance (formerly referred to as premium finance) and structured settlements. In the life finance business, the Company earns revenue/income from interest charged on loans, loan origination fees, agency fees from referring agents, changes in the fair value of life insurance policies that the Company acquires and receipt of death benefits with respect to matured life insurance policies it owns. The Company voluntarily terminated its business of financing insurance premiums in connection with the USAO Investigation. See “Legal Proceedings.” In the structured settlement business, the Company purchases structured settlement receivables at a discounted rate and sells these receivables to third parties.

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 provides additional information about our business, operations and financial condition.

Recent Developments, Uncertainties & Outlook

In connection with the Non-Prosecution Agreement, Imperial voluntarily terminated its business of financing insurance premiums. Accordingly, the Company did not recognize any agency fees during the nine months ended September 30, 2012 and, once the Company’s remaining premium finance loans mature, the Company will no longer recognize revenue from interest income or origination fees. The only material revenue that the Company expects to recognize from legacy premium finance business in 2012 is from changes in fair value of life settlements acquired upon default of premium finance loans and strategic sales of certain life insurance policies in its portfolio that were acquired upon default of premium finance loans. As a result, we expect our revenue in our Life Finance segment to be materially lower in 2012 than in prior year.

Additionally, the Company’s ability to generate new business in the life finance segment continued to be limited in the nine months of 2012 as the Company did not purchase policies through life settlement-related acquisitions in order to conserve capital. As a consequence, the Company’s portfolio of life insurance policies is smaller than previously projected, which may result in more volatility and adversely affect the portfolio’s performance.

In the structured settlements segment, on January 12, 2012, the Company resumed financing term certain structured settlements using its dedicated facility for those receivables after signing an acknowledgement that provided for certain payments in respect of, the transfer of the ownership of certain lock-box accounts associated with the facility. The Company also continued to fund life-contingent structured settlements under a forward purchase and sale arrangement entered into on December 30, 2011. However, this new arrangement compressed the Company’s margins as it required the Company to sell life-contingent structured settlements at a discount rate that was 50 basis points higher than the rate used in the prior facility at September 30, 2012.

The Company has also expended considerable resources in connection with the USAO Investigation, as well as responding to the SEC Investigation, class-action and derivative litigation and, advancing indemnification costs on behalf of certain employees. As of September 30 2012, the Company’s legal and related fees in respect of these matters was $19.6 million, including $12.8 million incurred during the nine months ended September 30, 2012. Moreover, the Company’s D&O carriers have disputed several of the claims and reserved their rights, and the Company’s primary D&O carrier filed a declaratory judgment action on June 13, 2012 seeking a judgment that the claims submitted by the Company are precluded under a prior and pending litigation exemption. While the declaratory judgment action and the class action and derivative litigation may be settled under the framework embodied by the Term Sheet for Global Settlement Regarding Imperial Holdings, Inc. Matters (the “Term Sheet”), which was signed on December 18, 2012, the Company expects that its obligations under the Term Sheet will further strain its liquidity position. See Liquidity and Capital Resources and Item 1A — Risk Factors — Under the terms proposed to settle the Company’s class action, derivative and D&O carrier litigation, the Company will undertake certain indemnification and advancement obligations, which could have a material adverse affect on the Company’s liquidity position.

42

At the time of the Company’s initial public offering, the Company intended to hold the majority of the life insurance policies it acquired to maturity while strategically trading in and out of certain policies. In light of the USAO Investigation, the SEC Investigation, the related shareholder litigation and the related unbudgeted expenses incurred by the Company, the Company is re-examining its strategy and cash management objectives. We estimate that we will need to pay $6.9 million in premiums to keep our current portfolio of life insurance policies in force from September 30, 2012 through December 31, 2012 and an additional $27.8 million to keep the portfolio in force through 2013. As of September 30, 2012, we had approximately $41.8 million of cash and cash equivalents, and marketable securities, including $1.1 million of restricted cash. Additionally, we have not yet experienced the mortalities of insureds or received the resulting death benefits from our life insurance policies (other than from policies with subrogation rights that are not reported on our balance sheet and that are considered contingent assets). We will need to proactively manage our cash in advance of any liquidity shortfall, which we anticipate, based on our current internal forecast, will occur in the second quarter of 2013. We are seeking additional capital to pay the premiums, by means of debt or equity financing and may otherwise raise capital through the sale of some of the policies that we own. We may also seek to reduce our operating expenses in order to preserve the value of our existing portfolio of policies, and/or, under certain scenarios, lapse or sell certain of our policies or some combination of the above. The lapsing of policies, if any, would create losses as the assets would be written down to zero.

Use of Updated Life Expectancies and Change in Mortality Table

In the quarter ended September 30, 2012, the Company began receiving updated life expectancy reports on the insureds represented in the Company’s portfolio of life insurance policies. These reports were ordered from both its historical provider of life expectancy reports, AVS Underwriting LLC (“AVS”), and another third party life expectancy provider, 21st Services, LLC (“21st Services”). The procurement of these reports was undertaken in anticipation of a potential financing transaction as the Company believes that potential lenders in any such financing will likely require updated life expectancy reports and that lenders may establish a loan-to-value ratio or borrowing base in any financing based off of a composite mortality factor or “blend” of life expectancy results furnished by these two providers. Additionally, the Company believes that many participants in the secondary and tertiary markets utilize a blend by these life expectancy providers in pricing life insurance policies and that using a second life expectancy provider mitigates the effects of potential underwriting biases. Having taken these factors into consideration, the Company has determined to input a composite mortality factor based off of AVS and 21st Services into its fair value model at September 30, 2012. See Valuation of Insurance Policies in this Management’s Discussion and Analysis of Financial Condition and Results of Operations.

While the Company is endeavoring to obtain updated life expectancy reports for all of its policies, at September 30, 2012, the Company had only received updated life expectancies for 64 of the 212 policies in its portfolio at that time. Since September 30, 2012 , the Company received updated life expectancies on 79 more policies, which have been blended and inputted in the Company’s fair value model at September 30, 2012. In cases where the Company has not received updated life expectancy reports, the results of original AVS life expectancy reports together with life expectancy reports from 21st Services that were obtained when the original AVS life expectancy reports were obtained have been blended.

As part of the effort to update its entire portfolio, the Company expects to continue to obtain updated life expectancies into the first quarter of 2013. Beginning in the third quarter of 2013, the Company presently intends to endeavor to obtain updated life expectancies on approximately one-eighth of its portfolio each quarter or more frequently if the definitive terms of a financing agreement so require. However, the Company does not expect that it will ever receive updated life expectancy reports on 100% its policies as it anticipates a portion of the insureds represented by its portfolio to be unresponsive to requests for updated medical information, which is generally required by life expectancy providers to determine new life expectancy reports. The Company believes that insureds who have deteriorated in health are generally less likely to be responsive to requests for updated medical information. As a result, the periodic updating of life expectancy reports may conservatively skew fair value estimates lower as any health deteriorations experienced by unresponsive insureds would not be reflected in the life expectancy inputs that are used to calculate the value of the Company’s investment in life settlements.

The input of updated life expectancy reports into the Company’s fair value model has driven a decline of $30.3 million in the fair market value of the Company’s portfolio of life insurance policies, which was partially offset by premium payments, accretion due to the passage of time, and other changes to the Company’s fair value model, which resulted in a net unrealized change in fair value of approximately $17.5 million during the third quarter of 2012. As reported at September 30, 2012, the Company’s portfolio of life insurance policies had a fair market value of $102.3 million, and this amount would have been lower absent the implementation of blended life expectancies from AVS and 21st services on those policies for which life expectancies had been updated. If the 143 policies for which the Company blended updated life expectancy reports in the third quarter were valued solely using updated AVS life expectancy reports, the aggregate fair value of those policies would decrease from $88.5 million to $44.2 million.

43

Additionally, the Company replaced its mortality table with a modified version of the 2008 Valuation Basic Table in the third quarter of 2012 as the third party that developed the Company’s table has ceased operations. The Company believes that the table utilized in the third quarter is consistent with tables used by other market participants and medical underwriters and did not have a material impact on the valuation of the Company’s life insurance policies.

Critical Accounting Policies

Critical Accounting Estimates

The preparation of the financial statements requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our judgments, estimates and assumptions on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions and conditions. We evaluate our judgments, estimates and assumptions on a regular basis and make changes accordingly. We believe that the judgments, estimates and assumptions involved in the accounting for the loan impairment valuation, allowance for doubtful accounts, income taxes, valuation of structured settlements and the valuation of investments in life settlements have the greatest potential impact on our financial statements and accordingly believe these to be our critical accounting estimates. Below we discuss the critical accounting policies associated with the estimates, as well as selected other critical accounting policies.

Life Finance Loans Receivable

We report loans receivable acquired or originated by us at cost, adjusted for any deferred fees or costs in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 310-20, Receivables—Nonrefundable Fees and Other Costs, discounts, and loan impairment valuation. All loans are collateralized by life insurance policies. Interest income is accrued on the unpaid principal balance on a monthly basis based on the applicable rate of interest on the loans.

In accordance with ASC 310, Receivables, we specifically evaluate all loans for impairment based on the fair value of the underlying policies as collectability is primarily collateral dependent. The loans are considered to be collateral dependent as the repayment of the loans is expected to be provided by the underlying insurance policies. In the event of default, the borrower typically relinquishes ownership of the policy to us in exchange for our release of the debt (or we enforce our security interests in the beneficial interests in the trust that owns the policy). For loans that have lender protection insurance, we make a claim against the lender protection insurance policy and, subject to terms and conditions of the lender protection insurance policy, our lender protection insurer has the right to direct control or take beneficial ownership of the policy upon payment of our claim. For loans without lender protection insurance, we have the option of selling the policy or maintaining it on our balance sheet for investment.

We evaluate the loan impairment valuation on a monthly basis based on our periodic review of the estimated value of the underlying collateral. This evaluation is inherently subjective as it requires estimates that are susceptible to significant revision as more information becomes available. The loan impairment valuation is established as losses on loans are estimated and the provision is charged to earnings. Once established, the loan impairment valuation cannot be reversed to earnings.

In order to originate premium finance transactions our lenders required that we procure lender protection insurance. This lender protection insurance mitigates our exposure to losses which may be caused by declines in the fair value of the underlying policies. At the end of each reporting period, for loans that have lender protection insurance, a loan impairment valuation is established if the carrying value of the loan receivable exceeds the amount of coverage. The lender protection insurance program was terminated as of December 31, 2010, and all loans originated after December 31, 2010, do not carry lender protection insurance coverage. Thus, for all loans originated in 2011 and beyond, a loan impairment valuation is established if the carrying value of a loan receivable exceeds the fair value of the underlying collateral. The provision for losses on loans receivable has increased during the nine months ended September 30, 2012 as a result of the decline in the estimated fair value of the collateral due to the higher discount rate applied in the fair value model. See Notes 7, 11 and 12 to the accompanying consolidated and combined financial statements.

Fair Value Option

As of July 1, 2010, we elected to adopt the fair value option, in accordance with ASC 825, Financial Instruments, to record newly-acquired structured settlements at fair value. We have the option to measure eligible financial assets, financial liabilities, and commitments at fair value on an instrument-by-instrument basis. This option is available when we first recognize a financial asset or financial liability or enter into a firm commitment. Subsequent changes in the fair value of assets, liabilities, and commitments where we have elected the fair value option are recorded in our consolidated and combined statement of operations. We have made this election for our structured settlement assets because it is our intention to sell these assets within the next twelve months, and we believe it significantly reduces the disparity that exists between the GAAP carrying value of these structured settlements and our estimate of their economic value.

44

Fair Value Measurement Guidance

We follow ASC 820, Fair Value Measurements and Disclosures, which defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions the guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Accordingly, the actual exit price for any Level 3 asset, such as the Company’s investments in life insurance policies, may be substantially higher or lower than the reported valuation for such asset. See Valuation of Insurance Policies. In addition to the Company’s investments in life insurance policies, structured settlements are considered Level 3 assets as there is currently no active market where we are able to observe quoted prices for identical assets and our valuation model incorporates significant inputs that are not observable. Our impaired loans are measured at fair value on a non-recurring basis, as the carrying value is based on the fair value of the underlying collateral. The method used to estimate the fair value of impaired collateral-dependent loans depends on the nature of the collateral. For collateral that has lender protection insurance coverage, the fair value measurement is considered to be Level 3 as the insured value is an observable input to the Company, but not observable to market participants. For collateral that does not have lender protection insurance coverage, the fair value measurement is considered to be Level 3 as the estimated fair value is based on a model whose significant inputs are the life expectancy of the insured and the discount rate, which are not observable.

Ownership of Life Insurance Policies

In the ordinary course of business, a large portion of our borrowers default by not paying off the loan and relinquish ownership of the life insurance policy to us in exchange for our release of the obligation to pay amounts due. We also buy life insurance policies in the secondary and tertiary markets. We account for life insurance policies that we own as investments in life settlements (life insurance policies) in accordance with ASC 325-30, Investments in Insurance Contracts, which requires us to use either the investment method or the fair value method. The election is made on an instrument-by-instrument basis and is irrevocable. We have elected to account for these life insurance policies as investments using the fair value method.

We initially record investments in life settlements at the transaction price. For policies acquired upon relinquishment by our borrowers, we determine the transaction price based on fair value of the acquired policies at the date of relinquishment. The difference between the net carrying value of the loan and the transaction price is recorded as a gain (loss) on loan payoffs and settlement. For policies acquired for cash, the transaction price is the amount paid.

45

Valuation of Insurance Policies

Our valuation of insurance policies is a critical component of our estimate for the loan impairment valuation and the fair value of our investments in life settlements (life insurance policies). We currently use a probabilistic method of valuing life insurance policies, which we believe to be the preferred valuation method in the industry. The most significant assumptions which we estimate are the life expectancy of the insured and the discount rate.

In determining the life expectancy estimate, we analyze medical reviews from independent secondary market life expectancy providers (each a “LE provider”). An LE provider reviews the medical records and identifies all medical conditions it feels are relevant to the life expectancy of the insured. Debits and credits are then assigned by each LE provider to the individual’s health based on these medical conditions. The debit or credit that an LE provider assigns to a medical condition is derived from the experience of mortality attributed to this condition in the portfolio of lives that it monitors. The health of the insured is summarized by the LE provider into a life assessment of the individual’s life expectancy expressed both in terms of months and in mortality factor.

The resulting mortality factor represents an indication as to the degree to which the given life can be considered more or less impaired than a standard life having similar characteristics (e.g. gender, age, smoking, etc.). For example, a standard insured (the average life for the given mortality table) would carry a mortality rating of 100%. A similar but impaired life bearing a mortality rating of 200% would be considered to have twice the chance of dying earlier than the standard life. Historically, the Company has procured the majority of its life expectancy reports from two life expectancy report providers and only used AVS life expectancy reports for valuation purposes. Beginning in the quarter ended September 30, 2012, the Company began utilizing life expectancy reports from 21st Services for valuation purposes and began averaging or “blending,” the results of the two life expectancy reports to establish a composite mortality factor. However, when “blending” the AVS and 21st Services life expectancy reports, if the probability of mortality between the reports is greater than 150%, the Company will reduce the higher mortality factor until the difference is 150%.

The probability of mortality for an insured is then calculated by applying the blended life expectancy estimate to a mortality table. The mortality table is created based on the rates of death among groups categorized by gender, age, and smoking status. By measuring how many deaths occur before the start of each year, the table allows for a calculation of the probability of death in a given year for each category of insured people. The probability of mortality for an insured is found by applying the mortality rating from the life expectancy assessment to the probability found in the actuarial table for the insured’s age, sex and smoking status. As discussed above in Use of Updated Life Expectancies and Change in Mortality Table in Management’s Discussion and Analysis of Financial Condition and Results of Operations, the Company has historically applied an actuarial table developed by a third party. However, beginning in the quarter ended September 30, 2012, the Company transitioned to a table developed by the U.S. Society of Actuaries known as the 2008 Valuation Basic Table, or the 2008 VBT. However, because the 2008 VBT table does not account for anticipated improvements in mortality in the insured population, the table was modified by outside consultants to reflect these expected mortality improvements. The Company believes that the change in mortality table does not materially impact the valuation of its life insurance policies and that its adoption of a modified 2008 VBT table is consistent with modified tables used by market participants and third party medical underwriters. The Company believes that the change in mortality table does not materially impact the valuation of its life insurance policies and that its adoption of a modified 2008 VBT table is consistent with modified tables used by market participants and third party medical underwriters.

The mortality rating is used to create a range of possible outcomes for the given life and assign a probability that each of the possible outcomes might occur. This probability represents a mathematical curve known as a mortality curve. This curve is then used to generate a series of expected cash flows over the remaining expected lifespan of the insured and the corresponding policy. A discounted present value calculation is then used to determine the price of the policy. If the insured dies earlier than expected, the return will be higher than if the insured dies when expected or later than expected.

The calculation allows for the possibility that if the insured dies earlier than expected, the premiums needed to keep the policy in force will not have to be paid. Conversely, the calculation also considers the possibility that if the insured lives longer than expected, more premium payments will be necessary. Based on these considerations, each possible outcome is assigned a probability and the range of possible outcomes is then used to create a price for the policy.

As is the case with most market participants, the Company now uses a blend of life expectancies that are provided by two third-party LE providers. These are estimates of an insured’s remaining years. If all of the insured lives in the Company’s life settlement portfolio live six months shorter or longer than the life expectancies provided by these third parties, the change in fair market value would be as follows (dollars in thousands):

Life Expectancy Months Adjustment	Value		Change in Value
+6		85,305		(17,023	)
—		102,328		—
-6		120,596		18,268

        As noted above, the Company takes an average, or blend, of the two life expectancy reports to derive a composite mortality factor, unless the probability of mortality between the reports is greater than 150%. In such instances and as reflected in the fair market value at September 30, 2012, the Company will cap the higher mortality factor at amount that is 150% above the lower mortality factor , which ultimately reduces the mortality factor inputted into the Company’s fair value model. At September 30, 2012, had the Company not implemented such a cap on affected policies, the fair value of the Company’s portfolio would have increased from the reported amount by $9.2 million.

46

The Company believes that investors in esoteric assets such as life insurance policies typically target yields averaging between 12%—17% for investments of more than a 5 year duration, and had historically used a 15%—17% range of discount rates to value its life insurance policies. In the third quarter of 2011 and in the immediate aftermath of becoming aware of the USAO investigation, the Company substantially increased the discount rates inputted into its fair value model as it believed that USAO Investigation along with certain unfavorable court decisions unrelated to the Company contributed to a contraction in the marketplace that has continued to reverberate. Since that time, the Company has been re-evaluating its discount rates at the end of every reporting period in order to reflect the estimated discount rates that could reasonably be used in a market transaction involving the Company’s portfolio of life insurance policies. In doing so, the Company relies on management insight, engages third party consultants to corroborate its assessment, engages in discussions with other market participants and potential financing sources and extrapolates the discount rate underlying actual sales of policies.

Although the Company believes that its entry into the Non-Prosecution Agreement had a positive effect on the market generally and for premium financed life insurance policies specifically, the Company believes that, when given the choice to invest in a policy that was associated with the Company’s premium finance business and a similar policy without such an association, all else being equal, an investor would have generally opted to invest in the policy that was not associated with the Company’s premium finance business. However, since entering into the Non-Prosecution Agreement, investors have required less of a risk premium to transact in these policies and the Company expects that, in time, investors will continue to require less of a risk premium to transact in policies associated with its premium finance business. Accordingly, the Company expects that its discount rates for policies associated with its premium finance business will continue to decrease in future periods.

As of September 30, 2012, the Company owned 212 policies with an aggregate investment in life settlements of $102.3 million. Of these 212 policies, 169 were previously premium financed and are valued using discount rates that range from 20.05% –30.65%. The remaining 43 policies are valued using a discount rate of 18.05%.

The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require. The extent to which the fair value could vary in the near term has been quantified by evaluating the effect of changes in the weighted average discount rate on the death benefit used to estimate the fair value. If the weighted average discount rate were increased or decreased by 1/2 of 1% and the other assumptions used to estimate fair value remained the same, the change in fair market value would be as follows (dollars in thousands):

Weighted Average Rate	Rate Adjustment			Value		Change in Value
24.11%		-.50	%		104,992		2,663
24.61%		—			102,328		—
25.11%		+.50	%		99,769		(2,560	)

Future changes in the discount rates we use to value life insurance policies could have a material effect on our yield on life settlement transactions, which could have a material adverse effect on our business, financial condition and results of our operations.

At the end of each reporting period we re-value the life insurance policies using our valuation model in order to update our loan impairment valuation for loans receivable and our estimate of fair value for investments in policies held on our balance sheet. This includes reviewing our assumptions for discount rates and life expectancies as well as incorporating current information for premium payments and the passage of time.

Revenue/Income Recognition

Our primary sources of revenue/income are in the form of unrealized change in fair value of life settlements, agency fees, interest income, origination fee income, servicing income and realized gains on sales of structured settlements. Our revenue/income recognition policies for these sources of revenue/income are as follows:

• Unrealized Change in Fair Value of Life Settlements—The Company acquires certain life insurance policies through purchases in the secondary and tertiary markets and others as a result of certain of the Company’s borrowers defaulting on premium finance loans and relinquishing the underlying policy to the Company in exchange for being released from further obligations under the loan. We initially record these investments at the transaction price, which is the fair value of the policy for those acquired upon relinquishment or the amount paid for policies acquired for cash. The fair value of the investment in insurance policies is evaluated at the end of each reporting period. Changes in the fair value of the investment based on evaluations are recorded as changes in fair value of life settlements in our consolidated and combined statement of operations. The fair value is determined on a discounted cash flow basis that incorporates current life expectancy assumptions. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require.

• Agency Fees—Agency fees are paid by the referring life insurance agents based on negotiations between the parties and are recognized at the time a life finance loan is funded. Because agency fees are not paid by the borrower, such fees do not accrue over the term of the loan. A separate origination fee is charged to the borrower which is amortized into income over the life of the loan.

• Interest Income—Interest income on life finance loans is recognized when it is realizable and earned, in accordance with ASC 605, Revenue Recognition. Discounts on structured settlement receivables are accreted over the life of the settlement using the effective interest method.

• Origination Fee Income—Loans often include origination fees which are fees payable to us on the date the loan matures. The fees are negotiated at the inception of the loan on a transaction by transaction basis. The fees are accreted into income over the term of the loan using the effective interest method.

• Servicing Income—We receive income from servicing life insurance policies controlled by a third party. These services include verifying premiums are paid and correctly applied and updating files for medical history and ongoing premiums.

• Realized Gains on Sales of Structured Settlements—Realized gains on sales of structured settlements are recorded when the structured settlements have been transferred to a third party and we no longer have continuing involvement, in accordance with ASC 860, Transfers and Servicing.

Interest and origination income on impaired loans is recognized when it is realizable and earned in accordance with ASC 605, Revenue Recognition. Persuasive evidence of an arrangement exists through a loan agreement which is signed by a borrower prior to funding and sets forth the agreed upon terms of the interest and origination fees. Interest income and origination income are earned over the term of the loan and are accreted using the effective interest method. The interest and origination fees are fixed and

47

determinable based on the loan agreement. For impaired loans, we do not recognize interest and origination income which we believe is uncollectible. At the end of the reporting period, we review the accrued interest and accrued origination fees in conjunction with our loan impairment analysis to determine our best estimate of uncollectible income that is then reversed. We continually reassess whether the interest and origination income are collectible as the fair value of the collateral typically increases over the term of the loan. Since our loans are due upon maturity, we cannot determine whether a loan is performing or non-performing until maturity. For impaired loans, our estimate of proceeds to be received upon maturity of the loan is generally correlated to our current estimate of fair value of the collateral, but also incorporates expected increases in fair value of the collateral over the term of the loan, trends in the market, sales activity for life insurance policies and our experience with loans payoffs.

Deferred Costs

Deferred costs include costs incurred in connection with acquiring and maintaining credit facilities and costs incurred in connection with securing lender protection insurance. These costs are amortized over the life of the related loan using the effective interest method and are classified as amortization of deferred costs in the accompanying consolidated and combined statement of operations.

Loss in Loan Payoffs and Settlements, Net

When a premium finance loan matures, we record the difference between the net carrying value of the loan and the cash received, or the fair value of the life insurance policy that is obtained in the event of payment default, as a gain or loss on loan payoffs and settlements, net.

Income Taxes

The Company and its subsidiaries are subject to U.S. federal income tax as well as to income tax in Florida and other states in which it operates.

Except as noted below, our provision for income taxes is estimated to result in an annual effective tax rate of 0.0% in 2012, except as noted below. The 0.0% effective tax rate is a result of our recording of a valuation allowance for those deferred tax assets that are not expected to be recovered in the future. Due to large losses in 2011, the uncertainties that resulted from the USAO Investigation and expectation of taxable losses in the foreseeable future, we may not have sufficient taxable income of the appropriate character in the future to realize any portion of the net deferred tax asset.

Generally, the amount of tax expense or benefit allocated to continuing operations is determined without regard to the tax effects of other categories of income or loss, such as other comprehensive income. However, an exception to the general rule is provided when, in the presence of a valuation allowance against deferred tax assets, there is a pretax loss from continuing operations and pretax income from other categories. In such instances, income from other categories must offset the current loss from operations, the tax benefit of such offset being reflected in continuing operations. For the period ended September 30, 2012 we reduced the deferred tax valuation allowance from continuing operations by $46,000 to reflect the future taxable income associated with unrealized gains in accumulated other comprehensive income.

On February 3, 2011, we converted from a Florida limited liability company to a Florida corporation (the “Conversion”). Prior to the Conversion we were treated as a partnership for federal and state income tax purposes. As a partnership our taxable income and losses were attributed to our members, and accordingly, no provision or liability for income taxes was reflected in the accompanying consolidated financial statements for periods prior to the Conversion. As a result of the Conversion, we recorded a one-time deferred tax liability of approximately $4.4 million for the federal and state tax effects of cumulative differences between financial and tax reporting which existed at the time of the conversion. Pursuant to ASC 740 these deferred taxes were recorded in income tax expense for the first quarter of 2011. In the second quarter of 2011, the deferred tax liability was increased by $175,000 to account for changes in the estimated differences at the date of conversion. In addition, following the conversion and prior to the initial public offering, one of the founding members entered into a reorganization that allowed the company to assume the corporate shareholder’s tax attributes. These tax attributes include approximately $11.2 million of net operating loss carryovers (“NOLs”). During the second quarter, we completed an evaluation of this transaction and determined that we were entitled to assume the NOLs of this founding member. Accordingly, in the second quarter we recorded a one-time deferred tax asset of approximately $4.3 million related to these tax attributes and this amount was recorded as an income tax benefit during that period. For the post-conversion period ended September 30, 2011, we used an estimated annual effective tax rate of 38.6% resulting in a tax provision of $1.1 million. For the third quarter ended September 30, 2011 the total provision was $1.4 million.

At September 30, 2012, income taxes payable includes an estimated liability for unrecognized tax benefits of $6.3 million that related to the Conversion and was charged to paid-in-capital in the first quarter of 2011.

48

Stock-Based Compensation

We have adopted ASC 718, Compensation—Stock Compensation. ASC 718 addresses accounting for share-based awards, including stock options, with compensation expense measured using fair value and recorded over the requisite service or performance period of the award. The fair value of equity instruments awarded upon or after the closing of our initial public offering will be determined based on a valuation using an option pricing model which takes into account various assumptions that are subjective. Key assumptions used in the valuation will include the expected term of the equity award taking into account both the contractual term of the award, the effects of expected exercise and post-vesting termination behavior, expected volatility, expected dividends and the risk-free interest rate for the expected term of the award.

Investment Securities Available for Sale

Investment securities available for sale are carried at fair value, inclusive of unrealized gains and losses, and net of discount accretion and premium amortization computed using the level yield method. Net unrealized gains and losses are included in accumulated other comprehensive income (loss) net of applicable income taxes. Gains or losses on sales of investment securities available for sale are recognized on the specific identification basis.

Management evaluates securities for other than-temporary-impairment on a quarterly basis. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the Company’s intent to hold the security until maturity or for a period of time sufficient for a recovery in value, whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, the length of time and extent to which fair value has been less than amortized cost, the historical and implied volatility of the fair value of the security, failure of the issuer of the security to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency and recoveries or additional declines in fair value subsequent to the balance sheet date.

Gain on Maturities of Life Settlements with Subrogation Rights, net

Every credit facility entered into by subsidiaries of the Company between December 2007 and December 2010 to finance the premium finance lending business required lender protection insurance for each loan originated under such credit facility. Generally, when the Company exercises its right to foreclose on collateral the Company’s lender protection insurer has the right to direct control or take beneficial ownership of the life insurance policy, subject to the terms and conditions of the lender protection insurance policy, including notice and timing requirements. Otherwise, the lender protection insurer maintains its salvage collection and subrogation rights. The lender protection insurer’s salvage collection and subrogation rights generally provide a remedy by which the insurer can seek to recover the amount of the lender protection claim paid plus premiums paid by it, expenses and interest thereon.

In those instances where the Company has foreclosed on the collateral, the lender protection insurer has maintained its salvage collection and subrogation rights, and has been covering the cost of the ongoing premiums needed to maintain certain of these life insurance policies. However, the lender protection insurer may elect at any time to discontinue the payment of premiums which would result in lapse of the policies if the Company does not otherwise pay the premiums. The Company views these policies as having uncertain value because the lender protection insurer controls what happens to the policy from a payment of premium standpoint, and the amount of the lender protection insurer’s salvage collection and subrogation claim rights on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. For these reasons, these policies are considered contingent assets and not included in the amount of life settlements on the accompanying consolidated and combined balance sheet.

The Company accounts for the maturities of life settlements with subrogation rights, net of subrogation expenses as contingent gains in accordance with Accounting Standards Codification (ASC) 450, Contingencies and recognizes the revenue from the maturities of these policies when all contingencies are resolved.

Recent Accounting Pronouncements

Note 2 of the Condensed Notes to Consolidated and Combined Financial Statements discusses accounting standards adopted during the nine months ended September 30, 2012, as well as accounting standards recently issued but not yet adopted and the expected impact of these changes in accounting standards. The Company does not expect any material impact from the adoption of such standards.

49

Results of Operations

The following is our analysis of the results of operations for the periods indicated below. This analysis should be read in conjunction with our financial statements, including the related condensed notes to the financial statements. Our results of operations are discussed below in two parts: (i) our consolidated results of operations and (ii) our results of operations by segment.

Imperial Holdings, Inc. and Subsidiaries

CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2012			2011			2012			2011
	(in thousands, except per share data)
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		252			2,289			1,856			7,031
Interest and dividends on investment securities available for sale		72			247			332			441
Origination fee income		45			1,753			483			5,858
Realized gain on sale of structured settlements		2,187			2,240			7,796			5,457
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other income		123			155			989			481
Total income		(14,171	)		(1,763	)		11,978			52,308
Expenses
Interest expense		141			1,660			1,219			7,431
Provision for losses on loans receivable		—			3,583			441			3,712
(Gain) loss on loan payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlement write off		140			—			140			—
Amortization of deferred costs		254			1,409			1,751			4,913
Personnel costs		3,595			4,836			12,317			14,158
Marketing costs		1,034			1,754			4,481			4,185
Legal fees		9,328			1,821			22,918			4,187
Professional fees		1,559			1,452			5,272			4,238
Insurance		626			186			1,712			548
Other selling, general and administrative expenses		771			1,652			2,730			4,173
Total expenses		17,309			18,614			52,995			51,472
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Loss per share:
Basic	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Diluted	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Weighted average shares outstanding:
Basic		21,206,121			21,202,614			21,205,622			18,728,435
Diluted		21,206,121			21,202,614			21,205,622			18,728,435

50

Life Finance Segment Results (in thousands)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2012			2011			2012			2011
	(Unaudited)						(Unaudited)
Income	$	(17,018	)	$	(5,469	)	$	1,206		$	43,647
Expenses		3,682			11,231			14,038			29,162
Segment operating (loss) income	$	(20,700	)	$	(16,700	)	$	(12,832	)	$	14,485

Structured Settlements Segment Results (in thousands)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2012			2011			2012			2011
	(Unaudited)						(Unaudited)
Income	$	2,769		$	3,362		$	9,980		$	8,116
Expenses		5,260			6,901			16,873			15,235
Segment operating loss	$	(2,491	)	$	(3,539	)	$	(6,893	)	$	(7,119	)

Reconciliation of Segment Results to Consolidated Results (in thousands)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Life finance
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		180			2,145			1,613			6,712
Origination income		45			1,753			483			5,858
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other		16			8			175			182
		(17,018	)		(5,469	)		1,206			43,647
Direct segment expenses
Interest expense		140			1,660			1,215			7,135
Provision for losses on loan receivables		—			3,583			441			3,712
(Gain) loss on loans payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlements write off		140			—			140			—
Amortization of deferred costs		255			1,409			1,752			4,913
Personnel costs		1,099			2,192			4,663			5,121
Marketing		—			—			—			16
Legal fees		1,116			803			2,622			1,456
Professional fees		315			460			1,180			1,359
Insurance		313			—			806			133
Other selling, general and administrative expenses		443			863			1,205			1,390
		3,682			11,231			14,038			29,162
Segment operating (loss) income	$	(20,700	)	$	(16,700	)	$	(12,832	)	$	14,485
Structured settlements
Income
Realized gain on sale of structured settlements	$	2,187		$	2,240		$	7,796		$	5,457
Interest income		72			144			243			319
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Other income		101			50			354			195
		2,769			3,362			9,980			8,116
Direct segment expenses
Personnel costs		2,443			2,959			7,033			6,544
Marketing		1,034			1,754			4,481			4,169
Legal fees		527			455			1,671			1,803
Professional fees		615			199			1,527			930
Insurance		313			67			799			216
Other selling, general and administrative expenses		328			1,467			1,362			1,573
		5,260			6,901			16,873			15,235
Segment operating loss	$	(2,491	)	$	(3,539	)	$	(6,893	)	$	(7,119	)
Consolidated
Segment operating (loss) income		(23,191	)		(20,239	)		(19,725	)		7,366
Unallocated income
Other income		78			344			969			545
Unallocated expenses
Interest expense		—			—			3			296
Personnel costs		53			(315	)		621			2,498
Legal fees		7,685			563			18,625			928
Professional fees		629			793			2,565			2,157
Insurance		—			119			107			199
Other selling, general and administrative expenses		—			(678	)		340			997
		8,367			482			22,261			7,075
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)

Three Months Ended September 30, 2012 Compared to Three Months Ended September 30, 2011

Net loss for the three months ended September 30, 2012 was $31.5 million compared to a net loss of $12.6 million for the three months ended September 30, 2011, an increase of $18.9 million. Total income was ($14.2 million) for the three months ended September 30, 2012, compared to a total income of ($1.8 million) for the three months ended in 2011, a decrease of $12.4 million or 689%. Total expenses were $17.3 million for the three months ended September 30, 2012, compared to $18.6 million for the three months ended September 30, 2011.

In our life finance segment, which includes our premium finance business, segment operating income decreased by $11.5 million to ($17.0 million). This is primarily driven by a decrease in gain on maturities of life settlements with subrogation rights, net of $3.2 million, a decrease in change in unrealized fair value of life settlement of $3.4 million, a decreases in interest income of $2.0 million, origination income of $1.7 million, and agency fee income of $937,000.

Life finance segment expenses were $3.7 million during the three months ended September 30, 2012 compared to $11.2 million during the three months ended September 30, 2011, a decline of $7.5 million, or 67%. These declines were driven primarily by provision for losses on loans receivable of $3.6 million, reductions in interest expenses of $1.5 million, $1.2 million in amortization of deferred costs and $1.1 million in personnel costs.

51

Results of operations in our life finance segment continued to be adversely impacted by the fallout from the USAO Investigation and related matters. Shortly after the Company was informed on September 27, 2011 that its premium finance loan business was the subject of the USAO Investigation, the Company decided to suspend originating new premium finance loans. In connection with the Non-Prosecution Agreement, we voluntarily terminated our premium finance business and, once the premium finance loans on our balance sheet mature, we will no longer have any revenue generated from interest income, origination income and agency fees.

During the three months ended September 30, 2012, we originated no loans, compared to 8 loans originated during the three months ended September 30, 2011. This decrease in number of loans originated resulted in a reduction in agency fees from $937,000 during the three months ended September 30, 2011 to $0 during the three months ended September 30, 2012. As of September 30, 2012, we had loans receivable totaling $5.4 million compared to $46.4 million as of September 30, 2011, a decrease of $41.0 million, or 88%. Loans outstanding declined from 179 to 31. As a result, origination income and interest income, which accrue over the life of the loan and are therefore a function of the amount of loans outstanding, declined from $1.8 million and $2.1 million, respectively during the three months ended September 30, 2011, to $45,000 and $180,000, respectively, a reduction of $1.7 million and $2.0 million or 94% and 95% respectively, during the same period in 2012.

In the third quarter of 2011, two individuals covered under policies, which were subject to subrogation claims, unexpectedly passed away. The Company collected the death benefit on one of these policies in the amount of $3.2 million, net of subrogation rights during the third quarter of 2011. There were no such transactions during the three months ended September 30, 2012.

Interest expense declined to $140,000 compared to $1.7 million at September 30, 2011, a reduction of $1.5 million or 92%, as notes payable declined from $28.2 million as of September 30, 2011 to $1.2 million as of September 30, 2012 a reduction of $27.0 million or 96%. These notes payable, the majority of which were guaranteed under the lender protection insurance program (“LPIC”) which was discontinued as of December 2010, continue to decline as premium finance loans serving as collateral for these notes mature.

Amortizations of deferred costs, which are comprised primarily of upfront premiums previously paid to the LPIC insurer, were $255,000 during the three months ended September 30, 2012 compared to $1.4 million during the three months ended September 30, 2011, a reduction of $1.1 million or 79%. After December 31, 2010, we ceased originating premium finance loans with LPIC insurance.

As of September 30, 2012, the Company owned 212 policies compared to 170 policies at September 30, 2011, with a fair market value of investment in life settlements of $102.3 million compared to $92.0 million at September 30, 2011, an increase of $10.3 million. During the three months ended September 30, 2012, the Company acquired 9 life insurance policies compared to 52 policies during the three months ended September 30, 2011. Total aggregate death benefit of polices acquired was $43.4 million and $288.4 million for September 30, 2012 and September 30, 2011, respectively. Of the 9 policies acquired during the three months ended September 30, 2012, all 9 were as a result of certain of the Company’s borrowers defaulting on premium finance loans and relinquishing the underlying policy to the Company, compared to 2 policies acquired in the same manner for the three months ended September 30, 2011. As of September 30, 2012, the aggregate death benefit of the Company’s investment in life settlements is $1.1 billion.

Of these 212 policies, 169 were previously premium financed and are valued using discount rates that range from 20.05% – 30.65%. The remaining 43 policies are valued using a discount rate of 18.05%.

Unrealized change in fair value of life settlements was a loss of approximately $17.5 million for the three months ended September 30, 2012 compared to a loss of $14.1 million for the three months ended September 30, 2011, an increase of $3.4 million or 24%. This loss was primarily driven by increased life expectancy inputs to the Company’s fair value model reflected in the updated life expectancy reports procured by the Company in respect of 143 insured lives. These reports showed that, in the aggregate, there was less health impairment and thus longer life expectancies relative to the original life expectancy reports inputted into the Company’s fair value model. This increase was also driven in part by an increase in the weighted average discount rate of 19.51% at September 30, 2011 to 24.61% at September 30, 2012, in addition to a decrease in policy acquisitions during the three months ended September 30, 2012 to 9 polices compared to 52 policies during the three months ended September 30, 2011. Further, the $14.1 million at September 30, 2011 included $3.0 million attributable to revisions made to the application of our valuation technique and assumptions used in our fair value calculation made in the quarter, as described in Note 2, Principles of Consolidation and Basis of Presentation. During the three months ended September 30, 2012, 9 policies were acquired resulting in a loss in unrealized change in fair value of $118,000.

Two updated life expectancy reports show discrepancies with the previously reviewed and relied upon medical records of two insureds, resulting in significant extensions to the insureds’ life expectancies. Unrealized change in fair value of life settlements for these two policies accounted for approximately $3.3 million of the $17.5 million loss for the three months ended September 30, 2012.

In our structured settlements segment, income was $2.8 million for the three months ended September 30, 2012 compared to $3.4 million for the three months ended September 30, 2011, a decrease of $600,000 or 18%. This was due to lower gain per deal in 2012 compared to 2011, this lower gain was attributable to the Company’s decision to increase market share by focusing on acquiring deals that were at the margin unprofitable, in an effort to assure the Company would enjoy repeat transactions with these customers. Furthermore, a substantial minority of the completed transactions during the quarter was shorter in duration and therefore we recorded lower than average gains per average transaction. During the three months ended September 30, 2012, 252 structured settlements were sold which resulted in a gain of $2.2 million compared to 178 structured settlements sold resulting in a gain $2.2 million during the

52

three months ended September 30, 2011. Unrealized change in fair value of structured settlements receivable was $409,000 for the three months ended September 30, 2012 compared to $928,000 for the three months ended September 30, 2011. Unrealized change in fair value of structured settlements receivable generally applies to certain newly-acquired structured settlements. In the normal course of business, these receivables are held on balance sheet at quarter end and are generally sold early in the subsequent quarter.

Segment selling, general and administrative expenses decreased by $1.6 million to $5.3 million as we slowed our expansion costs and refocused the segment on cash flow generation. This segment continues to be characterized by high growth in lead generation and sales as well as high operating costs. This led to a segment operating loss of $2.5 million during the three months ended September 30, 2012 compared to segment operating losses of $3.5 million recorded during the three months ended September 30, 2011. Significant expense decreases were advertising expenses of $720,000 and payroll and related costs of $516,000 which is attributable to a reduction of direct and indirect head count.

Non-direct segment expense was $8.4 million compared to $482,000 for the three months ended September 30, 2012, an increase of $7.9 million This is primarily driven by increases in legal fees of $7.1 million of which $2.0 million is mainly associated with the USAO Investigation and $5.1 million associated with the proposed settlement of the class action settlement and derivative actions.

Our provision for income taxes is estimated to result in an annual effective tax rate of 0.0% in 2012. The 0.0% effective tax rate is a result of our recording of a valuation allowance for those deferred tax assets that are not expected to be recovered in the future. Due to large losses in 2011, the uncertainties that resulted from the USAO Investigation and expectation of taxable losses in the foreseeable future, we may not have sufficient taxable income of the appropriate character in the future to realize any portion of the net deferred tax asset.

Upon the implementation of ASC 740 in 2011, the Company recorded a one-time deferred tax liability of approximately $4.4 million for the federal and state tax effects of cumulative differences between financial and tax reporting which existed at the time of the Conversion. For the post-conversion period ended September 30, 2011, we used an estimated annual effective tax rate of 38.6% resulting in a tax provision of $1.1 million. For the quarter ended September 30, 2011, the total provision was $1.4 million.

The Company has also expended considerable resources resolving the USAO Investigation, as well as defending itself in the SEC investigation and related litigation, advancing indemnification costs on behalf of certain employees and in conducting an independent investigation of the facts and circumstances surrounding the USAO Investigation. As of September 30, 2012, the Company’s cumulative legal and related fees in respect of these matters were $19.6 million, including $2.6 million incurred during the quarter ending September 30, 2012.

Nine Months Ended September 30, 2012 Compared to Nine Months Ended September 30, 2011

Net loss for the nine months ended September 30, 2012 was $41.0 million compared to a net loss of $516,000 for the nine months ended September 30, 2011, an increase of $41.5 million. Total income was $12.0 million for the nine months ended September 30, 2012, compared to $52.3 million for the nine months ended in 2011, a reduction of $40.3 million or 77%. Total expenses were $53.0 million for the nine months ended September 30, 2012, compared to $51.5 million for the nine months ended September 30, 2011, an increase of $1.5 million, or 3%.

In our life finance segment, which includes our premium finance business, segment operating profit decreased by $27.3 million to a loss of $12.8 million. This is primarily driven by a decrease in unrealized change in fair value in life settlements of $23.2 million, decreases in agency fee income of $6.6 million, origination income of $5.4 million, interest income of $5.1 million, and forgiveness of debt of $4.9 million. These were offset by a decrease in interest expense of $5.9 million, loss on loan payoffs and settlements, net of $3.9 million, decrease in provision for loss on loans receivable of $3.3 million, and an increase in maturity of life settlements with subrogation rights, net of 2.9 million.

Life finance segment expenses were $14.0 million during the nine months ended September 30, 2012 compared to $29.2 million during the nine months ended September 30, 2011, a decline of $15.2 million, or 52%. These declines were driven primarily by a reduction in interest expense of $5.9 million, loss on loan payoffs and settlements, net of $3.9 million, provision for loss on loans receivable of $3.3 million and amortization of deferred costs of $3.2 million. These declines were offset by an increase in legal fees of $1.2 million.

Results of operations in our life finance segment were adversely impacted by the USAO Investigation and related matters. Once the premium finance loans on our balance sheet mature, we will no longer have any revenue generated from interest income, origination income and agency fees.

Shortly after the Company was informed on September 27, 2011 that its premium finance loan business was the subject of the USAO Investigation, the Company decided to suspend originating new premium finance loans. During the nine months ended September 30, 2012, we originated no loans, compared to 55 loans originated during the nine months ended September 30, 2011. This

53

decrease in number of loans originated resulted in a reduction in agency fees from $6.6 million during the nine months ended September 30, 2011 to $0 during the nine months ended September 30, 2012. As of September 30, 2012, we had loans receivable totaling $5.4 million compared to $46.4 million as of September 30, 2011, a decrease of $41.0 million, or 88%. Loans outstanding declined from 179 to 31. As a result, origination income and interest income, which accrue over the life of the loan and are therefore a function of the amount of loans outstanding, declined from $5.9 million and $6.7 million, respectively during the nine months ended September 30, 2011, to $483,000 and $1.6 million, respectively, a reduction of $5.4 million and $5.0 million or 92% and 75% respectively, during the same period in 2012.

In the third quarter of 2011, two individuals covered under policies which were subject to subrogation claims unexpectedly passed away. The Company collected the death benefit on one of these policies in the amount of $3.2 million, net of subrogation expense during the third quarter of 2011. In the nine months ended September 30, 2012, the Company negotiated a settlement in respect of the larger policy and collected approximately $6.1 million, net of subrogation expenses, and has reported a gain in accordance with ASC 450, Contingencies in its consolidated and combined statement of operations for the nine months ended September 30, 2012 as all contingencies were resolved.

Interest expense declined to $1.2 million compared to $7.1 million at September 30, 2011, a reduction of $5.9 million or 83%, as notes payable declined from $28.2 million as of September 30, 2011 to $1.2 million as of September 30, 2012 a reduction of $27.0 million or 96%. These notes payable, the majority of which were guaranteed under LPIC which was discontinued as of December 2010, continue to decline as premium finance loans serving as collateral for these notes mature.

Provision for losses on loans receivable was $441,000 during the nine months ended September 30, 2012, compared to $3.7 million during the nine months ended September 30, 2011, a decrease of $3.3 million or 89%. This provision records loan impairments on existing loans in order to adjust the carrying value of the loan receivable to the fair value of the underlying policy. The provision for losses on loans receivable was $441,000 because three loans have been delayed in being paid off for the nine months ended September 30, 2012. See Note 12 to the accompanying consolidated and combined financial statements.

Amortizations of deferred costs, which are comprised primarily of upfront premiums previously paid to the LPIC insurer, were $1.8 million during the nine months ended September 30, 2012 compared to $4.9 million during the nine months ended September 30, 2011, a reduction of $3.1 million or 63%. After December 31, 2010, we ceased originating premium finance loans with LPIC insurance.

As of September 30, 2012, the Company owned 212 policies compared to 170 policies at September 30, 2011, with a fair market value of investment in life settlements of $102.3 million compared to $92.0 million at September 30, 2011, an increase of $10.3 million or 11%. During the nine months ended September 30, 2012, the Company acquired 29 life insurance policies compared to 131 policies during the nine months ended September 30, 2011. Total aggregate death benefit of polices acquired was $151.0 million and $662.3 million for September 30, 2012 and September 30, 2011, respectively. The 29 policies acquired during the nine months ended September 30, 2012, 27 were as a result of certain of the Company’s borrowers defaulting on premium finance loans and relinquishing the underlying policy to the Company, compared to 2 policies acquired in the same manner for the nine months ended September 30, 2011. As of September 30, 2012, the aggregate death benefit of the Company’s investment in life settlements is $1.1 billion.

Of these 212 policies, 169 were previously premium financed and are valued using discount rates that range from 20.05% – 30.65%. The remaining 43 policies are valued using a discount rate of 18.05%.

Unrealized change in fair value of life settlements was a loss of approximately $8.4 million for the nine months ended September 30, 2012 compared to a gain of $14.8 million for the nine months ended September 30, 2011, a decrease of $23.2 million or 157%. This loss was primarily driven by increased life expectancy inputs to the Company’s fair value model reflected in the updated life expectancy reports procured by the Company in respect of 143 insured lives. These reports showed that, in the aggregate, there was less health impairment and thus longer life expectancies relative to the original life expectancy reports inputted into the Company’s fair value model. This increase was also driven in part by an increase in the weighted average discount rate of 19.51% at September 30, 2011 to 24.61% at September 30, 2012, in addition to a decrease in policy acquisitions during the nine months ended September 30, 2012 to 29 polices compared to 131 policies during the nine months ended September 30, 2011. Further, the $14.8 million at September 30, 2011 included $3.0 million attributable to revisions made to the application of our valuation technique and assumptions used in our fair value calculation made in the third quarter, as described in Note 2, Principles of Consolidation and Basis of Presentation. During the nine months ended September 30, 2012, 29 policies were acquired resulting in a decrease an unrealized change in fair value of $114,000 and 6 polices were sold resulting in a gain of $291,000.

In our structured settlements segment, income was $10.0 million for the nine months ended September 30, 2012 compared to $8.1 million for the nine months ended September 30, 2011, an increase of $1.8 million or 22%. This was due to an increase in the number of transactions sold. During the nine months ended September 30, 2012, 980 structured settlements were sold which resulted in a gain of $7.8 million compared to 586 structured settlements sold resulting in a gain $5.5 million during the nine months ended September 30, 2011. Unrealized change in fair value of structured settlements receivable was $1.6 million for the nine months ended September 30, 2012 compared to $2.1 million for the nine months ended September 30, 2011.

Segment selling, general and administrative expenses increased by $1.6 million to $16.9 million as we continued to build our infrastructure and expand market share. This segment continues to be characterized by high growth in lead generation and sales as well as high operating costs. Further, segment financing costs remains high as a result of the USAO Investigation and our challenge in negotiating more favorable financing terms. This led to a segment operating loss of $6.9 million during the nine months ended September 30, 2012 a decrease of $226,000 over segment operating loss of $7.1 million recorded during the nine months ended September 30, 2011. Significant expense increases were marketing costs of $312,000 associated with increased promotional activities to drive new business, personnel costs of $489,000, professional fees of $597,000 and D&O insurance of $583,000.

54

Non-direct segment expense was $22.3 million compared to $7.1 million for the nine months ended September 30, 2012, an increase of $15.2 million. This is primarily driven by increases in legal fees of $17.7 million of which $13.6 million is mainly associated with the USAO Investigation and $5.1 million associated with the proposed settlement of the class action settlement and derivative action: this was offset by a reduction in personnel cost of $1.9 million associated with a redistribution of costs directly to Company segments.

Our provision for income taxes is estimated to result in an annual effective tax rate of 0.0% in 2012. The 0.0% effective tax rate is a result of our recording of a valuation allowance for those deferred tax assets that are not expected to be recovered in the future. Due to large losses in 2011, the uncertainties that resulted from the USAO Investigation and present expectations of taxable losses in the foreseeable future, we may not have sufficient taxable income of the appropriate character in the future to realize any portion of the net deferred tax asset.

Upon the implementation of ASC 740 in 2011, the Company recorded a one-time deferred tax liability of approximately $4.4 million for the federal and state tax effects of cumulative differences between financial and tax reporting which existed at the time of the Conversion. Pursuant to ASC 740, these deferred taxes were recorded in income tax expense during the nine months ended September 30, 2011. For the post-conversion period ended September 30, 2011, we used an estimated annual effective tax rate of 38.6% resulting in a tax provision of $1.1 million. For the quarter ended September 30, 2011, the total provision was $1.4 million.

The Company has also expended considerable resources resolving the USAO Investigation, as well as responding to the SEC investigation and related litigation, advancing indemnification costs on behalf of certain employees and in conducting an independent investigation of the facts and circumstances surrounding the USAO Investigation. As of September 30, 2012, the Company’s cumulative legal and related fees in respect of these matters were $19.6 million, including $12.8 million incurred during the nine months ending September 30, 2012.

We operate our business through two reportable segments: life finance and structured settlements. Our segment data discussed below may not be indicative of our future operations.

55

Life Finance Business

Our results of operations for our life finance segment for the periods indicated are as follows (in thousands):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Life finance
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		180			2,145			1,613			6,712
Origination income		45			1,753			483			5,858
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other		16			8			175			182
		(17,018	)		(5,469	)		1,206			43,647
Direct segment expenses
Interest expense		140			1,660			1,215			7,135
Provision for losses on loan receivables		—			3,583			441			3,712
(Gain) loss on loans payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlements write off		140			—			140			—
Amortization of deferred costs		255			1,409			1,752			4,913
Personnel costs		1,099			2,192			4,663			5,121
Marketing		—			—			—			16
Legal fees		1,116			803			2,622			1,456
Professional fees		315			460			1,180			1,359
Insurance		313			—			806			133
Other selling, general and administrative expenses		443			863			1,205			1,390
		3,682			11,231			14,038			29,162
Segment operating (loss) income	$	(20,700	)	$	(16,700	)	$	(12,832	)	$	14,485

56

The following table highlights certain selected operating data in our life finance segment for the periods indicated (in thousands except number of loans percentage, age and life expectancy):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Period Acquisitions—Policies Owned
Number of policies acquired		9			52			29			131
Average age of insured at acquisition		76.1			78.4			75.1			78.2
Average life expectancy—Calculated LE (Years)		12.7			10.1			13.4			10.1
Average death benefit	$	4,817		$	5,547		$	5,206		$	5,056
Aggregate purchase price	$	2,255		$	24,451		$	5,034		$	50,155
End of Period—Policies Owned
Number of policies owned		212			170			212			170
Average Life Expectancy—Calculated LE (Years)		10.5			10.5			10.5			10.5
Aggregate Death Benefit	$	1,058,156		$	853,492		$	1,058,156		$	853,492
Aggregate fair value	$	102,328		$	91,967		$	102,328		$	91,967
Monthly premium—average per policy	$	10.9		$	11.0		$	10.9		$	11.0
End of Period Loan Portfolio
Loans receivable, net	$	5,394		$	46,446		$	5,394		$	46,446
Number of policies underlying loans receivable		31			179			31			179
Aggregate death benefit of policies underlying loans receivable	$	135,725		$	868,752		$	135,725		$	868,752
Number of loans with insurance protection		11			121			11			121
Loans receivable, net (insured loans only)	$	1,821		$	29,923		$	1,821		$	29,923
Average Per Loan:
Age of insured in loans receivable		75.8			75.2			75.8			75.2
Life expectancy of insured (years)		15.2			15.2			15.2			15.2
Monthly premium	$	6		$	6		$	6		$	6
Loan receivable, net	$	186		$	259		$	186		$	259
Interest rate		12.9	%		12.2	%		12.9	%		12.2	%
Period Originations:
Number of loans originated (by type):
Type 1*		—			6			—			44
Type 2**		—			2			—			11
Principal balance of loans originated	$	—		$	2,549		$	—		$	18,385
Aggregate death benefit of policies underlying loans originated	$	—		$	38,000		$	—		$	311,850
Average Per Origination During Period:
Age of insured at origination		—			76.0			—			75.7
Life expectancy of insured (years)		—			13.8			—			14.5
Monthly premium (year of origination)	$	—		$	7		$	—		$	11
Death benefit of policies underlying loans originated	$	—		$	4,750		$	—		$	5,377
Principal balance of the loan	$	—		$	319		$	—		$	334
Interest rate charged		—			14.0	%		—			14.0	%
Agency fee	$	—		$	118		$	—		$	110
Agency fee as % of principal balance
Type 1*		—			43.4	%		—			39.0	%
Type 2**		—			29.1	%		—			20.7	%
Origination fee	$	—		$	80		$	—		$	80
Annualized origination fee as % of principal balance		—			18.9	%		—			24.3	%

57

* We define Type 1 loans as loans that are collateralized by life insurance policies that have been in force less than two years.

** We define Type 2 loans as loans that are collateralized by life insurance policies that have been in force longer than two years.

Three Months ended September 30, 2012 Compared to Three Months Ended September 30, 2011

Income

Agency Fee Income. Agency fee income was $0 for the three months ended September 30, 2012 compared to $937,000 for the three months ended September 30, 2011, a decrease of $937,000. Agency fee income is earned solely as a function of originating loans. We funded no loans during the three months ended September 30, 2012, compared to the 8 loans funded during the three months ended September 30, 2011. As a result of the voluntary termination of our premium finance business, we will not receive any revenue from agency fees in 2012 and beyond. Agency fees as a percentage of the principal balance of the loans (which we refer to in the Form 10-Q as the principal amount loaned without including origination fees or interest) originated during each period was as follows (dollars in thousands):

	For the Three Months Ended
	September 30,
	2012			2011
Principal balance of loans originated	$	—		$	2,549
Number of transactions originated		—			8
Agency fees	$	—		$	937
Agency fees as a percentage of the principal balance of loans originated		0.0	%		36.8	%

Interest Income. Interest income was $180,000 for the three months ended September 30, 2012 compared to $2.1 million for the three months ended September 30, 2011, a decrease of $2.0 million, or 92%. During the quarters ended September 30, 2012 and September 30, 2011, the Company originated zero and 8 loans respectively. Interest income declined as the balance of loans receivable, net decreased from $46.4 million as of September 30, 2011 to $5.4 million as of September 30, 2012 due to significant loan maturities. There were no significant changes in interest rates. The weighted average per annum interest rate for life finance loans outstanding as of September 30, 2012 and 2011 was 13.3% and 12.2%, respectively. As a result of the voluntary termination of our premium finance business, we will cease earning interest income once our outstanding premium finance loans mature.

Origination Fee Income. Origination fee income was $45,000 for the three months ended September 30, 2012, compared to $1.8 million for the three months ended September 30, 2011, a decrease of $1.7 million, or 94%. Origination fee income decreased due to a decline in the average balance of loans receivable, net, as noted above. Origination fees as a percentage of the principal balance of the loans originated was 18.9% for the three months ended September 30, 2011. As a result of the voluntary termination of our premium finance business, we will cease accruing origination fee income once our outstanding premium finance loans mature.

Gain on Forgiveness of Debt. Gain on forgiveness of debt was $0 for the three months ended September 30, 2012 compared to $198,000 for the three months ended September 30, 2011, a decrease of $198,000. These gains arise out of a settlement agreement with Acorn Capital. This facility was terminated during October 2011; accordingly, zero loans out of 119 loans financed in the Acorn facility remained outstanding as of September 30, 2012.

Unrealized Change in Fair Value of Life Settlements. Unrealized change in fair value of life settlements was a loss of approximately $17.5 million for the three months ended September 30, 2012 compared to a loss of $14.1 million for the three months ended September 30, 2011, an increase of $3.4 million or 24%. This loss was primarily driven by increased life expectancy inputs to the Company’s fair value model reflected in the updated life expectancy reports procured by the Company in respect of 143 insured lives. These reports showed that, in the aggregate, there was less health impairment and thus longer life expectancies relative to the original life expectancy reports inputted into the Company’s fair value model. This increase was also driven in part by an increase in the weighted average discount rate of 19.51% at September 30, 2011 to 24.61% at September 30, 2012, in addition to a decrease in policy acquisitions during the three months ended September 30, 2012 to 9 polices compared to 52 policies during the three months ended September 30, 2011. Further, the $14.1 million at September 30, 2011 included $3.0 million attributable to revisions made to the application of our valuation technique and assumptions used in our fair value calculation made in the quarter, as described in Note 2, Principles of Consolidation and Basis of Presentation. During the three months ended September 30, 2012, 9 policies were acquired resulting in an unrealized change in fair value of $118,000.

The discount rates used in the fair value calculation for the three months ended September 30, 2012 ranged from 18.05% to 30.65% an increase from the range 17.25% to 30.85% rates used during the three months ended June 30, 2012. See Note 11 to the accompanying consolidated and combined financial statements.

Servicing Fee Income. Servicing income was $271,000 for the three months ended September 30, 2012 compared to $376,000 for the three months ended September 30, 2011, a decrease of $105,000 or 28%. Servicing fee income was earned in providing asset servicing for third parties, which we began providing during the fourth quarter of 2010. The decrease was primarily due to a reduction in the number of policies serviced.

58

Gain on maturities of life settlements with subrogation rights, net. In the third quarter of 2011, two individuals covered under policies which were subject to subrogation claims unexpectedly passed away. The Company collected the death benefit on one of these policies in the amount of $3.2 million, net of subrogation expense during the third quarter of 2011. There were no such transactions during the three months ended September 30, 2012.

Expenses

Interest Expense. Interest expense was $140,000 for the three months ended September 30, 2012 compared to $1.7 million for the same period in 2011, a decrease of $1.6 million, or 94%. The decrease in interest expense was due to a decline in notes payable from $28.2 million as of September 30, 2011 to $1.2 million as of September 30, 2012, a decrease of $27.0 million, or 96%.

Provision for Losses on Loans Receivable. Provision for losses on loans receivable was $0 for the three months ended September 30, 2012 compared to $3.6 million for the same period in 2011, a decrease of $3.6 million. This provision records loan impairments on existing loans in order to adjust the carrying value of the loan receivable to the fair value of the underlying policy. See Notes 10, 15 and 16 to the accompanying consolidated and combined financial statements.

Gain/Loss on Loan Payoffs and Settlements, Net. Gain on loan payoffs and settlements, net, was $139,000 for the three months ended September 30, 2012 compared to a loss of $261,000 for the same period in 2011, a change of $400,000. In the three months ended September 30, 2012, we wrote off zero loans compared to 1 loan written off in the same period in 2011, all of which were included in the Acorn settlement. Excluding the impact of the Acorn settlements, we had a gain on loan payoffs and settlements, net, of approximately $34,000 for the three months ended September 30, 2011.

Amortization of Deferred Costs. Amortization of deferred costs was $255,000 during the three months ended September 30, 2012 as compared to $1.4 million for the same period in 2011, a decrease of $1.1 million, or 79%. Lender protection insurance related costs accounted for $232,000 and $1.1 million of total amortization of deferred costs during the three months ended September 30, 2012 and 2011, respectively. As described previously, the lender protection insurance program was terminated as of December 31, 2010. 7 loans with lender protection insurance were outstanding at September 30, 2012. Only $100,000 of lender protection insurance related costs remains to be amortized.

Selling, General and Administrative Expenses. Selling, general and administrative expenses (“SG&A”) were $3.3 million for the three months ended September 30, 2012 compared to $4.3 million for the three months ended September 30, 2011, a decrease of $1.0 million or 23%. The decrease is due primarily to a reduction in personnel costs of $1.0 million.

Life Finance Business

Nine Months ended September 30, 2012 Compared to Nine Months Ended September 30, 2011

Income

Agency Fee Income. Agency fee income was $0 for the nine months ended September 30, 2012 compared to $6.6 million for the nine months ended September 30, 2011, a decrease of $6.6 million. Agency fee income is earned solely as a function of originating loans. We funded no loans during the nine months ended September 30, 2012, compared to the 55 loans funded during the nine months ended September 30, 2011. As a result of the voluntary termination of our premium finance business, we will not receive any revenue from agency fees in 2012 and beyond.

59

Agency fees as a percentage of the principal balance of the loans (which we refer to in the Form 10-Q as the principal amount loaned without including origination fees or interest) originated during each period was as follows (dollars in thousands):

	For the Nine Months Ended
	September 30,
	2012			2011
Principal balance of loans originated	$	—		$	18,385
Number of transactions originated		—			55
Agency fees	$	—		$	6,564
Agency fees as a percentage of the principal balance of loans originated		0.0	%		35.7	%

Interest Income. Interest income was $1.6 million for the nine months ended September 30, 2012 compared to $6.7 million for the nine months ended September 30, 2011, a decrease of $5.1million, or 76%. During the nine months ended September 30, 2012 and September 30, 2011, the Company originated zero and 55 loans respectively. Interest income declined as the balance of loans receivable, net decreased from $46.4 million as of September 30, 2011 to $5.4 million as of September 30, 2012 due to significant loan maturities. There were no significant changes in interest rates. The weighted average per annum interest rate for life finance loans outstanding as of September 30, 2012 and 2011 was 13.3% and 12.2%, respectively. As a result of the voluntary termination of our premium finance business, we will cease earning interest income once our outstanding premium finance loans mature.

Origination Fee Income. Origination fee income was $483,000 for the nine months ended September 30, 2012, compared to $5.9 million for the nine months ended September 30, 2011, a decrease of $5.4 million, or 92%. Origination fee income decreased due to a decline in the average balance of loans receivable, net, as noted above. Origination fees as a percentage of the principal balance of the loans originated was 12.7% for the nine months ended September 30, 2011. As a result of the voluntary termination of our premium finance business, we will cease accruing origination fee income once our outstanding premium finance loans mature.

Gain on Forgiveness of Debt. Gain on forgiveness of debt was $0 for the nine months ended September 30, 2012 compared to $4.9 million for the nine months ended September 30, 2011, a decrease of $4.9 million. These gains arise out of a settlement agreement with Acorn Capital. This facility was terminated during October 2011; accordingly, zero loans out of 119 loans financed in the Acorn facility remained outstanding as of September 30, 2012.

Unrealized Change in Fair Value of Life Settlements. Unrealized change in fair value of life settlements was a loss of $8.4 million for the nine months ended September 30, 2012 compared to a gain of $14.8 million for the nine months ended September 30, 2011, an decrease of $23.2 million or 157%. This loss was primarily driven by increased life expectancy inputs to the Company’s fair value model reflected in the updated life expectancy reports procured by the Company in respect of 143 insured lives. These reports showed that, in the aggregate, there was less health impairment and thus longer life expectancies relative to the original life expectancy reports inputted into the Company’s fair value model. This increase was also driven in part by an increase in the weighted average discount rate of 19.51% at September 30, 2011 to 24.61% at September 30, 2012, in addition to a decrease in policy acquisitions during the three months ended September 30, 2012 to 29 polices compared to 131 policies during the three months ended September 30, 2011. Further, the $14.8 million at September 30, 2011 included $3.0 million attributable to revisions made to the application of our valuation technique and assumptions used in our fair value calculation made in the quarter, as described in Note 2, Principles of Consolidation and Basis of Presentation. During the nine months ended September 30, 2012, 9 policies were acquired resulting in an unrealized change in fair value of $118,000

The discount rates used in the fair value calculation for the nine months ended September 30, 2012 ranged from 18.05% to 30.65% an increase from the range 17.25% to 30.85% rates used during the nine months ended June 30, 2012. See Note 11 to the accompanying consolidated and combined financial statements.

Servicing Fee Income. Servicing income was $955,000 for the nine months ended September 30, 2012 compared to $1.4 million for the nine months ended September 30, 2011, a decrease of $492,000 or 34%. Servicing fee income was earned in providing asset servicing for third parties, which we began providing during the fourth quarter of 2010. The decrease was primarily due to a reduction in the number of policies serviced.

Gain on maturities of life settlements with subrogation rights, net. In the third quarter of 2011, two individuals covered under policies which were subject to subrogation claims unexpectedly passed away. The Company collected the death benefit on one of these policies in the amount of $3.2 million, net of subrogation expense during the third quarter of 2011. There were no such transactions during the nine months ended September 30, 2012.

60

Expenses

Interest Expense. Interest expense was $1.2 million for the nine months ended September 30, 2012 compared to $7.1 million for the same period in 2011, a decrease of $5.9 million, or 83%. The decrease in interest expense was due to a decline in notes payable from $28.2 million as of September 30, 2011 to $1.2 million as of September 30, 2012, a decrease of $27.0 million, or 96%.

Provision for Losses on Loans Receivable. Provision for losses on loans receivable was $441,000 for the nine months ended September 30, 2012 compared to $3.7 million for the same period in 2011, a decrease of $3.3 million. This provision records loan impairments on existing loans in order to adjust the carrying value of the loan receivable to the fair value of the underlying policy. See Notes 10, 15 and 16 to the accompanying consolidated and combined financial statements.

Gain/Loss on Loan Payoffs and Settlements, Net loss on loan payoffs and settlements, net, was $14,000 for the nine months ended September 30, 2012 compared to $3.9 million for the same period in 2011, a change of $3.9 million. In the nine months ended September 30, 2012, we wrote off zero loans compared to 1 loan written off in the same period in 2011, all of which were included in the Acorn settlement. Excluding the impact of the Acorn settlements, we had a gain on loan payoffs and settlements, net, of approximately $34,000 for the nine months ended September 30, 2011.

Amortization of Deferred Costs. Amortization of deferred costs was $1.8 million during the nine months ended September 30, 2012 as compared to $4.9 million for the same period in 2011, a decrease of $3.2 million, or 65%. Lender protection insurance related costs accounted for $232,000 and $1.1 million of total amortization of deferred costs during the nine months ended September 30, 2012 and 2011, respectively. As described previously, the lender protection insurance program was terminated as of December 31, 2010. 7 loans with lender protection insurance were outstanding at September 30, 2012. Only $100,000 of lender protection insurance related costs remains to be amortized.

Selling, General and Administrative Expenses. SG&A were $10.5 million for the nine months ended September 30, 2012 compared to $9.5 million for the nine months ended September 30, 2011, an increase of $1.0 million or 11%. The increase is due primarily to legal fees of $1.2 million.

61

Structured Settlements

Our results of operations for our structured settlement business segment for the periods indicated are as follows (in thousands):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Income
Realized gain on sale of structured settlements	$	2,187		$	2,240		$	7,796		$	5,457
Interest income		72			144			243			319
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Other income		101			50			354			195
		2,769			3,362			9,980			8,116
Direct segment expenses
Personnel costs		2,443			2,959			7,033			6,544
Marketing		1,034			1,754			4,481			4,169
Legal fees		527			455			1,671			1,803
Professional fees		615			199			1,527			930
Insurance		313			67			799			216
Other selling, general and administrative expenses		328			1,467			1,362			1,573
		5,260			6,901			16,873			15,235
Segment operating loss	$	(2,491	)	$	(3,539	)	$	(6,893	)	$	(7,119	)
Consolidated
Segment operating (loss) income		(23,191	)		(20,239	)		(19,725	)		7,366
Unallocated income
Other income		78			344			969			545
Unallocated expenses
Interest expense		—			—			3			296
Personnel costs		53			(315	)		621			2,498
Legal fees		7,685			563			18,625			928
Professional fees		629			793			2,565			2,157
Insurance		—			119			107			199
Other selling, general and administrative expenses		—			(678	)		340			997
		8,367			482			22,261			7,075
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)

62

The following table highlights certain selected operating data in our structured settlements segment for the periods indicated (dollars in thousands):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Period Originations:
Number of transactions		253			211			756			618
Number of transactions from repeat customers		94			78			263			218
Weighted average purchase discount rate		18.9	%		17.6	%		18.8	%		18.0	%
Face value of undiscounted future payments purchased	$	34,186		$	26,033		$	99,565		$	67,749
Amount paid for settlements purchased	$	5,604		$	5,774		$	17,519		$	14,425
Marketing costs	$	1,034		$	1,806		$	4,481		$	4,266
Selling, general and administrative (excluding marketing costs)	$	4,226		$	5,095		$	12,392		$	10,969
Average Per Origination During Period:
Face value of undiscounted future payments purchased	$	135		$	123		$	132		$	110
Amount paid for settlement purchased	$	22		$	27		$	23		$	23
Time from funding to maturity (months)		121.9			147.9			129.2			151.9
Marketing cost per transaction	$	4		$	9		$	6		$	7
Segment selling, general and administrative (excluding marketing costs) per transaction	$	17		$	24		$	16		$	18
Period Sales:
Number of transactions originated and sold		252			178			692			586
Realized gain on sale of structured settlements	$	2,187		$	2,243		$	7,796		$	5,460
Average sale discount rate		10.7	%		10.6	%		10.7	%		10.3	%
End of Period Portfolio:
Number of transactions on balance sheet		130			115			130			115

Structured Settlements

Three Months Ended September 30, 2012 Compared to Three Months Ended September 30, 2011

Income

Interest Income. Interest income, comprised solely of accretion on the structured settlements assets held on balance sheet prior to their sale, was $72,000 for three months ended September 30, 2012 compared to $144,000 for the three months ended September 30, 2011, a decrease of $72,000.

Realized Gain on Sale of Structured Settlements. Realized gain on sale of structured settlements was $2.2 million for the three months ended September 30, 2012 compared to $2.2 million for the three months ended September 30, 2011. During the three months ended September 30, 2012, we sold 252 structured settlements for a gain of $2.2 million compared to 178 for a gain of $2.2 million for the three months ended September 30, 2011. Of the 252 structured settlements sold, 198 were originated during the period, and 54 were originated and marked to market during the second quarter of 2012. See Note 10 to the accompanying consolidated and combined financial statements.

Unrealized Change in Fair Value of Structured Settlement Receivables. Unrealized change in fair value of structured settlement receivables was $409,000 for the three months ended September 30, 2012 compared to $928,000 for the same period in 2011. At September 30, 2012 we had 130 structured receivables on our balance sheet compared with 115 structured settlement receivables on our balance sheet as of September 30, 2011. As of July 1, 2010, we elected to adopt the fair value option, in accordance with ASC 825, Financial Instruments, to record certain newly-acquired structured settlements at fair value.

Expenses

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $5.3 million for the three months ended September 30, 2012 compared to $6.9 million the three months ended September 30, 2011, a decrease of $1.6 million or 24%. The decrease is due primarily to decreases marketing costs of $720,000 and personnel costs of $516,000.

63

Nine Months Ended September 30, 2012 Compared to Nine Months Ended September 30, 2011

Income

Interest Income. Interest income, comprised solely of accretion on the structured settlements assets held on balance sheet prior to their sale was $243,000 for nine months ended September 30, 2012 compared to $319,000 for the nine months ended September 30, 2011, a decrease of $76,000 or 24%. Interest income is accretion during the period on the structured settlement assets held on our balance sheet.

Realized Gain on Sale of Structured Settlements. Realized gain on sale of structured settlements was $7.8 million for the nine months ended September 30, 2012 compared to $5.5 million for the nine months ended September 30, 2011, an increase of $2.3 million or 43%. During the nine months ended September 30, 2012, we sold 980 structured settlements for a gain of $7.8 million compared to 586 with a gain of $5.5 million for the nine months ended September 30, 2011. Of the 980 structured settlements sold, 692 were originated during the period, and 288 were originated during the fourth quarter of 2011 and held on balance sheet pending the resumption of funding under the Company’s credit facilities. See Note 10 to the accompanying consolidated and combined financial statements.

Unrealized Change in Fair Value of Structured Settlement Receivables. Unrealized change in fair value of structured settlement receivables was $1.6 million for the nine months ended September 30, 2012 compared to $2.1 million for the same period in 2011. At September 30, 2012 we had 130 structured receivables on our balance sheet compared with 115 structured settlement receivables on our balance sheet as of September 30, 2011. As of July 1, 2010, we elected to adopt the fair value option, in accordance with ASC 825, Financial Instruments, to record certain newly-acquired structured settlements at fair value.

Expenses. Selling, General and Administrative Expenses. Selling, general and administrative expenses were $16.9 million for the nine months ended September 30, 2012 compared to $15.2 million for the nine months ended September 30, 2011, an increase $1.7 million or 11%. The increase is due primarily to increases in professional costs of $597,000 and D&O insurance premiums of $583,000.

Liquidity and Capital Resources

We anticipate that our liquidity needs for the remainder of 2012 and for 2013 will be in excess of the amounts previously budgeted by the Company as a result of matters associated with the USAO and SEC Investigations and related shareholder litigation. The Company has expended considerable resources resolving the USAO Investigation, as well as responding to the SEC investigation and related litigation, advancing indemnification costs on behalf of certain employees and in conducting an independent investigation of the facts and circumstances surrounding the USAO Investigation. As of September 30, 2012, the Company’s cumulative legal and related fees in respect of these matters were $19.6 million, including $2.6 million incurred during the quarter ending September 30, 2012.

We believe we will continue to spend significant amounts on legal matters related to the USAO and SEC investigations, shareholder litigation and other potential claims over the next year, and possibly beyond. We expect to meet our liquidity needs for the next year primarily through our cash resources and, to a lesser extent, through cash flows from sales and financings of structured settlements. We have not purchased life settlements during the quarter in an effort to conserve capital, are seeking capital and may also sell certain life insurance policies in our portfolio. We may also seek to reduce our operating expenses in order to preserve the value of our existing portfolio of policies, and/or, under certain scenarios, lapse or sell certain of our policies or some combination of the above. The lapsing of policies, if any, would create losses as such assets would be written down to zero. In connection with the Non-Prosecution Agreement, we have ceased originating new premium finance loans. We expect debt maturities to be covered by cash receipts from LPIC claims as discussed further below, and we do not currently have any material planned capital expenditures.

We estimate that we will need to pay $6.9 million in premiums to keep our current portfolio of life insurance policies in force through 2012 and an additional $27.8 million to keep the portfolio in force through 2013. As of September 30, 2012, we had approximately $41.8 million of cash and cash equivalents, and marketable securities, including $1.1 million of restricted cash. Additionally, we have not yet experienced the mortalities of insureds or received the resulting death benefits from our life insurance policies (other than from policies with subrogation rights that are not reported on our balance sheet and that are considered contingent assets). We will need to proactively manage our cash in advance of any liquidity shortfall, which we anticipate, based on our current internal forecast, will occur in the second quarter of 2013.

The Company also expects during the next 12 months that, as part of the framework for the settlement embodied by the Term Sheet, it will, among other things, agree to pay $1.0 million of a $12.0 million payment to settle the class action litigation and will agree to contribute $500,000 to a trust to cover certain claims under its director and officer liability insurance policies, which will further stress the Company’s liquidity position. In addition, under the Term Sheet, the Company will undertake to advance legal fees

64

and indemnify certain individuals covered under the its director and officer liability insurance policies. The obligation to advance and indemnify on behalf of these individuals, while currently unquantifiable, may be substantial and could have a adverse effect on the Company’s financial position and results of operations. See Item 1A — Risk Factors — Under the terms proposed to settle the Company’s class action, derivative and D&O carrier litigation, the Company will undertake certain indemnification and advancement obligations, which could have a material adverse effect on the Company’s liquidity position.

Financing Arrangements Summary

We had the following debt outstanding as of September 30, 2012, which relates to our credit facility previously used to fund life finance loans (in thousands):

	Weighted		Principal		Principal and Interest Payable
	Average		and Interest		Three Months		Year
	Interest		Outstanding		Ending		Ending
Credit Facility	Rate		at 9/30/2012		12/31/2012		12/31/2013
Cedar Lane		15.4%		1,580		1,472		108
Weighted average interest rate				15.4%		15.4%		15.4%

The Cedar Lane facility is collateralized by life insurance policies with lender protection insurance underlying premium finance loans that we have assigned, or in which we have sold participations rights, to our special purpose entities. We have guaranteed 5% of the applicable special purpose entity’s obligations. Our chief executive officer and our former chief operating officer made certain guaranties to lenders for the benefit of the special purpose entities for matters other than financial performance. These guaranties are not unconditional sources of credit support, but are intended to protect the lenders against acts of fraud, willful misconduct or a borrower commencing a bankruptcy filing. To the extent lenders sought recourse against our chief executive officer and our former chief operating officer for such non-financial performance reasons, then our indemnification obligations to our chief executive officer and our former chief operating officer may require us to indemnify them for losses they may incur under these guaranties.

We expect the lender protection insurance, subject to its terms and conditions, to ensure liquidity at the time of loan maturity and, therefore, we do not anticipate significant, if any, additional cash outflows at the time of debt maturities in excess of the amounts to be received by the loan payoffs or lender protection insurance claims.

Premium Finance Credit Facility

Cedar Lane Capital LLC Facility. On March 12, 2010, Imperial PFC Financing II, LLC, a special purpose entity and wholly-owned subsidiary, entered into an amended and restated financing agreement with Cedar Lane Capital, LLC, to enable Imperial PFC Financing II, LLC to purchase premium finance loans originated by us or participation interests therein. The financing agreement provides for a $15.0 million multi-draw term loan commitment. The term loan commitment is for a 1-year term and the borrowings bear an annual interest rate of 14.0%, 15.0% or 16.0%, depending on the tranche of loans as designated by Cedar Lane Capital, LLC and are compounded monthly. All of the assets of Imperial PFC Financing II, LLC serve as collateral under this credit facility. In addition, the obligations of Imperial PFC Financing II, LLC have been guaranteed by Imperial Premium Finance, LLC; however, except for certain expenses, the obligations are generally non-recourse to us, except to the extent of Imperial Premium Finance, LLC’s equity interest in Imperial PFC Financing II, LLC. Our lender protection insurer ceased providing us with lender protection insurance under this credit facility on December 31, 2010. As a result, we ceased borrowing under the Cedar Lane facility after December 31, 2010.

We are subject to several restrictive covenants under the facility. The restrictive covenants include that Imperial PFC Financing II, LLC cannot: (i) create, incur, assume or permit to exist any lien on or with respect to any property, (ii) create, incur, assume, guarantee or permit to exist any additional indebtedness (other than certain types of subordinated indebtedness), (iii) declare or pay any dividend or other distribution on account of any equity interests of Imperial PFC Financing II, LLC, (iv) make any repurchase, redemption, retirement, defeasance, sinking fund or similar payment, or acquisition for value of any equity interests of Imperial PFC Financing II, LLC or its parent (direct or indirect), or (v) issue or sell or enter into any agreement or arrangement for the issuance and sale of any shares of its equity interests, any securities convertible into or exchangeable for its equity interests or any warrants. Imperial Holdings has executed a guaranty of payment for 5.0% of amounts outstanding under the facility. The Company believes it is in compliance at September 30, 2012 and 2011.

Structured Settlement Financing Arrangements

8.39% Fixed Rate Asset Backed Variable Funding Notes. We formed Imperial Settlements Funding (“ISF”) as a subsidiary of Washington Square Financial, LLC (“WSF”) to serve as a special purpose financing entity to allow us to borrow against certain of our structured settlements and assignable annuities, which we refer to as receivables, to provide us liquidity. On September 24, 2010, we entered into an arrangement to provide us up to $50 million in financing. Under this arrangement, a subsidiary of Partner Re, Ltd., or the noteholder, became the initial holder of ISF 2010’s 8.39% Fixed Rate Asset Backed Variable Funding Notes issued under a master

65

trust indenture and related indenture supplement, or the indenture, pursuant to which the noteholder has committed to advance up to $50 million upon the terms and conditions set forth in the indenture. The note is secured by the receivables that ISF 2010 acquires from Washington Square from time to time. The note is due and payable on or before January 1, 2057, but principal and interest must be repaid pursuant to a schedule of fixed payments from the receivables that secure the notes. The arrangement generally has a concentration limit of 15% for the providers of the receivables that secure the notes. Wilmington Trust is the collateral trustee.

Upon the occurrence of certain events of default under the indenture, all amounts due under the note are automatically accelerated. ISF 2010 is subject to several restrictive covenants under the terms of the indenture. The restrictive covenants include that ISF 2010 cannot: (i) create, incur, assume or permit to exist any lien on or with respect to any assets other than certain permitted liens, (ii) create, incur, assume, guarantee or permit to exist any additional indebtedness, (iii) declare or pay any dividend or other distribution on account of any equity interests of ISF 2010 other than certain permitted distributions from available cash, (iv) make any repurchase or redemption of any equity interests of ISF 2010 other than certain permitted repurchases or redemptions from available cash, (v) enter into any transactions with affiliates other than the transactions contemplated by the indenture, or (vi) liquidate or dissolve.

During the third quarter ended 2011, the Company suspended financing under this agreement, but resumed financing on January 12, 2012 pursuant to an acknowledgement that provided for WSF to make a $258,000 payment in respect of, the transfer of the ownership of certain lock-box accounts associated with the facility. As of September 30, 2012, the Company had available commitments under this facility of $9.6 million. We also have other parties to whom we have sold term-certain structured settlement assets and to whom we believe we can sell such assets in the future.

Life Contingent Purchase and Sale Agreement

On December 30, 2011, WSF entered into a forward purchase and sale agreement (“PSA”) to sell up to $40.0 million of life-contingent structured settlement receivables to Compass Settlements, LLC (“Compass”). Subject to predetermined eligibility criteria and on-going funding conditions, Compass committed, in increments of $5.0 million, up to $40.0 million to purchase life-contingent structured settlement receivables from WSF. The PSA obligates WSF to sell the eligible life-contingent structured settlement receivables it originates to Compass on an exclusive basis for twenty-four months, subject to Compass maintaining certain purchase commitment levels. Additionally, the Company agreed to guaranty WSF’s obligation to repurchase any ineligible receivables sold under the PSA and certain other related obligations.

66

Premium Finance Loan Maturities

The following table summarizes the maturities of our life finance loans outstanding as of September 30, 2012 (dollars in thousands):

	Principal and Interest Payable
	Total at			Year Ending			Year Ending
	9/30/2012			12/31/2012			12/31/2013
Carrying value (loan principal balance, accreted origination fees, and accrued interest receivable)	$	11,597		$	5,305		$	6,292
Weighted average per annum interest rate		13.0	%		11.9	%		13.8	%
Per annum origination fee as a percentage of the principal balance of the loan at origination		15.6	%		19.3	%		12.2	%

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities for the nine months ended September 30, 2012 and 2011 (in thousands):

	For the Nine Months Ended
	September 30,
	2012			2011
Statement of Cash Flows Data:
Total cash provided by (used in):
Operating activities	$	(24,225	)	$	(29,305	)
Investing activities		42,479			(115,813	)
Financing activities		(18,054	)		149,734
Increase in cash and cash equivalents	$	200		$	4,616

Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2012 was $24.2 million, a decrease of $5.1 million from $29.3 million of cash used in operating activities during the nine months ended September 30, 2011. This decrease was mainly due to a reduction in accounts payable and accrued expenses of $4.5 million and interest payable of $1.0 million as a result of paying down loans outstanding. These were offset by increased structured settlement receivables of $11.8 million, other liabilities of $27.0 million, which is mainly attributable to liabilities associated with the class action and derivative action proposed settlement, prepaid expenses and other assets of $9.1 million that are mainly associated with insurance coverage for Directors and Officers, insurance recoverable related to the class action and derivative proposed settlement and deposits of $1.3 million.

Investing Activities

Net cash provided by investing activities for the nine months ended September 30, 2012 was $42.5 million, an increase of $158.3 million from $115.8 million of cash used in investing activities for the nine months ended September 30, 2011. The increase was primarily due to $23.2 million increase in proceeds from the sale and repayment of investment securities available-for-sale, $18.7 million decrease in originations of loans receivable, $14.5 million increase in cash proceeds from loan payoffs and lender protection insurance claims received in advance and $5.6 million increase in proceeds from sale of life settlements. These were offset by $86.3 million decrease in purchases of investment securities available-for-sale, $10.2 million increase in premiums paid on investments in life settlements and $47.9 million decrease in purchases of life insurance policies.

Financing Activities

Net cash used in financing activities for the nine months ended September 30, 2012 was $18.1 million, a decrease of $167.8 million from $149.7 million of cash provided by financing activities for the nine months ended September 30, 2011. The decrease was primarily due to a decrease of $174.2 million in proceeds from our initial public offering, net of offering costs, $9.3 million decrease in cash used in the repayment of borrowings under credit facilities, $2.6 million decrease in borrowings from affiliates and a $234,000 decrease in borrowings under credit facilities.

67

Contractual Obligations

The following table summarizes our contractual obligations as of September 30, 2012 (in thousands):

Contractual Obligations

	Total		Due in Less than 1 Year		Due 1- 3 Years		Due 3- 5 Years		More than 5 Years
Credit facilities(1)	$	1,222	$	1,222	$	—	$	—	$	—
Expected interest payments(2)		358		358		0		—		—
Operating leases		1,157		541		616		—		—
Estimated tax payments for uncertain tax positions		3,481		—		3,481		—		—
Total	$	6,218	$	2,121	$	4,097	$	—	$	—

(1) Credit facilities consist of the principal outstanding related to the Cedar Lane facility that was previously used to fund life finance loans.

(2) Expected interest payments are calculated based on outstanding balances of our credit facilities as of September 30, 2012 and assumes repayment of principal and interest at the maturity date of the related life finance loan, which may be prior to the final maturity of the credit facility.

Inflation

Our assets and liabilities are, and will be in the future, interest-rate sensitive in nature. As a result, interest rates may influence our performance far more than does inflation. Changes in interest rates do not necessarily correlate with inflation or changes in inflation rates. We do not believe that inflation had any material impact on our results of operations in the periods presented in our financial statements presented in this report.

Off-Balance Sheet Arrangements

Except as described below in “—Subrogation Rights, Net,” there are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Subrogation Rights, Net

As described above in “—Critical Accounting Policies—Gain on Maturities of Life Settlements with Subrogation Rights, Net,” the Company considers policies that it acquired as a result of borrower default as contingent assets and does not include those policies in the amount of life settlement policies on its consolidated and combined balance sheet. In the third quarter of 2011, two individuals covered under policies which were subject to subrogation claims passed away. The Company collected the death benefit on one of these policies in the amount of $3.5 million during the third quarter of 2011.

The other was the result of an accidental death and the $10.0 million face value of the policy was larger than average. The Company accounted for the maturities of each of these polices as contingent gains in accordance with ASC 450, Contingencies and recognized the collection of the $3.5 million death benefit net of subrogation expenses of $312,000 in its consolidated and combined statement of operations during the third quarter of 2011. In the second quarter of 2012, the Company negotiated a settlement in respect of the larger policy and collected approximately $6.1 million, net of subrogation expenses of 910,000, in respect of the larger policy and reported a gain in accordance with ASC 450, Contingencies in its consolidated and combined statement of operations for the second quarter of 2012. The Company believes these contingent gains to be unpredictable because the lender protection insurer can discontinue paying the premiums necessary to keep policies subject to subrogation and salvage claims in force at any time and the amount of the lender protection insurer’s subrogation and salvage claim on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. No expectations for similar gains in the future should be inferred from the events occurring in the third quarter of 2011 or the second quarter of 2012.

68

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk is the risk of potential economic loss principally arising from adverse changes in the fair value of financial instruments. The major components of market risk are credit risk, interest rate risk and foreign currency risk. We have no exposure in our operations to foreign currency risk.

Credit Risk

In our life finance business segment, with respect to life insurance policies collateralizing our loans or that we acquire upon relinquishment, credit risk consists primarily of the potential loss arising from adverse changes in the financial condition of the issuers of the life insurance policies. We manage our credit risk related to these life insurance policy issuers by generally only funding premium finance loans for policies issued by companies that have a credit rating of at least “A” by Standard & Poor’s, at least “A2” by Moody’s, at least “A” by A.M. Best Company or at least “A-” by Fitch. At September 30, 2012, all of our loan collateral was for policies issued by companies rated “investment grade” (credit ratings of “A+” to “BBB-”) by Standard & Poor’s, and we owned 7 policies issued by a carrier rated below investment grade.

69

The following table shows the percentage of the total number of loans outstanding with lender protection insurance and the percentage of our total loans receivable balance covered by lender protection insurance as of the dates indicated below:

	September 30,
	2012			2011
Percentage of total number of loans outstanding with lender protection insurance		35.5	%		74.6	%
Percentage of total loans receivable, net balance covered by lender protection insurance		27.1	%		69.5	%

For the loans that had lender protection insurance and that matured during the nine months ended September 30, 2012 and 2011, the lender protection insurance claims paid to us were 88.0% and 85.1%, respectively, of the contractual amount of the insured loans.

Our premium finance loans are originated with borrowers residing throughout the United States. We do not believe there are any geographic concentrations of loans that would cause them to be similarly impacted by economic or other conditions. However, there is concentration in the life insurance carriers that issued these life insurance policies that serve as our loan collateral. The following table provides information about the life insurance issuer concentrations that exceed 10% of total death benefit of the collateral and 10% of outstanding loan balance as of September 30, 2012:

	Percentage of			Percentage of
	Total Outstanding			Total Death			Moody’s		S&P
Carrier	Loan Balance			Benefit			Rating		Rating
Lincoln National Life Insurance Company		34.9	%		23.4	%		A2		AA-
AXA Equitable Life Insurance Company		14.6	%		24.1	%		Aa3		AA-
Lincoln Benefit Life Company		14.4	%		11.1	%		A1		A+

As of September 30, 2012, our lender protection insurer, Lexington, had a financial strength rating of “A” with a stable outlook by Standard & Poor’s.

The following table provides information about the life insurance issuer concentration that exceed 10% of total death benefit and 10% of total fair value of our investment in life settlements as of September 30, 2012:

Carrier	Percentage of Total Fair Value			Percentage of Total Death Benefit			Moody’s Rating		S&P Rating
Lincoln National Life Insurance Company		20.1	%		14.4	%		A2		AA-
AXA Equitable Life Insurance Company		11.3	%		13.7	%		Aa3		AA-

In our structured settlements segment, credit risk consists of the potential loss arising principally from adverse changes in the financial condition of the issuers of the annuities that arise from a structured settlement. Although certain purchasers of structured settlements may require higher credit ratings, we manage our credit risk related to the obligors of our structured settlements by generally requiring that they have a credit rating of “A–” or better by Standard & Poor’s. The risk of default in our structured settlement portfolio is mitigated by the relatively short period of time that we hold structured settlements as investments. We have not experienced any credit losses in this segment and we believe such risk is minimal.

Interest Rate Risk

In our life finance segment, most of our credit facilities and promissory notes provide us with fixed-rate financing. Therefore, fluctuations in interest rates currently have minimal impact, if any, on our interest expense under these facilities. However, increases in interest rates may impact the rates at which we are able to obtain financing in the future.

We earn revenue from interest charged on loans, loan origination fees and fees from referring agents. In addition, we earn income on the unrealized changes in fair value of life insurance policies we acquire in the life settlement and secondary markets. We receive interest income that accrues over the life of the life finance loan and is due at maturity. Substantially all of the interest rates we charge on our life finance loans are floating rates that are calculated at the one-month LIBOR rate plus an applicable margin. In addition, our life finance loans have a floor interest rate and are capped at 16.0% per annum. For loans with floating rates, each month the interest rate is recalculated to equal one-month LIBOR plus the applicable margin, and then, if necessary, adjusted so as to remain at or above the stated floor rate and at or below the capped rate of 16.0% per annum. While the floor and cap interest rates mitigate our exposure to changes in interest rates, our interest income may nonetheless be impacted by changes in interest rates. Origination fees are fixed and are therefore not subject to changes based on movements in interest rates, although we do charge interest on origination fees.

70

As of September 30, 2012, we owned investments in life settlements (life insurance policies) in the amount of $102.3 million. A rise in interest rates could potentially have an adverse impact on the sale price if we were to sell some or all of these assets. There are several factors that affect the market value of life settlements (life insurance policies), including the age and health of the insured, investors’ demand, available liquidity in the marketplace, duration and longevity of the policy, and interest rates. We currently do not view the risk of a decline in the sale price of life settlements (life insurance policies) due to normal changes in interest rates as a material risk.

In our structured settlements segment, our profitability is affected by levels of and fluctuations in interest rates. Such profitability is largely determined by the difference, or “spread,” between the discount rate at which we purchase the structured settlements and the discount rate at which we can resell these assets or the interest rate at which we can finance those assets. Structured settlements are purchased at effective yields, which are fixed, while rates at which structured settlements are sold, with the exception of forward purchase arrangements, are generally a function of the prevailing market rates for short-term borrowings. As a result, increases in prevailing market interest rates after structured settlements are acquired could have an adverse effect on our yield on structured settlement transactions. Currently, we do not view this risk to be material because nearly all of our structured settlements acquired are sold into forward purchase arrangements.

Risks Associated with Investments Securities Available for Sale

Imperial purchases fixed income securities and U.S. treasuries to provide consistent investment income, may or may not preserve capital unless held to maturity and provide liquidity to fund expected premium payments. Changes in market interest rates associated with Imperial’s investment securities could have a material adverse effect on Imperial’s carrying value of its securities. Temporary changes in the carrying value of securities classified as available for sale are reflected, net of taxes, as a component of stockholders’ equity, while other-than-temporary impairment charges, if any, are recorded in earnings.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

As previously disclosed on a Form 12b-25 filed on November 7, 2012, the Company has been delayed in filing this Form 10-Q for the quarter ended September 30, 2012 as it first needed to establish the fair value of premium finance loans on its balance sheet and of certain policies in the Company’s portfolio for prior periods in light of the USAO Investigation. The Company’s management believes that the failure to timely file the required reports stemmed from the challenge of establishing an appropriate discount rate with which to value the Company’s Level 3 assets in light of the substantial uncertainty generated by the USAO Investigation and related matters, rather than from ineffective disclosure controls and procedures. The Company’s chief executive officer and chief financial officer considered the failure to timely file this and other periodic reports when assessing the effectiveness of the Company’s disclosure controls and procedure. Because the delay was not a result of a deficiency in the Company’s disclosure controls and procedures and no material weaknesses in internal controls over financial reporting were reported, the Company’s chief executive officer and chief financial officer concluded that the disclosure controls and procedures were effective notwithstanding the delayed filings.

71

Limitations on Controls

Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based on certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

72

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Litigation

The SEC Investigation

As of the filing of this Quarterly Report, we are also subject to an investigation by the SEC. We received a subpoena issued by the staff of the SEC on February 17, 2012, seeking documents from 2007 through the present that are generally related to the Company’s premium finance business and corresponding financial reporting. The SEC is investigating whether any violations of federal securities laws have occurred and the Company is cooperating with the SEC regarding this matter. The Company is unable to predict the outcome of the SEC investigation or estimate the amount of any possible sanction, which could include a fine, penalty, or court order prohibiting specific conduct, any of which could be material. No provision for losses has been recorded for this exposure.

The Class Action Litigation

Initially on September 28, 2011, the Company, and certain of its officers and directors were named as defendants in a putative securities class action filed in the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entitled Martin J. Fuller v. Imperial Holdings, Inc. et al. Also named as defendants were the underwriters of the Company’s initial public offering. That complaint asserted claims under Sections 11, 12 and 15 of the Securities Act of 1933, as amended, alleging that the Company should have but failed to disclose in the registration statement for its initial public offering purported wrongful conduct relating to its life finance business which gave rise to the USAO Investigation. On October 21, 2011, an amended complaint was filed that asserts claims under Sections 11, 12 and 15 of the Securities Act of 1933, based on similar allegations. On October 25, 2011, defendants removed the case to the United States District Court for the Southern District of Florida.

On October 31, 2011, another putative class action case was filed in the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entitled City of Roseville Employees Retirement System v. Imperial Holdings, et al, naming the same defendants and also bringing claims under Sections 11, 12 and 15 of the Securities Act based on similar allegations. On November 28, 2011, defendants removed the case to the United States District Court for the Southern District of Florida. The plaintiffs in the Fuller and City of Roseville cases moved to remand their cases back to state court. Those motions were fully briefed and argued.

On November 18, 2011, a putative class action case was filed in the United States District Court for the Southern District of Florida, entitled Sauer v. Imperial Holdings, Inc., et al, naming the same defendants and bringing claims under Sections 11 and 15 of the Securities Act of 1933 based on similar allegations.

On December 14, 2011, another putative class action case filed in United States District Court for the Southern District of Florida, entitled Pondick v. Imperial Holdings, Inc., et al., naming the same defendants and bringing claims under Sections 11, 12, and 15 of the Securities Act of 1933 based on similar allegations.

On February 24, 2012, the four putative class actions were consolidated and designated: Fuller v. Imperial Holdings et al. in the United States District Court for the Southern District of Florida, and lead plaintiffs were appointed.

In addition, the underwriters of the Company’s initial public offering have asserted that the Company is required by its Underwriting Agreement to indemnify the underwriters’ expenses and potential liabilities in connection with the litigation. On December 18, 2012, attorneys for the Company signed the Term Sheet, which provides the terms upon which of the parties would be willing to settle these matters. See Item 1, Note 18 – Subsequent Events.

The Insurance Coverage Declaratory Relief Complaint

On June 13, 2012, Catlin Insurance Company (UK) Ltd. (“Catlin”) filed a declaratory relief action against the Company in the United States District Court for the Southern District of Florida. The complaint seeks a determination that there is no coverage under Catlin’s primary Directors, Officers and Company Liability Policy (the “Policy”) issued to the Company for the period February 3, 2011 to February 3, 2012, based on a prior and pending litigation exclusion (the “Exclusion”). Catlin also seeks a determination that it is entitled to reimbursement of the approximately $0.8 million in defense costs and fees advanced to the Company in the first quarter of 2012 under the Policy if it is determined that the Exclusion precludes coverage. As of the filing of this Form 10-Q, the Company has not yet been served with the complaint.

On December 18, 2012, attorneys for the Company signed the Term Sheet, which provides the terms upon which of the parties would be willing to settle this matter. See Item 1, Note 18 – Subsequent Events.

73

The Florida Litigation

On March 14, 2012, Opportunity served the Company with a complaint in the Circuit Court of the 15^th Judicial Circuit in and for Palm Beach County, Florida seeking to compel the Company to hold an annual meeting of shareholders as soon as possible and seeking recovery of all costs and expenses, including reasonable attorney’s fees and expenses of experts in connection with the complaint. On March 28, 2012, Opportunity filed a motion to compel an annual meeting of shareholders. The Company filed a motion to dismiss the complaint on April 3, 2012 and an opposition to the motion to compel on May 24, 2012. Following a hearing on June 1, 2012, the Court entered an Order dated June 15, 2012 granting Opportunity motion to compel an annual meeting of shareholders and denying the Company’s motion to dismiss. Pursuant to the Court’s Order, the Company was required to hold its annual meeting of shareholders on or before August 20, 2012. In addition, the Court ordered the Company to seek an exemption from the SEC pursuant to SEC Regulation 17 C.F.R. § 200.30-1(e)(18) on or before June 20, 2012 and to update the Court of any adverse response to its application on or before July 18, 2012.

On August 2, 2012, the Board of Directors of the Company appointed Andrew Dakos, Phillip Goldstein and Gerald Hellerman to serve as directors of the Company in connection with a settlement with Opportunity that resulted in Opportunity withdrawing its demand for a special meeting of shareholders, which it had submitted to the Company on May 23, 2012 and agreeing to dismiss its lawsuit to compel an annual meeting of shareholders. In connection with the Settlement, Walter Higgins and A. Penn Wyrough resigned from the Board of Directors. The Company complied with the Order dated June 15, 2012 prior to the settlement. The Court withdrew the Order dated June 15, 2012 with a subsequent Order dated August 9, 2012, in which the Court also dismissed the case without prejudice.

Derivative Claims

On November 16, 2011, the Company’s Board of Directors received a shareholder derivative demand from Harry Rothenberg (the “Rothenberg Demand”), which was referred to the special committee for a thorough investigation of the issues, occurrences and facts relating to, connected to, and arising from the USAO Investigation referenced in the Rothenberg Demand. On May 8, 2012, the Company’s Board of Directors received a derivative demand made by another shareholder, Robert Andrzejczyk (the “Andrzejczyk Demand”). The Andrzejczyk Demand, like the Rothenberg Demand was referred to the special committee, which determined that it did not contain any allegations that differed materially from those alleged in the Rothenberg Demand. On July 20, 2012, the Company (as nominal defendant) and certain of the Company’s officers, directors, and a former director were named as defendants in a shareholder derivative action filed in the Circuit Court of the 15^th Judicial Circuit in and for Palm Beach County, Florida, entitled Robert Andrzejczyk v. Imperial Holdings, Inc. et al. The complaint alleges, among other things, that the Special Committee’s refusal of the Andrzejczyk Demand was improper.

On December 18, 2012, attorneys for the Company signed the Term Sheet, which provides the terms upon which of the parties would be willing to settle these matters. See Item 1, Note 18 – Subsequent Events.

Other Matters

In addition to the proceedings above, we are party to various legal proceedings which arise in the ordinary course of business. From time to time, we also finance the cost of a policyholder’s defense of litigation initiated by a carrier to challenge the policyholder’s life insurance policy. While we cannot predict with certainty the outcome of these proceedings, we believe that the resolution of these other proceedings will not, based on information currently available to us, have a material adverse effect on our financial position or results of operations.

Item 1A. Risk Factors

Updates to our risk factors are discussed below. Other than the risk factors set forth below, our risk factors have not changed materially from those disclosed in our Annual Report on Form 10-K filed for the year ended December 31, 2011 with the SEC on October 5, 2012.

The Company currently anticipates a liquidity shortfall in the second quarter of 2013 and may not be able to raise capital in a timely manner on favorable terms or at all.

We estimate that we will need to pay $6.9 million in premiums to keep our current portfolio of life insurance policies in force from September 30, 2012 through December 31, 2012 and an additional $27.8 million to keep the portfolio in force through 2013. As of September 30, 2012, we had approximately $40.6 million of cash and cash equivalents, including cash, and marketable securities and we estimate that at December 31, 2012 we had approximately $20.3 million of cash and cash equivalents, including cash, and marketable securities. Based on our current internal forecast, we anticipate a liquidity shortfall in the second quarter of 2013. Accordingly, to avoid lapsing policies, the Company is actively seeking additional capital to pay premiums, by means of debt or equity financing. There can be no assurance, however, that the Company will be able to consummate a financing on favorable terms or at all. If the Company cannot obtain necessary financing, it may need to sell the policies that it owns, but there can be no assurance that the Company can consummate any sales or that, if consummated, sales of policies will be at or above their carrying values.

74

Under the terms proposed to settle the Company’s class action, derivative and D&O carrier litigation, the Company will undertake certain indemnification and advancement obligations, which could have a material adverse affect on the Company’s liquidity position.

As part of the framework for the settlement embodied by the Term Sheet, the Company will agree to advance the cost of legal expenses and otherwise indemnify certain individuals who would otherwise be entitled to coverage under portions of the Company’s director and officer liability insurance policies, including individuals who have been identified as “targets” of the USAO Investigation. The costs, individually or in the aggregate, of advancing for legal expenses on behalf of these individuals is currently not quantifiable, but could be substantial especially if any such individual is indicted as part of the USAO Investigation. These obligations will likely further strain the Company’s liquidity position and could have a material adverse affect on the Company’s financial position and results of operations.

Uncooperative co-trustees may impair the Company’s ability to service its life insurance policies.

In certain instances, change of ownership forms in respect of life insurance policies that the Company has acquired through foreclosures associated with defaulted premium finance loans have not been processed by the applicable insurance carrier and remain in their original trusts. In these instances, although the Company has, among other things, contractual rights entitling it to direct the proceeds of the policies and there is a professional co-trustee authorized to exercise all rights over the policies, it may still need the cooperation of the non-professional co-trustee to obtain information from the insurance carrier necessary to service the policy. Without this information, it is possible that a policy could lapse, as was the case with one policy in the quarter ended September 30, 2012. As a result of this lapse, the Company suffered a complete loss on its investment. While the value of this policy was immaterial, further lapses could have a material adverse affect on the Company’s financial position and results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On and effective January 14, 2013, David Buzen resigned from the Board of Directors of Imperial Holdings, Inc.

Item 6. Exhibits

See the Exhibit Index following the Signatures page of this Quarterly Report on Form 10-Q.

75

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMPERIAL HOLDINGS, INC.
/s/ Richard S. O’Connell, Jr.	Chief Financial Officer and Chief Credit Officer
Richard S. O’Connell, Jr.	(Principal Financial Officer)

Date: January 15, 2013

76

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 101.*	Interactive Data Files
Exhibit 101.INS**+	XBRL Instance Document
Exhibit 101.SCH**+	XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL**+	XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF**+	XBRL Taxonomy Definition Linkbase Document
Exhibit 101.LAB**+	XBRL Taxonomy Extension Label Linkbase Document 10.1 & 10.2
Exhibit 101.PRE**+	XBRL Taxonomy Extension Presentation Linkbase Document

* Furnished, not filed

** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 not filed for such purposes of Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under such sections.

+ Submitted electronically with this Quarterly Report

77

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Antony Mitchell, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Imperial Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Antony Mitchell

Antony Mitchell

Chief Executive Officer and Director

(Principal Executive Officer)

January 15, 2013

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Richard S. O’Connell, Jr., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Imperial Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Richard S. O’Connell, Jr.

Richard S. O’Connell, Jr.

Chief Financial Officer and Chief Credit Officer

(Principal Financial Officer)

January 15, 2013

EX-32.1

Exhibit 32.1

Certification of the Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Imperial Holdings, Inc. (the Registrant) on Form 10-Q for the period ended September 30, 2012 as filed with the U.S. Securities and Exchange Commission on the date hereof (the Report), I, Antony Mitchell, Chairman and Chief Executive Officer of the Registrant, certify to the best of my knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ Antony Mitchell

Antony Mitchell

Chief Executive Officer and Director

January 15, 2013

EX-32.2

Exhibit 32.2

Certification of the Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Imperial Holdings, Inc. (the Registrant) on Form 10-Q for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard S. O’Connell, Jr., Chief Financial Officer and Chief Credit Officer of the Registrant, certify to the best of my knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ Richard S. O’Connell, Jr.

Richard S. O’Connell, Jr.

Chief Financial Officer and Chief Credit Officer

January 15, 2013

XML

Earnings Per Share - Additional Information (Detail) (USD $)	1 Months Ended				3 Months Ended		9 Months Ended
	Feb. 28, 2011	Feb. 15, 2011	Feb. 11, 2011	Feb. 03, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock, shares outstanding				3,600,000	21,206,121	21,202,614	21,206,121	21,202,614	21,202,614
Common stock, shares issued					21,206,121	21,202,614	21,206,121	21,202,614	21,202,614
Conversion of Impex debt and membership units into common shares (shares)				2,300,273
Issuance of common stock, shares	17,602,614	935,947	16,666,667
Conversion of debt to common stock								$ 35,158,000
Interest expense					141,000	1,660,000	1,219,000	7,431,000
Pro Forma
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Conversion of Impex debt and membership units into common shares (shares)								2,300,273
Issuance of common stock, shares								27,000
Conversion of debt to common stock								30,000,000
Conversion of debt to common stock (shares)								1,272,727
Interest expense								$ 178,000

XML

Analysis of Credit Ratings (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012		Dec. 31, 2011
Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	$ 6,094		$ 13,648
Percent	100.00%		100.00%
Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	1,579	[1]	17,616	[2]
Percent	100.00%	[1]	100.00%	[2]
AAA | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Percent	0.00%		0.00%
AAA | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Percent	0.00%	[1]	0.00%	[2]
AA+ | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	694		694
Percent	11.39%		5.08%
AA+ | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance			222	[2]
Percent	0.00%	[1]	1.26%	[2]
AA | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Percent	0.00%		0.00%
AA | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Percent	0.00%	[1]	0.00%	[2]
AA- | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	3,550		6,558
Percent	58.25%		48.05%
AA- | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	696	[1]	9,085	[2]
Percent	44.10%	[1]	51.57%	[2]
A+ | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	1,242		3,060
Percent	20.38%		22.42%
A+ | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	93	[1]	1,287	[2]
Percent	5.87%	[1]	7.31%	[2]
Standard and Poors A One Rating | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Percent	0.00%		0.00%
Standard and Poors A One Rating | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Percent	0.00%	[1]	0.00%	[2]
A | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	543		3,336
Percent	8.91%		24.44%
A | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	101	[1]	7,022	[2]
Percent	6.40%	[1]	39.86%	[2]
A- | Uninsured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	65
Percent	1.07%		0.00%
A- | Insured Loans
Financing Receivable, Recorded Investment [Line Items]
Unpaid Principal Balance	$ 689	[1]
Percent	43.63%	[1]	0.00%	[2]

[1] All of the Company's insured loans have lender protection coverage with Lexington Insurance Company. As of September 30, 2012, Lexington had a financial strength rating of "A" with a stable outlook by Standard & Poor's.

[2] All of the Company's insured loans have lender protection coverage with Lexington Insurance Company. As of December 31, 2011, Lexington had a financial strength rating of "A" by Standard & Poor's.

XML

Investment Securities Available for Sale - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012 Securities	Sep. 30, 2011	Dec. 31, 2011
Schedule of Investments [Line Items]
Proceeds from sale and prepayments of investment securities available for sale	$ 67,915,000	$ 44,700,000
Gross realized gains on investment securities available for sale	80,000
Number of securities in unrealized loss positions	6
Unrealized loss	89,000		136,000
Insignificant Securities
Schedule of Investments [Line Items]
Unrealized loss	$ (89,000)

XML

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended					9 Months Ended		3 Months Ended	9 Months Ended					9 Months Ended
	Sep. 30, 2012 Contract	Sep. 30, 2011	Sep. 30, 2012 Contract	Sep. 30, 2011	Dec. 31, 2011 Contract	Sep. 30, 2012 Impaired Loans	Sep. 30, 2011 Impaired Loans	Sep. 30, 2012 Impaired Loans	Sep. 30, 2011 Impaired Loans	Sep. 30, 2012 Noninvestment grade BasisPoint Contract	Sep. 30, 2012 Structured settlements Contract	Sep. 30, 2012 Previously Premium Financed Contract	Sep. 30, 2012 Previously Premium not Financed Contract	Sep. 30, 2012 Previously had Lender Protection Insurance	Sep. 30, 2012 Subsequent Event Contract	Sep. 30, 2012 Six Months Increase Or Decrease in Life Expectancy	Sep. 30, 2012 Life Finance	Sep. 30, 2012 Life Expectancy Update Received Contract	Dec. 17, 2012 Life Expectancy Update Received Subsequent Event Contract	Sep. 30, 2012 Life Expectancy Update Received Subsequent Event Contract	Sep. 30, 2012 Minimum Previously Premium Financed	Sep. 30, 2012 Minimum Life Finance	Sep. 30, 2012 Maximum Previously Premium Financed	Sep. 30, 2012 Maximum Life Finance
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Life Settlement Contracts, Fair Value Method, Change in Expectations			In determining the life expectancy estimate, we analyze medical reviews from independent secondary market life expectancy providers (each a “LE provider”). Additionally, the Company began procuring updated life expectancy reports and has applied updated life expectancy reports on 143 policies to its fair value model at September 30, 2012, including 79 reports that were produced after the valuation date. See Note 18 – Subsequent Events. An LE provider reviews the medical records and identifies all medical conditions it feels are relevant to the life expectancy of the insured. Debits and credits are then assigned by the LE provider to the individual’s health based on these medical conditions. The debit or credit that an LE provider assigns to a medical condition is derived from the experience of mortality attributed to this condition in the portfolio of lives that it monitors. The health of the insured is summarized by the LE provider into a life assessment of the individual’s life expectancy expressed both in terms of months and in mortality factor.
Unrealized change in fair value of life settlements	$ (17,530,000)	$ (14,074,000)	$ (8,401,000)	$ 14,811,000											$ 20,100,000
Number of life insurance policies	212		212		190					6	70	169	43		212			143	79	64
Mortality rate Assumption			The resulting mortality factor represents an indication as to the degree to which the given life can be considered more or less impaired than a standard life having similar characteristics (e.g. gender, age, smoking, etc.). For example, a standard insured (the average life for the given mortality table) would carry a mortality rating of 100%. A similar but impaired life bearing a mortality rating of 200% would be considered to have twice the chance of dying earlier than the standard life. Historically, the Company has procured the majority of its life expectancy reports from two life expectancy report providers and only used AVS life expectancy reports for valuation purposes. Beginning in the quarter ended September 30, 2012, the Company began utilizing life expectancy reports from 21st Services for valuation purposes and began averaging or “blending,” the results of the two life expectancy reports to establish a composite mortality factor. However, when “blending” the AVS and 21st Services life expectancy reports, if the probability of mortality between the reports is greater than 150%, the Company will reduce the higher mortality factor until the difference is 150%.
Average life expectancy of insured			10 years 6 months		10 years 7 months 6 days											10 years 6 months
Change in fair value of portfolios			9.2
Expected yield rate																						12.00%		17.00%
Investment term																	5 years
Discount rates													18.05%	24.61%							20.05%	15.00%	30.65%	17.00%
Additional basis point risk premium										300
Investment in life settlements, at estimated fair value	102,328,000		102,328,000		90,917,000
Settlements with estimated fair value	2,496,000		2,496,000		12,376,000						2,500,000
Weighted average discount rate			24.61%								10.80%
Principal, accrued interest, and accreted origination fees, net of impairment, fair value	1,400,000		1,400,000		14,100,000
Principal, accrued interest, and accreted origination fees, net of impairment, carrying value	4,700,000		4,700,000		10,200,000
Provision for losses on loans receivable related to impaired loans		$ 3,583,000	$ 441,000	$ 3,712,000		$ 0	$ 3,600,000	$ 449,000	$ 3,700,000

XML

Summary of Investment in Impaired Loans (Detail) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Financing Receivable, Impaired [Line Items]
Loan receivable, net	$ 5,394,000	$ 29,376,000
Interest receivable, net	1,356,000	5,758,000
Impaired Loans
Financing Receivable, Impaired [Line Items]
Loan receivable, net	5,063,000	17,424,000
Interest receivable, net	1,068,000	6,799,000
Investment in impaired loans	$ 6,131,000	$ 24,223,000

XML

Segment Assets and Reconciliation to Consolidated Total Assets (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 174,319	$ 222,599
Other Unallocated Assets
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	45,048	66,924
Total Segment Assets
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	174,319	222,599
Direct Segment Assets
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	129,271	155,675
Direct Segment Assets | Life Finance
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	122,395	138,520
Direct Segment Assets | Structured settlements
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 6,876	$ 17,155

XML

Scheduled Maturities of Securities by Contractual Maturity (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Available for Sale - Amortized Cost
Due in one year or less	$ 14,628	$ 25,904
Due after one year but less than five years	4,802	20,243
Due after five years but less than ten years	4,690	11,160
Total available for sale securities	24,120	57,307
Available for Sale - Fair Value
Due in one year or less	14,655	25,892
Due after one year but less than five years	4,728	20,160
Due after five years but less than ten years	4,790	11,190
Total available for sale securities	$ 24,173	$ 57,242

XML

Investment in Life Settlements (Life Insurance Policies) (Tables)

9 Months Ended

Sep. 30, 2012

Investment in Life Settlements

The following table describes the Company’s investment in life settlements as of September 30, 2012 (dollars in thousands):

	Number of
	Life Settlement		Fair		Face
Remaining Life Expectancy (In Years)	Contracts		Value		Value
0 - 1		—	$	—	$	—
1 - 2		—		—		—
2 - 3		1		1,021		2,500
3 - 4		4		2,901		11,450
4 - 5		8		10,655		33,050
Thereafter		199		87,751		1,011,156
Total		212		102,328		1,058,156

The weighted average life expectancy calculated based on death benefit of insureds in the policies owned by the Company at December 31, 2011 was 10.6 years. The following table describes the Company’s investment in life settlements as of December 31, 2011 (in thousands):

Remaining Life Expectancy (In Years)	Number of Life Settlement Contracts		Fair Value		Face Value
0 - 1		—	$	—	$	—
1 - 2		1		3,033		5,000
2 - 3		2		2,484		4,500
3 - 4		4		7,084		20,200
4 - 5		3		2,357		7,950
Thereafter		180		75,959		897,816
Total		190		90,917		935,466

Estimated Premiums To Be Paid

Estimated premiums to be paid for each of the five succeeding fiscal years and thereafter, to keep the life insurance policies in force as of September 30, 2012, are as follows (in thousands):

Remainder of 2012		6,855
2013		27,755
2014		25,226
2015		25,462
2016		25,756
Thereafter		323,609
	$	434,663

XML

Stockholders Equity - Additional Information (Detail) (USD $)	1 Months Ended				9 Months Ended			9 Months Ended	1 Months Ended				1 Months Ended	9 Months Ended		3 Months Ended	1 Months Ended
	Feb. 28, 2011	Feb. 15, 2011	Feb. 11, 2011	Feb. 03, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2011 Common Stock	Feb. 11, 2011 Additional Warrants	Feb. 11, 2011 One-third	Feb. 11, 2011 One-third	Feb. 11, 2011 one-third	Feb. 11, 2011 Phantom Stock Agreement	Sep. 30, 2011 Omnibus Plan	Sep. 30, 2012 Omnibus Plan	Mar. 31, 2011 Omnibus Plan Phantom Stock Agreement	Jan. 31, 2011 Series F Preferred Stock Redeemable Preferred Stock	Jan. 31, 2011 Series F Preferred Stock Redeemable Preferred Stock Promissory Note	Feb. 11, 2011 Maximum	Sep. 30, 2011 Maximum
Stockholders Equity [Line Items]
Stock issued upon conversion of debt to equity								1,272,727									110,000
Debt converted to shares converted amount						$ 35,158,000		$ 30,000,000										$ 11,000,000
Cumulative rate of preferred return																	16.00%
Conversion of Impex debt and membership units into common shares (shares)				2,300,273
Stock issued under phantom stock agreements													27,000			27,000
Stock-based compensation expense					205,000	1,464,000							290,000			290,000
Warrants issued									187,188										4,053,333
Warrants exercise price			14.51
Warrant exercise price as percentage of offering price										120.00%	135.00%	150.00%
Warrant period expiry			7 years
Warrant vesting period			4 years
Sale of common stock in initial public offering	17,602,614	935,947	16,666,667
Common stock price per share	$ 10.75		$ 10.75
Proceeds from initial public offering	$ 174,233,000					$ 174,233,000
Common stock, shares outstanding				3,600,000	21,206,121	21,202,614	21,202,614
Common stock to be issued upon exercise of warrant																				4,240,521
Shares of common stock reserved for future grant														1,200,000
Options to purchase shares of common stock granted														665,956
Options to purchase shares of common stock, weighted average exercise price					$ 10.75		$ 10.75							$ 10.75	$ 10.75
Shares of restricted stock granted														3,507
Shares of common stock are available for future awards														530,537	1,200,000

XML

Changes in Fair Value for All Assets Using Material Level of Unobservable (Level 3) Inputs (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Life Finance
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	$ 90,917	$ 17,138
Purchase of contracts	130	48,057
Acquired in foreclosure	5,050	2,098
Unrealized change in fair value	(8,401)	14,811
Sale of contracts	(5,334)
Transfers into level 3
Transfers out of Level 3
Premiums paid	20,106	9,863
Policies lapsed/written off	(140)
Ending Balance	102,328	91,967
Changes in fair value included in earnings for the period relating to assets held	(8,638)	14,811
Structured settlements
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	12,376	1,446
Purchase of contracts	17,115	21,469
Unrealized change in fair value	1,588	2,145
Sale of contracts	(28,396)	(20,789)
Collections	(187)	(114)
Transfers into level 3
Transfers out of Level 3
Ending Balance	2,496	4,157
Changes in fair value included in earnings for the period relating to assets held	$ 429	$ 1,151

XML

Analysis of Unpaid Principal Balance Past due Loans (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Financing Receivable, Recorded Investment, Past Due [Line Items]
30-59 Days Past Due		$ 1,570
60-89 Days Past Due	43
Greater Than 90 Days Past Due	871	599
Total Past Due	914	2,169
Uninsured Loans
Financing Receivable, Recorded Investment, Past Due [Line Items]
Greater Than 90 Days Past Due	599	599
Total Past Due	599	599
Insured Loans
Financing Receivable, Recorded Investment, Past Due [Line Items]
30-59 Days Past Due		1,570
60-89 Days Past Due	43
Greater Than 90 Days Past Due	272
Total Past Due	$ 315	$ 1,570

XML

Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2012 Segment
Supplementary Insurance Information, by Segment [Line Items]
Number of operating segment	2

XML

Income Taxes - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
	Feb. 03, 2011	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income Taxes [Line Items]
Annual effective tax rate			0.00%	38.60%
Effective tax rate, valuation allowance for deferred tax assets			0.00%
Reduction in deferred tax valuation allowance associated with urealized gain in accumulated other comprehensive income			$ (46,000)
Provision for deferred tax liability	4,400,000
Deferred tax asset		4,300,000		4,300,000
Deferred tax liability increased				175,000
Deferred tax net of operating loss carry forward		11,200,000		11,200,000
Provision for current income taxes				1,100,000
Provision for income taxes		1,400,000
Unrecognized tax benefits			$ 6,300,000

XML

Segment Results and Reconciliation to Consolidated Net Income (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Agency fee income		$ 937,000		$ 6,564,000
Interest income	252,000	2,289,000	1,856,000	7,031,000
Origination income	45,000	1,753,000	483,000	5,858,000
Realized gain on sale of life settlements			291,000	5,000
Gain on forgiveness of debt		198,000		4,880,000
Unrealized change in fair value of structured settlements	409,000	928,000	1,587,000	2,145,000
Unrealized change in fair value of life settlements	(17,530,000)	(14,074,000)	(8,401,000)	14,811,000
Servicing fee income	271,000	376,000	955,000	1,447,000
Gain on maturities of life settlements with subrogation rights, net		3,188,000	6,090,000	3,188,000
Other income	123,000	155,000	989,000	481,000
Total income	(14,171,000)	(1,763,000)	11,978,000	52,308,000
Interest expense	141,000	1,660,000	1,219,000	7,431,000
Provision for losses on loan receivables		3,583,000	441,000	3,712,000
(Gain) loss on loans payoffs and settlements, net	(139,000)	261,000	14,000	3,927,000
Amortization of deferred costs	254,000	1,409,000	1,751,000	4,913,000
Legal fees	9,328,000	1,821,000	22,918,000	4,187,000
Professional fees	1,559,000	1,452,000	5,272,000	4,238,000
Insurance	626,000	186,000	1,712,000	548,000
Other selling, general and administrative expenses	771,000	1,652,000	2,730,000	4,173,000
(Loss) income before income taxes	(31,480,000)	(20,377,000)	(41,017,000)	836,000
(Benefit) provision for income taxes	5,000	7,827,000	46,000	(1,352,000)
Net loss	(31,475,000)	(12,550,000)	(40,971,000)	(516,000)
Life Finance
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Agency fee income		937,000		6,564,000
Interest income	180,000	2,145,000	1,613,000	6,712,000
Origination income	45,000	1,753,000	483,000	5,858,000
Realized gain on sale of life settlements			291,000	5,000
Gain on forgiveness of debt		198,000		4,880,000
Unrealized change in fair value of life settlements	(17,530,000)	(14,074,000)	(8,401,000)	14,811,000
Servicing fee income	271,000	376,000	955,000	1,447,000
Gain on maturities of life settlements with subrogation rights, net		3,188,000	6,090,000	3,188,000
Other income	16,000	8,000	175,000	182,000
Total income	(17,018,000)	(5,469,000)	1,206,000	43,647,000
Structured settlements
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Interest income	72,000	144,000	243,000	319,000
Realized gain on sale of life settlements	2,187,000	2,240,000	7,796,000	5,457,000
Unrealized change in fair value of structured settlements	409,000	928,000	1,587,000	2,145,000
Other income	101,000	50,000	354,000	195,000
Total income	2,769,000	3,362,000	9,980,000	8,116,000
Direct Segment Assets | Life Finance
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Interest expense	140,000	1,660,000	1,215,000	7,135,000
Provision for losses on loan receivables		3,583,000	441,000	3,712,000
(Gain) loss on loans payoffs and settlements, net	(139,000)	261,000	14,000	3,927,000
Loss on life settlements write off	140,000		140,000
Amortization of deferred costs	255,000	1,409,000	1,752,000	4,913,000
Personnel costs	1,099,000	2,192,000	4,663,000	5,121,000
Marketing				16,000
Legal fees	1,116,000	803,000	2,622,000	1,456,000
Professional fees	315,000	460,000	1,180,000	1,359,000
Insurance	313,000		806,000	133,000
Other selling, general and administrative expenses	443,000	863,000	1,205,000	1,390,000
Segment Reporting Information, Operating Expense, Total	3,682,000	11,231,000	14,038,000	29,162,000
Segment operating (loss) income	(20,700,000)	(16,700,000)	(12,832,000)	14,485,000
Direct Segment Assets | Structured settlements
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Personnel costs	2,443,000	2,959,000	7,033,000	6,544,000
Marketing	1,034,000	1,754,000	4,481,000	4,169,000
Legal fees	527,000	455,000	1,671,000	1,803,000
Professional fees	615,000	199,000	1,527,000	930,000
Insurance	313,000	67,000	799,000	216,000
Other selling, general and administrative expenses	328,000	1,467,000	1,362,000	1,573,000
Segment Reporting Information, Operating Expense, Total	5,260,000	6,901,000	16,873,000	15,235,000
Segment operating (loss) income	(2,491,000)	(3,539,000)	(6,893,000)	(7,119,000)
Consolidated
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segment operating (loss) income	(23,191,000)	(20,239,000)	(19,725,000)	7,366,000
(Benefit) provision for income taxes	(5,000)	(7,827,000)	(46,000)	1,352,000
Unallocated Income
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Other income	78,000	344,000	969,000	545,000
Unallocated Expenses
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Interest expense			3,000	296,000
Personnel costs	53,000	(315,000)	621,000	2,498,000
Legal fees	7,685,000	563,000	18,625,000	928,000
Professional fees	629,000	793,000	2,565,000	2,157,000
Insurance		119,000	107,000	199,000
Other selling, general and administrative expenses		(678,000)	340,000	997,000
Segment Reporting Information, Operating Expense, Total	$ 8,367,000	$ 482,000	$ 22,261,000	$ 7,075,000

XML

Changes in Life Expectancy Used to Estimate Fair Value (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Value	$ 102,328		$ 90,917
Change in Value	291	5
+6 LE Mths Adj
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Value	85,305
Change in Value	(17,023)
-6 LE Mths Adj
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Value	120,596
Change in Value	$ 18,268

XML

Subsequent Events

9 Months Ended

Sep. 30, 2012

Subsequent Events

(18) Subsequent Events

Class Action, Derivative Claims and the Insurance Coverage Declaratory Relief Complaint

On December 18, 2012, attorneys for Imperial signed a Term Sheet for Global Settlement Regarding Imperial Holdings, Inc. Matters (the “Term Sheet”). Also signing the Term Sheet were attorneys representing the plaintiffs in the previously disclosed class action lawsuits and derivative actions instituted against the Company as well attorneys for Imperial’s director and officer liability insurance carriers (“D&O Carriers”), certain individual defendants named in the class actions and the underwriters in Imperial’s initial public offering. The Term Sheet provides the terms upon which each of the parties represented by the signatories would be willing to settle the class action litigation and derivative actions as well as the declaratory relief action filed by Catlin, Imperial’s primary D&O Carrier.

While non-binding and subject to certain contingencies, the Term Sheet provides that each of the parties will endeavor to enter into definitive settlement agreements in respect of the class action litigation, derivative action and insurance coverage declaratory relief complaint, each of which are described in Note 16 above, by January 15, 2013. Although the Company does not expect that the definitive settlement agreements will be executed by January 15, 2013, the Company does expect to continue to work in good faith with the other parties to the Term Sheet to execute settlement agreements as soon as is practicable thereafter.

The terms of the class action settlement include a cash payment of $12.0 million, of which $11.0 million is to be contributed by Imperial’s primary and excess D&O Carriers; the issuance of two million warrants for shares of the Company’s stock with an estimated value of $3.1 million at the date of the signing of the Term Sheet. The value of the warrants will be re-assessed at issuance. The warrants will have a five-year term with an exercise price of $10.75 and will be issued when the settlement proceeds are distributed to the claimants. In addition, the underwriters in Imperial’s initial public offering are to waive their rights to indemnity and contribution by Imperial. The Company established a reserve related to the proposed settlement of $15.1 million, which is included in other liabilities and a receivable for insurance recoverable from the Company’s D&O Carrier of $11.0 million, which is included in prepaid and other assets. The $4.1 million net effect of the settlement is included in legal fees in the statement of operations for the three months ended September 30, 2012.

The derivative actions subject to ratification, would be settled for implementation of certain compliance reforms. The Term Sheet also contemplates payment by Imperial’s primary D&O carrier of $1.5 million for legal fees in respect of the derivative actions and the contribution of $500,000 in Imperial stock.

In addition, the Term Sheet contemplates that Imperial will contribute $500,000 to a trust to cover certain claims under its director and officer liability insurance policies.

The Company established a reserve related to the proposed derivative settlement and insurance trust of $2.5 million, which is included in other liabilities and a receivable for insurance recoverable from the Company’s D&O Carrier of $1.5 million, which is included in prepaid and other assets. The net effect of the settlement of $1.0 million is included in legal fees in the statement of operations for the three months ended September 30, 2012.

The proposed settlement also requires Imperial to advance legal fees to and indemnify certain individuals covered under the policies. The obligation to advance and indemnify on behalf of these individuals, while currently unquantifiable, may be substantial and could have a material adverse effect on the Company’s financial position and results of operations.

Use of Updated Life Expectancies

As stated in Note 12, during the quarter ended September 30, 2012 the Company began receiving updated life expectancy reports on all of the insureds represented in the Company’s portfolio of life insurance policies. While the Company is endeavoring to obtain updated life expectancy reports for all of its policies, at September 30, 2012, the Company had only received updated life expectancies for 64 of the 212 policies in its portfolio. Since September 30, 2012, however, the Company received additional updated life expectancies on 79 more policies. All updated reports that were obtained have been blended and inputted in the Company’s fair value model at September 30, 2012. The Company believes that applying the results of the 79 life expectancy reports produced after the valuation date is appropriate since it provides additional evidence about conditions that existed at the date of the balance sheet. The company recorded a non-cash charge of $20.1 million as unrealized loss on change in fair value of life settlements for the three months ended September 30, 2012.

Certain Balance Sheet Items

Cash and Cash Equivalents, inclusive of investment securities available for sale

We estimate that we will need to pay $6.9 million in premiums to keep our current portfolio of life insurance policies in force through 2012 and an additional $27.8 million to keep the portfolio in force through 2013. As of December 31, 2012 we had approximately $20.3 million of cash and cash equivalents, and marketable securities, including $1.1 million of restricted cash. Based on the Company’s current internal forecast, a liquidity shortfall will occur in the second quarter of 2013. Accordingly, to avoid lapsing policies, the Company is actively seeking additional capital to pay premiums by means of debt and/or equity financing. There can be no assurance, however, that the Company will be able to consummate a financing on favorable terms or at all. If the Company cannot obtain necessary financing, it may need to sell the policies that it owns, but there can be no assurance that the Company can consummate any sales or that, if consummated, sales of policies will be at or above their carrying values.

The Company also expects during that, as part of the framework for the settlement embodied by the Term Sheet, it will, among other things, agree to pay $1.0 million of a $12.0 million payment to settle the class action litigation and will agree to contribute $500,000 to a trust to cover certain claims under its director and officer liability insurance policies, which will further stress the Company’s liquidity position. In addition, under the Term Sheet, the Company will undertake to advance legal fees and indemnify certain individuals covered under its director and officer liability insurance policies. The obligation to advance and indemnify on behalf of these individuals, while currently unquantifiable, may be substantial and could have a adverse effect on the Company’s financial position and results of operations.

XML

Loans Receivable - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2011	Sep. 30, 2012 Loan	Sep. 30, 2011	Dec. 31, 2011 Loan	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2010
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest receivable		$ 1,356,000		$ 5,758,000
Loan impairment valuation	7,502,000	4,030,000	7,502,000	10,195,000			7,176,000
Investment in impaired loans with an allowance recorded investment		6,131,000		24,223,000
Related Allowance		0		0
With an allowance recorded, average recorded investment		15,177,000	34,100,000	31,611,000
Interest on impaired loans		166,000	1,100,000
Number of loans receivable originated		0		58
Loans principal balance	43,192,000	7,673,000	43,192,000	31,264,000	12,935,000	51,092,000	76,939,000
Loan impairment charges		1,100,000		1,900,000
Number of loans		31
Average loan daily balance		233,000
Proceeds from loan origination fees	2,549,000		18,385,000
Acorn Facility
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest receivable	545,000	0	545,000
Loans principal balance	2,400,000	0	2,400,000
Number of loans written off	8	0	8
Loans written off accreted origination fees		0	381,000
Loan impairment charges		0	72,000
Incurred loss in loans		0	3,300,000
Accrued and Unpaid Interest
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest receivable		1,100,000		5,300,000
Loan impairment valuation		1,100,000		1,900,000
Loan Origination
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans principal balance		0		18,300,000
Loan Portfolio
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan impairment charges		4,600,000	2,300,000
Average interest rate		12.90%
Number of loans paid off		79	131
Proceeds from loans payoff		24,000,000	26,300,000
Proceeds from loans principal balance		15,600,000	16,800,000
Proceeds from loans interest accrued		6,000,000	4,300,000
Proceeds from loan origination fees		6,600,000	6,700,000
Gain on loans transactions		$ 14,000	$ 736,000
Loan Portfolio | Minimum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan maturity period		2 years
Loan Portfolio | Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan maturity period		4 years

XML

Reconciliation of Pro Forma Basic and Diluted Earnings Per Share (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Numerator:
Net loss available to common stockholders	$ (31,475)		$ (12,550)		$ (40,971)		$ (516)
Denominator:
Weighted average common shares outstanding	21,206,121		21,202,614		21,205,622		18,728,435
Basic loss per share	$ (1.48)		$ (0.59)		$ (1.93)		$ (0.03)
Numerator:
Net loss available to common stockholders	(31,475)		(12,550)		(40,971)		(516)
Denominator:
Diluted weighted average shares outstanding	21,206,121		21,202,614		21,205,622		18,728,435
Diluted loss per share	$ (1.48)	[1],[2]	$ (0.59)	[1],[2]	$ (1.93)	[1],[2]	$ (0.03)	[1],[2]
Pro Forma
Numerator:
Net loss available to common stockholders							(338)	[3],[4]
Denominator:
Weighted average common shares outstanding							18,728,435
Basic loss per share							$ (0.02)
Numerator:
Net loss available to common stockholders							$ (338)	[3],[4]
Denominator:
Diluted weighted average shares outstanding							18,728,435
Diluted loss per share							$ (0.02)	[5]

[1] The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the three months and nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

[2] The computation of diluted EPS did not include 488,499 options and 4,240,521 warrants for the three months and nine months ended September 30, 2012, as the effect of their inclusion would have been anti-dilutive.

[3] Reflects a reduction of interest expense of $178,000, net of tax for the nine months ended September 30, 2011 due to the conversion of our promissory note in favor of IMPEX Enterprises, Ltd. into shares of our common stock, which occurred prior to the closing of our initial public offering, and the conversion of our promissory note in favor of Branch Office of Skarbonka Sp. z o.o into a $30.0 million debenture, and the conversion of that $30.0 million debenture into shares of our common stock, which occurred immediately prior to the closing of our initial public offering.

[4] For the pro forma period for the nine months ended September 30, 2011, the results of the Company being treated for the pro forma presentation as a "C" corporation resulted in no impact to the consolidated and combined balance sheet or statement of operations. The primary reasons for this are that the losses produce no current benefit and any net operating losses generated and other deferred assets (net of liabilities) at that time would have been fully reserved due to historical operating losses. The Company, therefore, has not recorded any pro forma tax provision.

[5] The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

XML

Notes and Debenture Payable - Additional Information (Detail) (USD $)			1 Months Ended			1 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2009 White Oak, Inc.	Sep. 30, 2012 White Oak, Inc.	Dec. 31, 2011 White Oak, Inc.	Sep. 30, 2009 White Oak, Inc. Minimum	Sep. 30, 2009 White Oak, Inc. Maximum	Dec. 02, 2009 Cedar Lane	Sep. 30, 2012 Cedar Lane	Dec. 31, 2011 Cedar Lane	Sep. 30, 2012 Cedar Lane Premium Financed	Dec. 31, 2011 Cedar Lane Premium Financed
Debt Instrument [Line Items]
Credit facility, minimum borrowing								$ 5,000,000
Credit facility, maximum borrowing			27,000,000					250,000,000
Credit facility, borrowing period								28 months
Credit facility, interest rate term								Annual interest rate of 14%, 15% or 16%, depending on the class of lender and are compounded monthly.
Credit facility covenants								The Company is subject to several restrictive covenants under the facility. The restrictive covenants include items such as restrictions on the ability to pay dividends or incur additional indebtedness by Imperial PFC Financing II, LLC. The Company believes it is in compliance at September 30, 2012.
Credit facility covenants compliance								The Company believes it is in compliance at September 30, 2012.
Credit facility outstanding				0	172,000						1,200,000	19,100,000
Accrued interest	358,000	5,505,000		0	104,000				358,000	5,400,000
Credit facility, principal percentage amount									2.00%	2.00%
Restricted cash	1,148,000	691,000							1,023,000	691,000
Credit facility, increase			$ 12,000,000
Notes payable repayment period						6 months	26 months
Credit facility, maturity date			Mar. 11, 2012

XML

Description of Business - Additional Information (Detail) (USD $)	1 Months Ended			9 Months Ended		12 Months Ended
	Feb. 28, 2011	Feb. 15, 2011	Feb. 11, 2011	Sep. 30, 2012 Segment	Sep. 30, 2011	Dec. 31, 2011
Organization and Nature of Operations [Line Items]
Number of reportable segments				2
Sale of common stock in initial public offering	17,602,614	935,947	16,666,667
Common stock price per share	$ 10.75		$ 10.75
Proceeds from initial public offering	$ 174,233,000				$ 174,233,000
Number of policies				12
Percentage of revenues						58.20%
US Government ongoing investigation for criminal conduct						$ 8,000,000
Non-Prosecution Agreement terms description						The Non-Prosecution Agreement has a term of three years, but after two years the Company may petition the USAO to forego the final year of the Non-Prosecution Agreement, if we otherwise comply with all of our obligations under the Non-Prosecution Agreement.
Non-Prosecution Agreement terms						3 years

XML

Loan Impairment Valuation (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Financing Receivable, Impaired [Line Items]
Balance at beginning of period			$ 10,195	$ 7,176
Provision for loan losses		(3,583)	(441)	(3,712)
Charge-offs			(6,525)	(3,011)
Balance at end of period	4,030	7,502	4,030	7,502
Loan Impairment Valuation
Financing Receivable, Impaired [Line Items]
Balance at beginning of period	6,826	6,390	12,115	8,516
Provision for loan losses		3,583	441	3,712
Charge-offs	(1,739)	(1,081)	(7,469)	(3,336)
Balance at end of period	5,087	8,892	5,087	8,892
Loans Receivable | Loan Impairment Valuation
Financing Receivable, Impaired [Line Items]
Balance at beginning of period	5,517	5,201	10,195	7,176
Provision for loan losses		3,264	360	3,337
Charge-offs	(1,487)	(963)	(6,525)	(3,011)
Balance at end of period	4,030	7,502	4,030	7,502
Interest Receivable | Loan Impairment Valuation
Financing Receivable, Impaired [Line Items]
Balance at beginning of period	1,309	1,189	1,920	1,340
Provision for loan losses		319	81	375
Charge-offs	(252)	(118)	(944)	(325)
Balance at end of period	$ 1,057	$ 1,390	$ 1,057	$ 1,390

XML

Estimated Premiums to be Paid (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012
Life Insurance Premiums and Related Investment Income [Line Items]
Remainder of 2012	$ 6,855
2013	27,755
2014	25,226
2015	25,462
2016	25,756
Thereafter	323,609
Estimated future premium payments	$ 434,663

XML

Common Stock Options Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012
Number of Shares
Options outstanding, December 31, 2011	627,419
Options granted
Options exercised
Options forfeited	(138,920)
Options expired
Options outstanding, September 30, 2012	488,499
Exercisable at September 30, 2012	287,988
Unvested at September 30, 2012	200,511
Weighted Average Price Per Share
Options outstanding, December 31, 2011	$ 10.75
Options granted
Options exercised
Options forfeited	$ 10.75
Options expired
Options outstanding, September 30, 2012	$ 10.75
Exercisable at September 30, 2012	$ 10.74
Unvested at September 30, 2012	$ 10.75
Weighted Average Remaining Contractual Term
Options outstanding, December 31, 2011	6 years 1 month 10 days
Exercisable at September 30, 2012	5 years 4 months 10 days
Unvested at September 30, 2012	5 years 4 months 10 days
Aggregate Intrinsic Value
Options outstanding, December 31, 2011
Options granted
Options exercised
Options forfeited
Options expired
Options outstanding, Ending Balance
Exercisable at September 30, 2012
Unvested at September 30, 2012

XML

Securities in Continuous Unrealized Loss Position (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Less than 12 Months Estimated Fair Value	$ 7,041	$ 31,978
Less than 12 Months Unrealized Loss	(89)	(136)
12 Months or More Estimated Fair Value
12 Months or More Unrealized Loss
Total Estimated Fair Value	7,041	31,978
Total Unrealized Loss	(89)	(136)
Corporate Bonds
Schedule of Available-for-sale Securities [Line Items]
Less than 12 Months Estimated Fair Value	7,041	26,051
Less than 12 Months Unrealized Loss	(89)	(127)
12 Months or More Estimated Fair Value
12 Months or More Unrealized Loss
Total Estimated Fair Value	7,041	26,051
Total Unrealized Loss	(89)	(127)
Government Bonds
Schedule of Available-for-sale Securities [Line Items]
Less than 12 Months Estimated Fair Value		5,927
Less than 12 Months Unrealized Loss		(9)
12 Months or More Estimated Fair Value
12 Months or More Unrealized Loss
Total Estimated Fair Value		5,927
Total Unrealized Loss		$ (9)

XML

Principles of Consolidation and Basis of Presentation

9 Months Ended

Sep. 30, 2012

Principles of Consolidation and Basis of Presentation

(2) Principles of Consolidation and Basis of Presentation

The accompanying unaudited consolidated and combined financial statements include the accounts of the Company, all of its wholly-owned subsidiaries and its special purpose entities, with the exception of Imperial Settlements Financing 2010, LLC (“ISF 2010”), an unconsolidated special purpose entity (see Note 10). The special purpose entities have been created to fulfill specific objectives. Also included in the consolidated and combined financial statements is Imperial Life Financing, LLC which is owned by two stockholders of the Company and is combined with the Company for reporting purposes. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited consolidated and combined financial statements have been prepared in conformity with the rules and regulations of the SEC for Form 10-Q and therefore do not include certain information, accounting policies, and footnote disclosures information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with generally accepted accounting principles. However, all adjustments (consisting of normal recurring accruals), which, in the opinion of management, are necessary for a fair presentation of the financial statements, have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. These interim financial statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in Imperial’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Gain on Maturities of Life Settlements with Subrogation Rights, net

Every credit facility entered into by subsidiaries of the Company between December 2007 and December 2010 to finance the premium finance lending business required lender protection insurance for each loan originated under such credit facility. Generally, when the Company exercises its right to foreclose on collateral the Company’s lender protection insurer has the right to direct control or take beneficial ownership of the life insurance policy, subject to the terms and conditions of the lender protection insurance policy, including notice and timing requirements. Otherwise, the lender protection insurer maintains its salvage collection and subrogation rights. The lender protection insurer’s salvage collection and subrogation rights generally provide a remedy by which the insurer can seek to recover an amount equal to but not greater than the amount of the lender protection claim paid plus premiums paid by it, expenses and interest thereon.

In those instances where the Company has foreclosed on the collateral, the lender protection insurer has maintained its salvage collection and subrogation rights, and has been covering the cost of the ongoing premiums needed to maintain these life insurance policies. However, the lender protection insurer may elect at any time to discontinue the payment of premiums which would result in lapse of the policies if the Company does not otherwise pay the premiums. The Company views these policies as having uncertain value because the lender protection insurer controls what happens to the policy from a payment of premium standpoint, and the amount of the lender protection insurer’s salvage collection and subrogation claim rights on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. For these reasons, these policies are considered contingent assets and not included in the amount of life settlements on the accompanying consolidated and combined balance sheet.

The Company accounts for the maturities of life settlements with subrogation rights, net of subrogation expenses as contingent gains in accordance with Accounting Standards Codification (ASC) 450, Contingencies and recognizes the revenue from the maturities of these policies when all contingencies are resolved.

Use of Estimates

The preparation of these consolidated and combined financial statements, in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and such differences could be material. Significant estimates made by management include the loan impairment valuation, allowance for doubtful accounts, income taxes, valuation of securities available for sale, valuation of structured settlements and the valuation of investments in life settlements.

Change in Accounting Estimate

The Company has elected to account for the life settlement policies it acquired using the fair value method. The fair value of life settlement policies is determined on a discounted cash flow basis, incorporating current life expectancy, expected premiums and discount rate assumptions (see Note 12). During the first quarter of 2011, the Company made revisions to the application of its valuation technique and assumptions used to measure fair value of the life settlement policies it acquired. The Company accounted for this change in accounting estimate prospectively in accordance with ASC 250-10-45-17, Change in Accounting Estimate, resulting in recognition of a pretax gain of $3.0 million recorded in unrealized change in fair value of life settlements in the accompanying consolidated and combined statement of operations for the nine months ended September 30, 2011.

The Company’s decision to revise its fair value calculations used to value all life insurance policies on hand at December 31, 2010 was driven by two factors. Firstly, with consideration to the wind-down of the lender protection insurance coverage (LPIC) program, which ended on December 31, 2010, the value of the collateral serving the Company’s new lending activity is no longer determined primarily by the limit of liability provided by the LPIC coverage. Instead, the value of the collateral was based solely on the Company’s valuation model. Secondly, as a result of the Company’s initial public offering in February, 2011 and the new capital structure provided by it, the Company planned to build and retain a large and diversified pool of life policies.

As discussed above, the Company uses a discounted cash flow model to calculate the fair value of its life insurance policy portfolio. That model is based on three principal factors: life expectancy, expected premiums and the discount rate. As discussed in Note 12, the Company began receiving updated life expectancy reports on the insureds represented in the Company’s portfolio of life insurance policies. As a result, the calculation of the life expectancy and discount rate inputs have changed. While the Company is endeavoring to obtain updated life expectancy reports for all of its policies, at September 30, 2012, the Company had only received updated life expectancies for 64 of the 212 policies in its portfolio. Since September 30, 2012, however, the Company received additional updated life expectancies on 79 more policies. All updated reports that were obtained have been blended and inputted in the Company’s fair value model at September 30, 2012, which drove a decline of $30.3 million in the fair market value of the Company’s portfolio of life insurance policies. This decline was partially offset by premium payments, accretion due to the passage of time, and other changes to the Company’s fair value model, which resulted in a net unrealized change in fair value of approximately $17.5 million during the quarter ended September 30, 2012. See Note 18 – Subsequent Event

XML

Activity of Unvested Restricted Common Shares (Detail)	9 Months Ended
	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding December 31, 2011	3,507
Granted
Vested	(3,507)
Forfeited
Outstanding September 30, 2012

XML

Reconciliation of Pro Forma Basic and Diluted Earnings Per Share (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Interest expense	$ 141,000	$ 1,660,000	$ 1,219,000	$ 7,431,000
Conversion of debt to common stock				35,158,000
Stock Options
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	488,499	665,956	488,499	665,956
Warrant
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	4,240,521	4,240,521	4,240,521	4,240,521
Pro Forma
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Interest expense				178,000
Conversion of debt to common stock				30,000,000
Pro Forma | Stock Options
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share				665,956
Pro Forma | Warrant
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share				4,240,521
After Conversion | Pro Forma
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Interest expense				$ 178,000

XML

Loans Receivable (Tables)

9 Months Ended

Sep. 30, 2012

Summary of Loans Receivable

A summary of loans receivables at September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,			December 31,
	2012			2011
Loan principal balance	$	7,673		$	31,264
Loan origination fees, net		1,751			8,307
Loan impairment valuation		(4,030	)		(10,195	)
Loans receivable, net	$	5,394		$	29,376

Changes In Loans Receivable Principal Balance

An analysis of the changes in loans receivable principal balance during the three months and nine months ended September 30, 2012 and 2011 is as follows (in thousands):

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2012			2011			2012			2011
Loan principal balance, beginning	$	12,935		$	51,092		$	31,264		$	76,939
Loan originations		—			2,549			—			18,385
Subsequent year premiums paid, net of reimbursement		—			34			—			326
Loan write-offs		—			(662	)		—			(2,950	)
Loan payoffs		(2,712	)		(8,809	)		(16,037	)		(47,867	)
Loans transferred to investments in life settlements		(2,550	)		(1,012	)		(7,554	)		(1,641	)
Loan principal balance, ending	$	7,673		$	43,192		$	7,673		$	43,192

Analysis of Loan Impairment Valuation

An analysis of the loan impairment valuation for the three months ended September 30, 2012 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period	$	5,517		$	1,309		$	6,826
Charge-offs		(1,487	)		(252	)		(1,739	)
Balance at end of period	$	4,030		$	1,057		$	5,087

An analysis of the loan impairment valuation for the three months ended September 30, 2011 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period	$	5,201		$	1,189		$	6,390
Provision for loan losses		3,264			319			3,583
Charge-offs		(963	)		(118	)		(1,081	)
Balance at end of period	$	7,502		$	1,390		$	8,892

An analysis of the loan impairment valuation for the nine months ended September 30, 2012 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period		10,195			1,920			12,115
Provision for loan losses		360			81			441
Charge-offs		(6,525	)		(944	)		(7,469	)
Balance at end of period	$	4,030		$	1,057		$	5,087

An analysis of the loan impairment valuation for the nine months ended September 30, 2011 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period		7,176			1,340			8,516
Provision for loan losses		3,337			375			3,712
Charge-offs		(3,011	)		(325	)		(3,336	)
Balance at end of period	$	7,502		$	1,390		$	8,892

Analysis of Allowance for Loan Losses and Recorded Investment in Loans by Loan Type

An analysis of the allowance for loan losses and recorded investment in loans by loan type for the nine months ended September 30, 2012 is as follows (in thousands):

	Uninsured			Insured
	Loans			Loans			Total
Loan impairment valuation
Balance at beginning of period		7,103			3,092			10,195
Provision for losses	$	—		$	360		$	360
Charge-offs		(3,687	)		(2,838	)		(6,525	)
Ending balance	$	3,416		$	614		$	4,030
Ending balance: individually evaluated for impairment	$	3,416		$	614		$	4,030

All loans were individually evaluated for impairment as of September 30, 2012. There were no loans collectively evaluated for impairment and there were no loans acquired with deteriorated credit quality.

An analysis of the allowance for loan losses and recorded investment in loans by loan type for the nine months ended September 30, 2011 is as follows (in thousands):

	Uninsured			Insured
	Loans			Loans			Total
Loan impairment valuation
Balance at beginning of period	$	869		$	6,307		$	7,176
Provision for loan losses		3,318			19			3,337
Charge-offs		(407	)		(2,604	)		(3,011	)
Ending balance	$	3,780		$	3,722		$	7,502
Ending balance: individually evaluated for impairment	$	3,780		$	3,722		$	7,502

Analysis of Credit Ratings

An analysis of the credit ratings of life insurance carriers that issued life insurance policies that serve as our loan collateral by loan type at September 30, 2012 is presented in the following table (dollars in thousands):

	Uninsured					Insured(1)
S&P Designation	Unpaid Principal Balance		Percent			Unpaid Principal Balance		Percent
AAA	$	—		0.00	%	$	—		0.00	%
AA+		694		11.39	%		—		0.00	%
AA		—		0.00	%		—		0.00	%
AA-		3,550		58.25	%		696		44.10	%
A+		1,242		20.38	%		93		5.87	%
A1		—		0.00	%		—		0.00	%
A		543		8.91	%		101		6.40	%
A-		65		1.07	%		689		43.63	%
Total	$	6,094		100	%	$	1,579		100	%

(1) All of the Company’s insured loans have lender protection coverage with Lexington Insurance Company. As of September 30, 2012, Lexington had a financial strength rating of “A” with a stable outlook by Standard & Poor’s.

An analysis of the credit ratings of life insurance carriers that issued life insurance policies that serve as our loan collateral by loan type at December 31, 2011 is presented in the following table (dollars in thousands):

	Uninsured					Insured(1)
S&P Designation	Unpaid Principal Balance		Percent			Unpaid Principal Balance		Percent
AAA	$	—		0.00	%	$	—		0.00	%
AA+		694		5.08	%		222		1.26	%
AA		—		0.00	%		—		0.00	%
AA-		6,558		48.05	%		9,085		51.57	%
A+		3,060		22.42	%		1,287		7.31	%
A1		—		0.00	%		—		0.00	%
A		3,336		24.44	%		7,022		39.86	%
A-		—		0.00	%		—		0.00	%
Total	$	13,648		100	%	$	17,616		100	%

(1) All of the Company’s insured loans have lender protection coverage with Lexington Insurance Company. As of December 31, 2011, Lexington had a financial strength rating of “A” by Standard & Poor’s.

Summary of Investment In Impaired Loans

A summary of our investment in impaired loans at September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,		December 31,
	2012		2011
Loan receivable, net	$	5,063	$	17,424
Interest receivable, net		1,068		6,799
Investment in impaired loans	$	6,131	$	24,223

Impaired Loans With and Without Related Allowance

An analysis of impaired loans with and without a related allowance at September 30, 2012 is presented in the following table by loan type (in thousands):

			Unpaid				Average		Interest
	Recorded		Principal		Related		Recorded		Income
	Investment		Balance		Allowance		Investment		Recognized
With no related allowance recorded:
Uninsured Loans	$	—	$	—	$	—	$	—	$	—
Insured Loans		—		—		—		—		—
With an allowance recorded:
Uninsured Loans		4,722		6,074		3,991		7,437		1,612
Insured Loans		1,409		1,374		1,097		7,740		513
Total Impaired Loans	$	6,131	$	7,448	$	5,088	$	15,177	$	2,125

An analysis of impaired loans with and without a related allowance at December 31, 2011 is presented in the following table by loan type (in thousands):

			Unpaid				Average		Interest
	Recorded		Principal		Related		Recorded		Income
	Investment		Balance		Allowance		Investment		Recognized
With no related allowance recorded:
Uninsured Loans	$	—	$	—	$	—	$	—	$	—
Insured Loans		—		—		—		—		—
With an allowance recorded:
Uninsured Loans		10,153		13,628		6,894		6,764		1,684
Insured Loans		14,070		10,391		3,301		24,847		3,195
Total Impaired Loans	$	24,223	$	24,019	$	10,195	$	31,611	$	4,879

Analysis of Unpaid Principal Balance of Past Due Loans

An analysis of the unpaid principal balance of past due loans at September 30, 2012 is presented in the following table by loan type (in thousands):

					Greater Than
	30-59 Days		60-89 Days		90 Days		Total
	Past Due		Past Due		Past Due		Past Due
Uninsured Loans	$	—	$	—	$	599	$	599
Insured Loans		—		43		272		315
Total	$	—	$	43	$	871	$	914

An analysis of the unpaid principal balance of past due loans at December 31, 2011 is presented in the following table by loan type (in thousands):

	30-59 Days Past Due		60-89 Days Past Due		Greater Than 90 Days Past Due		Total Past Due
Uninsured Loans	$	—	$	—	$	599	$	599
Insured Loans		1,570		—		—		1,570
Total	$	1,570	$	—	$	599	$	2,169

XML

Investment Securities Available for Sale (Tables)

9 Months Ended

Sep. 30, 2012

Amortized Cost and Estimated Fair Values of Securities Available for Sale

The amortized cost and estimated fair values of securities available for sale at September 30, 2012 are as follows (in thousands):

	September 30, 2012
	Amortized		Gross Unrealized		Gross Unrealized			Estimated
Description of Securities	Cost		Gains		Losses			Fair Value
Corporate bonds	$	19,118		39	$	(89	)	$	19,068
Government bonds		4,690		100		—			4,790
Other bonds		312		3		—			315
Total available for sale securities	$	24,120	$	142	$	(89	)	$	24,173

The amortized cost and estimated fair values of securities available for sale at December 31, 2011 are as follows (in thousands):

	December 31, 2011
Description of Securities	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate bonds	$	41,697	$	32	$	(127	)	$	41,602
Government bonds		14,789		39		(9	)		14,819
Other bonds		821		—		—			821
Total available for sale securities	$	57,307	$	71	$	(136	)	$	57,242

Scheduled Maturities of Securities by Contractual Maturity

The scheduled maturities of securities (in thousands) at September 30 2012, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	September 30, 2012
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	14,628	$	14,655
Due after one year but less than five years		4,802		4,728
Due after five years but less than ten years		4,690		4,790
Total available for sale securities	$	24,120	$	24,173

The scheduled maturities of securities (in thousands) at December 31, 2011, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	December 31, 2011
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	25,904	$	25,892
Due after one year but less than five years		20,243		20,160
Due after five years but less than ten years		11,160		11,190
Total available for sale securities	$	57,307	$	57,242

Securities in Continuous Unrealized Loss Position

Information pertaining to securities with gross unrealized losses (in thousands) at September 30, 2012, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position is as follows:

	September 30, 2012
	Less than 12 Months		12 Months or More							Total
	Estimated		Unrealized			Estimated		Unrealized		Estimated		Unrealized
Description of Securities	Fair Value		Loss			Fair Value		Loss		Fair Value		Loss
Corporate bonds		7,041		(89	)		—		—		7,041		(89	)
Total available for sale securities	$	7,041	$	(89	)	$	—	$	—	$	7,041	$	(89	)

Information pertaining to securities with gross unrealized losses (in thousands) at December 31, 2011, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position is as follows:

	December 31, 2011
	Less than 12 Months		12 Months or More							Total
Description of Securities	Estimated Fair Value		Unrealized Loss			Estimated Fair Value		Unrealized Loss		Estimated Fair Value		Unrealized Loss
Corporate bonds	$	26,051	$	(127	)	$	—	$	—	$	26,051	$	(127	)
Government bonds		5,927		(9	)		—		—		5,927		(9	)
Total available for sale securities	$	31,978	$	(136	)	$	—	$	—	$	31,978	$	(136	)

XML

Impaired Loans With and Without Related Allowance (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Financing Receivable, Impaired [Line Items]
With no Related Allowance	$ 0		$ 0
With an allowance recorded, recorded investment	6,131,000		24,223,000
With an related allowance recorded, unpaid principal balance	7,448,000		24,019,000
Related Allowance	5,088,000		10,195,000
With an allowance recorded, average recorded investment	15,177,000	34,100,000	31,611,000
With an allowance recorded, interest income recognized	2,125,000		4,879,000
Uninsured Loans
Financing Receivable, Impaired [Line Items]
With no related allowance recorded, recorded investment
With no related allowance recorded, unpaid principal balance
With no Related Allowance
With no related allowance recorded, recorded investment
With no related allowance recorded, interest income recognized
With an allowance recorded, recorded investment	4,722,000		10,153,000
With an related allowance recorded, unpaid principal balance	6,074,000		13,628,000
Related Allowance	3,991,000		6,894,000
With an allowance recorded, average recorded investment	7,437,000		6,764,000
With an allowance recorded, interest income recognized	1,612,000		1,684,000
Insured Loans
Financing Receivable, Impaired [Line Items]
With no related allowance recorded, recorded investment
With no related allowance recorded, unpaid principal balance
With no Related Allowance
With no related allowance recorded, recorded investment
With no related allowance recorded, interest income recognized
With an allowance recorded, recorded investment	1,409,000		14,070,000
With an related allowance recorded, unpaid principal balance	1,374,000		10,391,000
Related Allowance	1,097,000		3,301,000
With an allowance recorded, average recorded investment	7,740,000		24,847,000
With an allowance recorded, interest income recognized	$ 513,000		$ 3,195,000

XML

Gain on Maturities of Life Settlements with Subrogation Rights, net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Sep. 30, 2011	Sep. 30, 2011
Insurance Risks [Line Items]
Policy collection, net of subrogation expenses		$ 3,500,000
Face value of policy		10,000,000	10,000,000
Death benefit recognized, net of subrogation expenses			3,200,000
Subrogation Expenses	910,000		312,000
Proceed collected from insurance settlements	$ 6,100,000

XML

Origination Fees (Tables)

9 Months Ended

Sep. 30, 2012

Summary of Balance of Origination Fees

A summary of the balance of origination fees that is included in loans receivable in the consolidated and combined balance sheet as of September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,			December 31,
	2012			2011
Loan origination fees gross	$	2,127		$	10,844
Un-accreted origination fees		(399	)		(2,666	)
Amortized loan origination costs		23			129
	$	1,751		$	8,307

XML

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2012

Assumptions Used

Assumptions used for the periods covered herein, are outlined in the table below:

	Nine Months Ended September 30, 2011
Expected Volatility	54.18% — 54.23%
Expected Dividend	0%
Expected Term in Years	4.5
Risk Free Rate	2.16% — 2.29%

Activity of Outstanding Stock Options

The following table presents the activity of the Company’s outstanding stock options of common stock for the nine-month period ended September 30, 2012:

Common Stock Options	Number of Shares			Weighted Average Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Options outstanding, December 31, 2011		627,419		$	10.75		6.11	$	—
Options granted		—			—		—		—
Options exercised		—			—		—		—
Options forfeited		(138,920	)		10.75		—		—
Options expired		—					—		—
Options outstanding, September 30, 2012		488,499		$	10.75			$	—
Exercisable at September 30, 2012		287,988			10.74		5.36	$	—
Unvested at September 30, 2012		200,511		$	10.75		5.36	$	—

Activity of Unvested Restricted Common Shares

The following table presents the activity of the Company’s unvested restricted common shares for the nine-month period ended September 30, 2012:

Common Unvested Shares	Number of Shares
Outstanding December 31, 2011		3,507
Granted		—
Vested		(3,507	)
Forfeited		—
Outstanding September 30, 2012		—

XML

Description of Business

9 Months Ended

Sep. 30, 2012

Description of Business

(1) Description of Business

Imperial Holdings, Inc. (“Imperial,” the “Company,” “we” or “us”) was formed pursuant to an operating agreement dated December 15, 2006 between IFS Holdings, Inc., IMEX Settlement Corporation, Premium Funding, Inc. and Red Oak Finance, LLC. The Company, operating through its subsidiaries, is a specialty finance company with its corporate office in Boca Raton, Florida. The Company operates in two reportable business segments: life finance (formerly referred to as premium finance) and structured settlements. In the life finance business, the Company earns revenue/income from interest charged on loans, loan origination fees, agency fees from referring agents, servicing income, changes in the fair value of life settlements the Company acquires and receipt of death benefits with respect to matured life insurance policies it owns. In the structured settlement business, the Company purchases structured settlements at a discounted rate and sells such assets to third parties.

In February 2011, the Company completed the sale of 17,602,614 shares of common stock in its initial public offering at a price of $10.75 per share. The Company received net proceeds of approximately $174.2 million after deducting the underwriting discounts and commissions and its offering expenses.

Imperial Holdings, Inc. succeeded to the business of Imperial Holdings, LLC and its assets and liabilities pursuant to the corporate conversion of Imperial Holdings, LLC effective February 3, 2011.

On September 27, 2011, a search warrant was executed at the Company’s headquarters and the Company was informed that it was being investigated by the U.S. Attorney’s Office for the District of New Hampshire (the “USAO Investigation”). At that time, the Company was also informed that its chief executive officer and then chairman, president and chief operating officer, former general counsel, two vice presidents, three life finance sales executives and a funding manager were also considered “targets” of the USAO Investigation. The USAO Investigation focused on the Company’s premium finance loan business. On September 28, 2011, the Company’s board of directors formed a special committee, comprised of all of the Company’s independent directors, to conduct an independent investigation in connection with the USAO Investigation. In December 2011, the U.S. Attorney’s Office for the District of New Hampshire (the “USAO”) confirmed that Mr. Antony Mitchell, our chief executive officer, was no longer a target of the USAO investigation.

On February 17, 2012, the Company received a subpoena issued by the staff of the U.S. Securities and Exchange Commission (the “SEC”) seeking documents from 2007 through the present, generally related to the Company’s premium finance business and corresponding financial reporting. The SEC is investigating whether any violations of federal securities laws have occurred and the Company has been cooperating with the SEC regarding this matter. The Company is unable to predict what action, if any, might be taken in the future by the SEC or its staff as a result of the matters that are the subject of the subpoena or what impact, if any, the cost of responding to the subpoena might have on the Company’s financial position, results of operations, or cash flows. The Company has not established any provision for losses in respect of this matter or in respect of the class action lawsuits and derivative actions related to the USAO Investigation. See Notes 16 and 18 for more information regarding these matters.

On April 30, 2012, the Company entered into a Non-Prosecution Agreement (the “Non-Prosecution Agreement”) with the USAO, which agreed not to prosecute the Company for its involvement in the making of misrepresentations on life insurance applications in connection with its premium finance business or any potential securities fraud claims related to its premium finance business. In the Non-Prosecution Agreement, the USAO and the Company agreed among other things, that the following facts are true and correct: (i) at all relevant times (x) certain insurance companies required that the prospective insured applying for a life insurance policy, and sometimes the agent, disclose information relating to premium financing on applications for life insurance policies, and (y) the questions typically required the prospective insured to disclose if he or she intended to seek premium financing in connection with the policy and sometimes required the agent to disclose if he or she was aware of any such intent on the part of the applicant; (ii) in connection with a portion of the Company’s retail operation known as “retail non-seminar” that began in December 2006 and was discontinued in January 2009, Imperial had a practice of disclosing on applications that the prospective insured was seeking premium financing when the life insurance company allowed premium financing from Imperial; however, in certain circumstances, Imperial internal life agents facilitated and/or made misrepresentations on applications that the prospective insured was not seeking premium financing when the insurance carrier was likely to deny the policy on the basis of premium financing; and (iii) to the extent that external agents, brokers and insureds caused other misrepresentations to be made in life insurance applications in connection with the retail non-seminar business, Imperial failed to appropriately tailor controls to prevent potential fraudulent practices in that business. As of September 30, 2012, the Company had 12 policies in its portfolio that once served as collateral for premium finance loans derived through the retail non-seminar business.

In connection with the Non-Prosecution Agreement, Imperial voluntarily agreed to terminate its premium finance business, which accounted for approximately 58.2% of its revenues in the year ended December 31, 2011, and terminated certain senior sales staff associated with the premium finance business. Additionally, the Company paid the United States Government $8.0 million, and agreed to cooperate fully with the USAO’s ongoing investigation and to refrain from and self-report any criminal conduct. The Non-Prosecution Agreement has a term of three years, but after two years the Company may petition the USAO to forego the final year of the Non-Prosecution Agreement, if we otherwise comply with all of our obligations under the Non-Prosecution Agreement. Should the USAO conclude that Imperial has not abided by its obligations under the Non-Prosecution Agreement, the USAO could choose to terminate the Non-Prosecution Agreement, resume its investigation of the Company, or bring charges against Imperial.

On August 2, 2012, the Board of Directors of the Company appointed Andrew Dakos, Phillip Goldstein and Gerald Hellerman to serve as directors of the Company in connection with a settlement (the “Settlement”) with Opportunity Partners L.P. (“Opportunity”). The Settlement resulted in Opportunity withdrawing its demand for a special meeting of shareholders, which it had submitted to the Company on May 23, 2012 and agreeing to dismiss its lawsuit to compel an annual meeting of shareholders. In connection with the Settlement, Walter Higgins and A. Penn Wyrough resigned from the Board of Directors. On August 14, 2012, Antony Mitchell, the Company’s chief executive officer, resigned as Chairman of the Board (though he continues to serve as a director and the Company’s chief executive officer) and Mr. Goldstein was elected Chairman.

Life Finance

Our life finance segment is comprised of our premium finance loan and life settlements businesses. The Company historically provided premium finance loans for individual life insurance policies and, commencing in 2011, began using its life settlement provider licenses to purchase life insurance policies. As described above, the Company voluntarily terminated its premium finance business in connection with the Non-Prosecution Agreement with the USAO. We had effectively suspended originating premium finance loans, however, as of the end of the third quarter of 2011.

Structured Settlements

Washington Square Financial, LLC, a wholly owned subsidiary of the Company, purchases structured settlements from individuals. Structured settlements refer to a contract between a plaintiff and defendant, whereby the plaintiff agrees to settle a lawsuit (usually a personal injury, product liability or medical malpractice claim) in exchange for periodic payments over time. A defendant’s payment obligation with respect to a structured settlement is usually assumed by a casualty insurance company. This payment obligation is then satisfied by the casualty insurer through the purchase of an annuity from a highly rated life insurance company, thereby providing a high credit quality stream of payments to the plaintiff.

Recipients of structured settlements are permitted to sell their deferred payment streams to a structured settlement purchaser pursuant to state statutes that require certain disclosures, notice to the obligors and state court approval. Through such sales, the Company purchases a certain number of fixed, scheduled future settlement payments on a discounted basis in exchange for a single lump sum payment.

XML

Structured Settlements (Tables)

9 Months Ended

Sep. 30, 2012

Balances of Structured Settlements

The balances of the Company’s structured settlements are as follows (in thousands):

	September 30,		December 31,
	2012		2011
Structured settlements — at cost	$	1,783	$	1,553
Structured settlements—at fair value		2,496		12,376
Structured settlements receivable, net	$	4,279	$	13,929

XML

Reconciliation of Actual Basic and Diluted Earnings Per Share (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Numerator:
Net loss available to common stockholders	$ (31,475)		$ (12,550)		$ (40,971)		$ (516)
Denominator:
Weighted average common shares outstanding	21,206,121		21,202,614		21,205,622		18,728,435
Basic loss per share	$ (1.48)		$ (0.59)		$ (1.93)		$ (0.03)
Numerator:
Net loss available to common stockholders	$ (31,475)		$ (12,550)		$ (40,971)		$ (516)
Denominator:
Diluted weighted average shares outstanding	21,206,121		21,202,614		21,205,622		18,728,435
Diluted loss per share	$ (1.48)	[1],[2]	$ (0.59)	[1],[2]	$ (1.93)	[1],[2]	$ (0.03)	[1],[2]

[1] The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the three months and nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

[2] The computation of diluted EPS did not include 488,499 options and 4,240,521 warrants for the three months and nine months ended September 30, 2012, as the effect of their inclusion would have been anti-dilutive.

XML

Allowance for Loan Losses and Recorded Investment in Loans (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Financing Receivable, Allowance for Credit Losses [Line Items]
Balance at beginning of period	$ 10,195	$ 7,176
Provision for loan losses	360	3,337
Charge-offs	(6,525)	(3,011)
Balance at end of period	4,030	7,502
Ending balance: individually evaluated for impairment	4,030	7,502
Uninsured Loans
Financing Receivable, Allowance for Credit Losses [Line Items]
Balance at beginning of period	7,103	869
Provision for loan losses		3,318
Charge-offs	(3,687)	(407)
Balance at end of period	3,416	3,780
Ending balance: individually evaluated for impairment	3,416	3,780
Insured Loans
Financing Receivable, Allowance for Credit Losses [Line Items]
Balance at beginning of period	3,092	6,307
Provision for loan losses	360	19
Charge-offs	(2,838)	(2,604)
Balance at end of period	614	3,722
Ending balance: individually evaluated for impairment	$ 614	$ 3,722

XML

Changes in Weighted Average Discount Rate Used to Estimate Fair Value (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted Average Rate	24.61%
Value	$ 102,328		$ 90,917
Change in Value	291	5
.50% Decrease in Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted Average Rate	24.11%
Value	104,992
Change in Value	2,663
.50% Increase in Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted Average Rate	25.11%
Value	99,769
Change in Value	$ (2,560)

XML

Consolidated and Combined Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 16,455	$ 16,255
Restricted cash	1,148	691
Certificate of deposit - restricted		891
Investment securities available for sale, at estimated fair value	24,173	57,242
Deferred costs, net	123	1,874
Prepaid expenses and other assets	14,634	3,277
Deposits - other	2,078	761
Interest receivable, net	1,356	5,758
Loans receivable, net	5,394	29,376
Structured settlement receivables at estimated fair value, net	2,496	12,376
Structured settlement receivables at cost, net	1,783	1,553
Investment in life settlements, at estimated fair value	102,328	90,917
Fixed assets, net	289	585
Other receivable	2,062	1,043
Total assets	174,319	222,599
Liabilities
Accounts payable and accrued expenses	11,237	16,336
Other liabilities	24,993	4,279
Interest payable	358	5,505
Notes payable	1,222	19,277
Income taxes payable	6,295	6,295
Total liabilities	44,105	51,692
Commitments and contingencies (Note 16)
Stockholders' Equity
Common stock (par value $0.01 per share 80,000,000 and 80,000,000 authorized; 21,206,121 and 21,202,614 issued and outstanding as of September 30, 2012 and December 31, 2011, respectively)	212	212
Additional paid-in-capital	237,960	237,755
Accumulated other comprehensive (loss)	7	(66)
Accumulated deficit	(107,965)	(66,994)
Total stockholders' equity	130,214	170,907
Total liabilities and stockholders' equity	$ 174,319	$ 222,599

XML

Amortized Cost and Estimated Fair Values of Securities Available for Sale (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 24,120	$ 57,307
Gross Unrealized Gains	142	71
Gross Unrealized Losses	(89)	(136)
Estimated Fair Value	24,173	57,242
Corporate Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	19,118	41,697
Gross Unrealized Gains	39	32
Gross Unrealized Losses	(89)	(127)
Estimated Fair Value	19,068	41,602
Government Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,690	14,789
Gross Unrealized Gains	100	39
Gross Unrealized Losses		(9)
Estimated Fair Value	4,790	14,819
Other Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	312	821
Gross Unrealized Gains	3
Estimated Fair Value	$ 315	$ 821

XML

Consolidated and Combined Statements of Stockholders' Equity (USD $) In Thousands, except Share data	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2011	$ 170,907	$ 212	$ 237,755	$ (66,994)	$ (66)
Beginning Balance (in shares) at Dec. 31, 2011	21,202,614	21,202,614
Comprehensive loss	(40,898)			(40,971)	73
Stock-based compensation	205		205
Restricted stock issued		3,507
Ending Balance at Sep. 30, 2012	$ 130,214	$ 212	$ 237,960	$ (107,965)	$ 7
Ending Balance (in shares) at Sep. 30, 2012	21,206,121	21,206,121

XML

Share-Based Compensation - Additional Information (Detail) (USD $)	9 Months Ended					1 Months Ended	9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012 2013	Sep. 30, 2012 2014	Feb. 11, 2011 Phantom Stock Agreement	Sep. 30, 2012 Omnibus Plan	Sep. 30, 2011 Omnibus Plan	Sep. 30, 2012 Omnibus Plan Restricted Stock	Sep. 30, 2011 Omnibus Plan Restricted Stock	Sep. 30, 2012 Omnibus Plan Restricted Stock	Sep. 30, 2011 Omnibus Plan Restricted Stock	Sep. 30, 2012 Omnibus Plan Stock Option	Sep. 30, 2011 Omnibus Plan Stock Option	Sep. 30, 2012 Omnibus Plan Stock Option	Sep. 30, 2011 Omnibus Plan Stock Option	Mar. 31, 2011 Omnibus Plan Phantom Stock Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance							1,200,000	530,537
Stock-based compensation expense	$ 205,000	$ 1,464,000				$ 290,000			$ 0	$ 9,500	$ 4,000	$ 24,000	$ 105,000	$ 423,000	$ 201,000	$ 1,200,000	$ 290,000
Stock issued under phantom stock agreements						27,000											27,000
Options outstanding and unexercised	488,499		627,419				488,499
Options outstanding and unexercised, weighted average price	$ 10.75		$ 10.75				$ 10.75	$ 10.75
Options outstanding and unexercised, expiry period							7 years
Options outstanding and unexercised, vesting period							3 years				1 year
Remaining unamortized amounts	105,000			336,000	21,000
Restricted stock awards granted								3,507			3,507
Fair value of vested restricted stock											$ 38,016

XML

Notes and Debenture Payable (Tables)

9 Months Ended

Sep. 30, 2012

Principal Balances of Notes Payable

A summary of the principal balances of notes payable included in the consolidated and combined balance sheet as of September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,		December 31,
	2012		2011
Cedar Lane	$	1,222	$	19,104
White Oak, Inc.		—		173
Total	$	1,222	$	19,277

XML

Investment in Life Settlements - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2012 Contract	Dec. 31, 2011 Contract
Life Insurance Premiums and Related Investment Income [Line Items]
Number of policies owned fair value of investments	212	190
Investment in life settlements, at estimated fair value	$ 102,328	$ 90,917
Average life expectancy of insured	10 years 6 months	10 years 7 months 6 days
Estimated future premium payments	$ 434,663

XML

Stockholders' Equity

9 Months Ended

Sep. 30, 2012

Stockholders' Equity

(15) Stockholders’ Equity

In January 2011, Imex Settlement Corporation executed an agreement to purchase from the Company 110,000 Series F Preferred Units for an $11.0 million promissory note. The Series F Preferred Units were non-voting and would be redeemed at any time by the Company for an amount equal to the applicable unreturned preferred capital amount allocable to the Series F Preferred Units sought to be redeemed, plus any accrued and unpaid preferred return. The cumulative rate of preferred return was equal to 16.0% of the outstanding units, per annum. The Series F Preferred units and the $11 million promissory note were extinguished as a result of the corporate conversion.

On February 3, 2011, the Company converted from a Florida limited liability company to a Florida corporation at which time the members of Imperial Holdings, LLC became shareholders of Imperial Holdings, Inc. As a limited liability company, the Company was treated as a partnership for United States federal and state income tax purposes and, as such, the Company was not subject to taxation. For all periods subsequent to such conversion, the Company will be subject to corporate-level United States federal and state income taxes.

As part of the corporate conversion, the Company entered into a plan of conversion with its shareholders on January 12, 2011, as amended on February 3, 2011. Pursuant to the plan of conversion, all of the Company’s outstanding common units and Series A, B, C, D and E preferred units and all principal and accrued and unpaid interest outstanding under our promissory note in favor of IMPEX Enterprises, Ltd. were converted into 2,300,273 shares of our common stock. The plan of conversion, which describes the corporate conversion as well as other transactions and agreements by the parties with an interest in the Company’s equity, reflects an agreement among its then shareholders as to the allocation of the shares of common stock to be issued to its shareholders in the corporate conversion. Thus, there is no formula that may be used to describe the conversion of a common unit or a Series A, B, C, D and E preferred unit into common stock.

Immediately after the corporate conversion and prior to the conversion of the Skarbonka debenture and the closing of the Company’s initial public offering on February 11, 2011, the Company’s shareholders consisted of two Florida corporations and one Florida limited liability company. These three shareholders reorganized so that their beneficial owners received the same number of shares of common stock of Imperial Holdings, Inc. issuable to the members of Imperial Holdings, LLC in the corporate conversion.

After the corporate conversion and prior to the closing of the Company’s initial public offering on February 11, 2011, the Company converted two phantom stock agreements it had with two employees into 27,000 shares of common stock and incurred stock compensation of approximately $290,000.

In addition, following the corporate conversion and upon the closing of the Company’s initial public offering on February 11, 2011, three shareholders received ownership of warrants that may be exercised for up to a total of 4,053,333 shares of the Company’s common stock at a weighted average exercise price of $14.51 per share. In connection with the over-allotment option, the same three shareholders received ownership of 187,188 additional warrants. One-third of the warrants will have an exercise price equal to 120% of the price of the common stock sold in this offering, one-third of the warrants will have an exercise price equal to 135% of the price of the common stock sold in this offering, and one-third of the warrants will have an exercise price equal to 150% of the price of the common stock sold in this offering. The warrants will expire 7 years after the date of issuance and the exercisability of the warrant will vest ratably over four years.

On February 11, 2011, the Company closed its initial public offering of 16,666,667 shares of common stock at $10.75 per share. On February 15, 2011 Imperial Holdings, Inc. sold an additional 935,947 shares of common stock. The sale was in connection with the over-allotment option Imperial granted to its underwriters in connection with Imperial’s initial public offering. As a result, the total initial public offering size was 17,602,614 shares. All shares were sold to the public at a price of $10.75. The Company received net proceeds of approximately $174.2 million after deducting the underwriting discounts and commissions and our offering expenses.

After giving effect to (i) the corporate conversion, pursuant to which all outstanding common and preferred limited liability company units of Imperial Holdings, LLC (including all accrued and unpaid dividends thereon) and all principal and accrued and unpaid interest outstanding under the Company’s promissory note in favor of IMPEX Enterprises, Ltd. were converted into 2,300,273 shares of the Company’s common stock; (ii) the issuance of 27,000 shares of common stock to two employees pursuant to the terms of each of their respective phantom stock agreements; (iii) the conversion of a $30.0 million debenture into 1,272,727 shares of common stock (iv) the sale of 16,666,667 shares in the Company’s initial public offering, and (v) the sale of 935,947 shares in connection with the over-allotment option granted to the Company’s underwriters, there are 21,202,614 shares of common stock outstanding. Up to an additional 4,240,521 shares of common stock will be issuable upon the exercise of warrants issued to existing members of the Company. Moreover, the Company reserved an aggregate of 1,200,000 shares of common stock under its Omnibus Plan, of which 665,956 options to purchase shares of common stock were granted to existing employees, directors and named executive officers at a weighted average exercise price of $10.75 per share, and an additional 3,507 shares of restricted stock had been granted under the plan subject to vesting. The remaining 530,537 shares of common stock are available for future awards.

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2012

Segment Results and Reconciliation to Consolidated Net Income

Segment results and reconciliation to consolidated net income were as follows (in thousands):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Life finance
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		180			2,145			1,613			6,712
Origination income		45			1,753			483			5,858
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other		16			8			175			182
		(17,018	)		(5,469	)		1,206			43,647
Direct segment expenses
Interest expense		140			1,660			1,215			7,135
Provision for losses on loan receivables		—			3,583			441			3,712
(Gain) loss on loans payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlements write off		140			—			140			—
Amortization of deferred costs		255			1,409			1,752			4,913
Personnel costs		1,099			2,192			4,663			5,121
Marketing		—			—			—			16
Legal fees		1,116			803			2,622			1,456
Professional fees		315			460			1,180			1,359
Insurance		313			—			806			133
Other selling, general and administrative expenses		443			863			1,205			1,390
		3,682			11,231			14,038			29,162
Segment operating (loss) income	$	(20,700	)	$	(16,700	)	$	(12,832	)	$	14,485

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Structured settlements
Income
Realized gain on sale of structured settlements	$	2,187		$	2,240		$	7,796		$	5,457
Interest income		72			144			243			319
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Other income		101			50			354			195
		2,769			3,362			9,980			8,116
Direct segment expenses
Personnel costs		2,443			2,959			7,033			6,544
Marketing		1,034			1,754			4,481			4,169
Legal fees		527			455			1,671			1,803
Professional fees		615			199			1,527			930
Insurance		313			67			799			216
Other selling, general and administrative expenses		328			1,467			1,362			1,573
		5,260			6,901			16,873			15,235
Segment operating loss	$	(2,491	)	$	(3,539	)	$	(6,893	)	$	(7,119	)
Consolidated
Segment operating (loss) income		(23,191	)		(20,239	)		(19,725	)		7,366
Unallocated income
Other income		78			344			969			545
Unallocated expenses
Interest expense		—			—			3			296
Personnel costs		53			(315	)		621			2,498
Legal fees		7,685			563			18,625			928
Professional fees		629			793			2,565			2,157
Insurance		—			119			107			199
Other selling, general and administrative expenses		—			(678	)		340			997
		8,367			482			22,261			7,075
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)

Segment Assets and Reconcilation to Consolidated Assets

Segment assets and reconciliation to consolidated total assets were as follows (in thousands):

	September 30,		December 31,
	2012		2011
Direct segment assets
Life finance	$	122,395	$	138,520
Structured settlements		6,876		17,155
		129,271		155,675
Other unallocated assets		45,048		66,924
	$	174,319	$	222,599

XML

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Taxes

(17) Income Taxes

The Company and its subsidiaries are subject to U.S. federal income tax as well as to income tax in Florida and other states in which it operates.

Except as noted below, our provision for income taxes is estimated to result in an annual effective tax rate of 0.0% in 2012, except as noted below. The 0.0% effective tax rate is a result of our recording of a valuation allowance for those deferred tax assets that are not expected to be recovered in the future. Due to large losses in 2011, the uncertainties that resulted from the USAO Investigation and expectation of taxable losses in the foreseeable future, we may not have sufficient taxable income of the appropriate character in the future to realize any portion of the net deferred tax asset.

Generally, the amount of tax expense or benefit allocated to continuing operations is determined without regard to the tax effects of other categories of income or loss, such as other comprehensive income. However, an exception to the general rule is provided when, in the presence of a valuation allowance against deferred tax assets, there is a pretax loss from continuing operations and pretax income from other categories. In such instances, income from other categories must offset the current loss from operations, the tax benefit of such offset being reflected in continuing operations. For the period ended September 30, 2012 we reduced deferred tax valuation allowance from continuing operations by $46,000 to reflect the future taxable income associated with unrealized gains in accumulated other comprehensive income.

On February 3, 2011, we converted from a Florida limited liability company to a Florida corporation (the “Conversion”). Prior to the Conversion we were treated as a partnership for federal and state income tax purposes. As a partnership our taxable income and losses were attributed to our members, and accordingly, no provision or liability for income taxes was reflected in the accompanying consolidated financial statements for periods prior to the Conversion. As a result of the Conversion, we recorded a one-time deferred tax liability of approximately $4.4 million for the federal and state tax effects of cumulative differences between financial and tax reporting which existed at the time of the conversion. Pursuant to ASC 740 these deferred taxes were recorded in income tax expense for the first quarter of 2011. In the second quarter of 2011, the deferred tax liability was increased by $175,000 to account for changes in the estimated differences at the date of conversion. In addition, following the conversion and prior to the initial public offering, one of the founding members entered into a reorganization that allowed the company to assume the corporate shareholder’s tax attributes. These tax attributes include approximately $11.2 million of net operating loss carryovers (“NOLs”). During the second quarter, we completed an evaluation of this transaction and determined that we were entitled to assume the NOLs of this founding member. Accordingly, in the second quarter we recorded a one-time deferred tax asset of approximately $4.3 million related to these tax attributes and this amount was recorded as an income tax benefit during that period. For the post-conversion period ended September 30, 2011, we used an estimated annual effective tax rate of 38.6% resulting in a tax provision of $1.1 million. For the third quarter ended September 30, 2011 the total provision was $1.4 million.

At September 30, 2012, income taxes payable includes an estimated liability for unrecognized tax benefits of $6.3 million that related to the Conversion and was charged to paid-in-capital in the first quarter of 2011.

XML

Assets Measured at Fair Value on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in life settlements	$ 102,328	$ 90,917
Structured settlement receivables	2,496	12,376
Investment securities available for sale	24,173	57,242
Assets, Fair Value Disclosure, Total	128,997	160,535
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment securities available for sale	24,173	57,242
Assets, Fair Value Disclosure, Total	24,173	57,242
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in life settlements	102,328	90,917
Structured settlement receivables	2,496	12,376
Assets, Fair Value Disclosure, Total	$ 104,824	$ 103,293

XML

Consolidated and Combined Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities
Net loss	$ (40,971)	$ (516)
Adjustments to reconcile net loss to net cash used in operating activites:
Depreciation and amortization	325	457
Amoritzation of premiums and accretion of discounts on available for sale securities	845	823
Provision for doubtful accounts		575
Provision for losses on loans receivable	441	3,712
Stock-based compensation	205	1,464
Loss on loan payoffs and settlements, net	14	3,927
Loss on write-off of life settlment	140
Origination fee income	(483)	(5,858)
Unrealized change in fair value of life settlements	8,401	(14,811)
Unrealized change in fair value of structured settlements	(1,587)	(2,145)
Gain on forgiveness of debt		(4,880)
Interest income on loans	(1,856)	(7,031)
Amortization of deferred costs	1,751	4,913
Accretion of discount on debenture payable		233
Gain on sale of life settlements	(291)	(5)
Gain on sale and prepayment of investment securities available for sale	(80)	(51)
Change in assets and liabilities:
Certificate of deposit-restricted	895	(125)
Deposits-other	(1,317)	(61)
Restricted cash	(457)
Agency fees receivable		165
Structured settlement receivables	11,481	(354)
Prepaid expenses and other assets	(11,302)	(2,205)
Deferred costs		2,755
Other receivables	(1,022)
Accounts payable and accrued expenses	(5,100)	(599)
Other liabilities	20,715	(6,299)
Interest receiavble	221	(558)
Income tax liability		1,352
Deferred income taxes	(46)
Interest payable	(5,147)	(4,183)
Net cash used in operating activities	(24,225)	(29,305)
Cash flows from investing activities
Purchase of fixed assets, net of disposals	(21)	(265)
Purchase of investment securities available for sale	(35,492)	(121,818)
Proceeds from sale and prepayments of investment securities available for sale	67,915	44,700
Premiums paid on investments in life settlements	(20,106)	(9,863)
Deposits on purchases of life settlements (life insurance policies)		(965)
Purchases of investments in life settlements	(130)	(48,057)
Proceeds from sale of investments in life settlements	5,626
Proceeds from loan payoffs	24,687	39,166
Originations of loans receivable		(18,711)
Net cash provided by (used in) investing activities	42,479	(115,813)
Cash flows from financing activities
Proceeds from initial public offering		174,233
Repayment of borrowings under credit facilities	(18,054)	(27,378)
Borrowings under credit facilities		234
Borrowings from affiliates		2,645
Net cash (used in) provided by financing activities	(18,054)	149,734
Net increase in cash and cash equivalents	200	4,616
Cash and cash equivalents, at beginning of the period	16,255	14,224
Cash and cash equivalents, at end of the period	16,455	18,840
Supplemental disclosures of cash flow information:
Cash paid for interest during the period	6,353	11,314
Supplemental disclosures of non-cash financing activities:
Conversion of debt to common stock		35,158
Supplemental disclosures of non-cash investing activities:
Investment in life settlements acquired in foreclosure	$ 5,050	$ 2,098

XML

Consolidated and Combined Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	21,206,121	21,202,614
Common stock, shares outstanding	21,206,121	21,202,614

XML

Structured Settlements

9 Months Ended

Sep. 30, 2012

Structured Settlements

(10) Structured Settlements

The balances of the Company’s structured settlements are as follows (in thousands):

	September 30,		December 31,
	2012		2011
Structured settlements — at cost	$	1,783	$	1,553
Structured settlements—at fair value		2,496		12,376
Structured settlements receivable, net	$	4,279	$	13,929

All structured settlements that were acquired subsequent to July 1, 2010 were marked to fair value. Structured settlements that were acquired prior to July 1, 2010 were recorded at cost. During 2011, the Company reacquired certain structured settlements that were originally acquired prior to July 1, 2010 and the Company continued to carry those structured settlements at cost upon reacquisition.

Certain financing arrangements for the Company’s structured settlements are described below:

Life-Contingent Structured Settlement Facility

On December 30, 2011, Washington Square Financial, LLC (“WSF”) entered into a forward purchase and sale agreement (“PSA”) to sell up to $40.0 million of life contingent structured settlement receivables to Compass Settlements LLC (“Compass”). Subject to predetermined eligibility criteria and on-going funding conditions, Compass committed, in increments of $5.0 million, up to $40.0 million to purchase life-contingent structured settlement receivables from WSF. The PSA obligates WSF to sell the life-contingent structured settlement receivables it originates to Compass on an exclusive basis for twenty-four months, subject to Compass maintaining certain purchase commitment levels. Additionally, the Company has agreed to guaranty WSF’s obligation to repurchase any ineligible receivables sold under the PSA and certain other related obligations.

For the nine months ended September 30, 2012, the Company recognized income from the sale of 311 structured settlement transactions under this facility generating income of approximately $1.8 million recorded as gain on sale of structured settlements in the attached financial statements. Of the 311 structured transactions, 107 were previously recorded at the market rate generating income of approximately $1.1 million and the change in value was recorded as an unrealized change in fair value on the financial statements presented for the year ended December 31, 2011 and 55 were previously recorded at the market rate generating income of approximately $565,000 with the change in value recorded as an unrealized change in fair value on the financial statements presented for the two quarters ended June 30, 2012.

The Company also realized income of approximately $147,000 that was recorded as an unrealized change in fair value during the three months ended September 30, 2012 on structured settlements that are intended for sale to Compass.

8.39% Fixed Rate Asset Backed Variable Funding Notes

Imperial Settlements Financing 2010, LLC (“ISF 2010”) was formed as an affiliate of the Company to serve as a special purpose financing entity to allow the Company to sell structured settlements and assignable annuities, which are referred to as receivables, to ISF 2010 and ISF 2010 to borrow against certain of its receivables to provide ISF 2010 liquidity. ISF 2010 is a non-consolidated special purpose financing entity. On September 24, 2010, ISF 2010 entered into an arrangement to obtain up to $50 million in financing. Under this arrangement, a subsidiary of Partner Re, Ltd. (the “noteholder”) became the initial holder of ISF 2010’s 8.39% Fixed Rate Asset Backed Variable Funding Note issued under a master trust indenture and related indenture supplement (collectively, the “Indenture”) pursuant to which the noteholder committed to advance ISF 2010 up to $50 million upon the terms and conditions set forth in the Indenture. The note is secured by the receivables that ISF 2010 acquires from the Company from time to time. The note is due and payable on or before January 1, 2057, but principal and interest must be repaid pursuant to a schedule of fixed payments from the receivables that secure the notes. The arrangement generally has a concentration limit of 15% for the providers of the receivables that secure the notes. Wilmington Trust is the collateral trustee. As of September 30, 2012 and December 31, 2011, the balance of the notes outstanding on the special purpose financing entity’s books was $40.4 million and $20.6 million, respectively.

Upon the occurrence of certain events of default under the Indenture, all amounts due under the note are automatically accelerated. The Company’s maximum exposure related to ISF 2010 is limited to 5% of the dollar value of the ISF 2010 transactions, which is held back by ISF 2010 at the time of sale, and is designed to absorb potential losses in collecting the receivables. The obligations of ISF 2010 are non-recourse to the Company. The total funds held back by ISF 2010 as of September 30, 2012 and December 31, 2011 were approximately $2.1 million and $1.0 million and are included in other receivable in the accompanying consolidated balance sheet.

During the nine months ended September 30, 2012 and 2011, the Company sold 500 and 485 non-life contingent, or term certain structured settlements, respectively, 181 and 12 of which were originated in 2011 and 2010, respectively. These sales generated income of approximately of $3.2 million and $129,000, respectively, which was recorded as an unrealized change in fair value of structured settlements in 2011 and 2010, respectively. The Company originated and sold 319 and 307 term certain structured settlement transactions under this facility generating income of approximately $4.2 million and $3.8 million, respectively, which was recorded as a realized gain on sale of structured settlements during the nine months ended September 30, 2012 and 2011, respectively. During the nine months ended September 30, 2011, the Company also had three SPV’s that pledged 38 term certain structured settlement transactions under this facility generating income of approximately $32,000, which was recorded as an unrealized change in the fair value of structured settlements. The Company also realized income of approximately $548,000 and $582,000 that was recorded as an unrealized change in fair value during the nine months ended September 30, 2012 and 2011, respectively, on structured settlements that are intended for sale to ISF 2010. The Company receives 95% of the purchase price in cash from ISF 2010. Of the remaining 5%, which represents the Company’s interest in ISF 2010, 1% is required to be contributed to a cash reserve account held by Wilmington Trust. In addition, the Company also purchased and sold 131 guaranteed structure transactions generating income of $64,000, which was recorded as a realized gain on sale of structured settlements.

When the transfer of the receivables occurs, the Company records the transaction as a sale and removes the asset from its balance sheet. In determining whether the Company is the primary beneficiary of the trust, the Company concluded that it does not control the servicing, which is the activity that most significantly impacts the trust performance. An independent third party is the master servicer and they can only be replaced by the control partner, which is the entity that holds the majority of the outstanding notes. The Company is a back-up servicer, which is not significant to the performance of ISF 2010.

Washington Square Financial 3rd Party Sales

For the nine months ended September 30, 2012, in addition to its intended sales to Compass and ISF 2010, the Company also sold 169 deals to unrelated parties for $2.5 million generating income of $1.8 million recorded as a gain on sale of structured settlements and $134,000 that was previously recorded as an unrealized change in fair value.

During the nine months ended September 30, 2012 and 2011, respectively, the Company recorded income of approximately $188,000 and $107,000, respectively, that was recorded as unrealized change in fair value on structured settlements that are intended for sale to other parties

Total income recognized through accretion of interest income on structured settlement transactions for the nine months ended September 30, 2012 and 2011, respectively, was approximately $243,000 and $318,000, respectively, recognized in interest income in the accompanying consolidated and combined statement of operations. The receivables at September 30, 2012 and December 31, 2011 were approximately $4.3 million and $13.9 million, respectively, net of a discount of approximately $11.1 million and $27.8 million, respectively.

The Company recognized a gain on the sale of approximately $223,000 through the collection of holdback funds during the nine months ended September 30, 2011. The holdback is equal to the aggregate amount of payments due and payable by the annuity holder within 90 days after the date of sale. These amounts are held back in accordance with the purchase agreement and were released upon proof of collections by the Company acting as servicer.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012	Jan. 15, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	IFT
Entity Registrant Name	Imperial Holdings, Inc.
Entity Central Index Key	0001494448
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		21,206,121

XML

Investment in Life Settlements (Life Insurance Policies)

9 Months Ended

Sep. 30, 2012

Investment in Life Settlements (Life Insurance Policies)

(11) Investment in Life Settlements (Life Insurance Policies)

During the nine months ended September 30, 2012 and throughout the year ended December 31, 2011, the Company acquired life insurance policies as a result of certain of the Company’s borrowers defaulting on premium finance loans and relinquishing the underlying policy to the Company in exchange for being released from further obligations under the loan. In 2011, the Company also began acquiring life insurance policies in the secondary and tertiary markets. The Company elected to account for these policies using the fair value method in accordance with ASC 325-30-50 Investments – Other – Investment in Insurance Contracts. Under the fair value method, the Company recognizes the initial investment at the purchase price. For policies that were relinquished in satisfaction of premium finance loans at maturity, this is the loan carrying value and for policies purchased in the secondary or tertiary markets, this is the amount of cash outlay at the time of purchase. At each reporting period, the Company re-measures the investment at fair value in its entirety and recognizes changes in fair value in earnings in the period in which the changes occur. See Note 12.

As of September 30, 2012 and December 31, 2011, the Company owned 212 and 190 policies, respectively, with an aggregate estimated fair value of investments in life settlements of $102.3 million and 90.9 million, respectively.

The weighted average life expectancy calculated based on death benefit of insureds in the policies owned by the Company at September 30, 2012 was 10.5 years. The following table describes the Company’s investment in life settlements as of September 30, 2012 (dollars in thousands):

	Number of
	Life Settlement		Fair		Face
Remaining Life Expectancy (In Years)	Contracts		Value		Value
0 - 1		—	$	—	$	—
1 - 2		—		—		—
2 - 3		1		1,021		2,500
3 - 4		4		2,901		11,450
4 - 5		8		10,655		33,050
Thereafter		199		87,751		1,011,156
Total		212		102,328		1,058,156

The weighted average life expectancy calculated based on death benefit of insureds in the policies owned by the Company at December 31, 2011 was 10.6 years. The following table describes the Company’s investment in life settlements as of December 31, 2011 (in thousands):

Remaining Life Expectancy (In Years)	Number of Life Settlement Contracts		Fair Value		Face Value
0 - 1		—	$	—	$	—
1 - 2		1		3,033		5,000
2 - 3		2		2,484		4,500
3 - 4		4		7,084		20,200
4 - 5		3		2,357		7,950
Thereafter		180		75,959		897,816
Total		190		90,917		935,466

Estimated premiums to be paid for each of the five succeeding fiscal years and thereafter, to keep the life insurance policies in force as of September 30, 2012, are as follows (in thousands):

Remainder of 2012		6,855
2013		27,755
2014		25,226
2015		25,462
2016		25,756
Thereafter		323,609
	$	434,663

The amount of $434.7 million noted above represents the estimated total future premium payments required to keep the life insurance policies in force during the life expectancies of all the underlying insured lives and does not give effect to projected receipt of death benefits. The Company has not yet experienced the mortalities of insureds or received the resulting death benefits from our life insurance policies (other than from policies with subrogation rights that are not reported on our balance sheet and that are considered contingent assets). The estimated total future premium payments could increase or decrease significantly to the extent that actual mortalities of insureds differs from the estimated life expectancies.

XML

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended			9 Months Ended
	Apr. 26, 2012	Feb. 24, 2012 LegalMatter	Sep. 30, 2012	Mar. 31, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Feb. 15, 2012
Commitments and Contingencies [Line Items]
Amount of litigation fees			$ 9,328,000		$ 1,821,000	$ 22,918,000	$ 4,187,000
Separation payment	1,400,000
Entitled base salary, months								24 months
Putative class actions		4
Reimbursement of defense costs and fees				800,000
Other selling, general and administrative expenses			771,000		1,652,000	2,730,000	4,173,000
Other income			123,000		155,000	989,000	481,000
Guaranteed percentage of special purpose entity's obligations						5.00%
Pending Litigation
Commitments and Contingencies [Line Items]
Amount of litigation fees						200,000
Other selling, general and administrative expenses						800,000
Other income						600,000
Pending Litigation
Commitments and Contingencies [Line Items]
Amount of litigation fees			2,600,000		0	12,800,000	0
2012 | Minimum
Commitments and Contingencies [Line Items]
Expected bonus payment								250,000
2013 | Minimum
Commitments and Contingencies [Line Items]
Expected bonus payment								250,000

XML

Consolidated and Combined Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Income
Agency fee income			$ 937				$ 6,564
Interest income	252		2,289		1,856		7,031
Interest and dividends on investment securities available for sale	72		247		332		441
Origination fee income	45		1,753		483		5,858
Realized gain on sale of structured settlements	2,187		2,240		7,796		5,457
Realized gain on sale of life settlements					291		5
Gain on forgiveness of debt			198				4,880
Unrealized change in fair value of life settlements	(17,530)		(14,074)		(8,401)		14,811
Unrealized change in fair value of structured settlements	409		928		1,587		2,145
Servicing fee income	271		376		955		1,447
Gain on maturities of life settlements with subrogation rights, net			3,188		6,090		3,188
Other income	123		155		989		481
Total income	(14,171)		(1,763)		11,978		52,308
Expenses
Interest expense	141		1,660		1,219		7,431
Provision for losses on loans receivable			3,583		441		3,712
(Gain) loss on loan payoffs and settlements, net	(139)		261		14		3,927
Loss on life settlement write off	140				140
Amortization of deferred costs	254		1,409		1,751		4,913
Personnel costs	3,595		4,836		12,317		14,158
Marketing costs	1,034		1,754		4,481		4,185
Legal fees	9,328		1,821		22,918		4,187
Professional fees	1,559		1,452		5,272		4,238
Insurance	626		186		1,712		548
Other selling, general and administrative expenses	771		1,652		2,730		4,173
Total expenses	17,309		18,614		52,995		51,472
(Loss) income before income taxes	(31,480)		(20,377)		(41,017)		836
(Benefit) provision for income taxes	(5)		(7,827)		(46)		1,352
Net loss	$ (31,475)		$ (12,550)		$ (40,971)		$ (516)
Loss per share:
Basic	$ (1.48)		$ (0.59)		$ (1.93)		$ (0.03)
Diluted	$ (1.48)	[1],[2]	$ (0.59)	[1],[2]	$ (1.93)	[1],[2]	$ (0.03)	[1],[2]
Weighted average shares outstanding:
Basic	21,206,121		21,202,614		21,205,622		18,728,435
Diluted	21,206,121		21,202,614		21,205,622		18,728,435

[1] The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the three months and nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

[2] The computation of diluted EPS did not include 488,499 options and 4,240,521 warrants for the three months and nine months ended September 30, 2012, as the effect of their inclusion would have been anti-dilutive.

XML

Gain on Maturities of Life Settlements with Subrogation Rights, net

9 Months Ended

Sep. 30, 2012

Gain on Maturities of Life Settlements with Subrogation Rights, net

(5) Gain on Maturities of Life Settlements with Subrogation Rights, net

In the third quarter of 2011, two individuals covered under policies, which were subject to subrogation claims unexpectedly passed away. The Company collected the death benefit on one of these policies in the amount of $3.5 million during the third quarter of 2011. The other was the result of an accidental death and the $10.0 million face value of the policy was larger than average.

The Company accounted for the maturities of each of these polices as contingent gains in accordance with ASC 450, Contingencies and recognized $3.2 million in death benefits net of subrogation expenses of $312,000 in its consolidated and combined statement of operations for the nine months ended September 30, 2011. In the second quarter of 2012, the Company negotiated a settlement in respect of the larger policy and collected approximately $6.1 million, net of subrogation expenses of $910,000, and has reported a gain in accordance with ASC 450, Contingencies in its consolidated and combined statement of operations for the nine months ended September 30, 2012 as all contingencies were resolved.

The Company believes these contingent gains to be unpredictable because the lender protection insurer can discontinue paying the premiums necessary to keep a policy subject to subrogation and salvage claims in force at any time and the amount of the lender protection insurer’s subrogation and salvage claim on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. No expectations for similar gains in the future should be inferred from the events occurring in the third quarter of 2011 and second quarter of 2012.

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2012

Earnings Per Share

(4) Earnings Per Share

As of February 3, 2011, the Company had 3,600,000 shares of common stock outstanding. The impact of the Company’s corporate conversion has been applied on a retrospective basis to January 1, 2011 to determine earnings per share for the nine months ended September 30, 2011.

As of September 30, 2011, there were 21,202,614 issued and outstanding shares.

Basic net income per share is computed by dividing the net earnings attributable to common shareholders by the weighted average number of common shares outstanding during the period.

Diluted earnings per share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding, increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Conversion or exercise of the potential common shares is not reflected in diluted earnings per share, unless the effect is dilutive. The dilutive effect, if any, of outstanding common share equivalents is reflected in diluted earnings per share by application of the treasury stock method, as applicable. In determining whether outstanding stock options, restricted stock, and common stock warrants should be considered for their dilutive effect, the average market price of the common stock for the period has to exceed the exercise price of the outstanding common share equivalent.

The following tables reconcile actual basic and diluted earnings per share for the three months and nine months ended September 30, 2012 and 2011 (in thousands except share and per share data).

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2012			2011			2012			2011
Basic (loss) earnings per share:
Numerator:
Net loss available to common stockholders	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Denominator:
Weighted average common shares outstanding		21,206,121			21,202,614			21,205,622			18,728,435
Basic loss per share	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Diluted earnings per share:
Numerator:
Net loss available to common stockholders	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Denominator:
Diluted weighted average shares outstanding		21,206,121			21,202,614			21,205,622			18,728,435
Diluted loss per share(1)(2)	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)

(1) The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the three months and nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

(2) The computation of diluted EPS did not include 488,499 options and 4,240,521 warrants for the three months and nine months ended September 30, 2012, as the effect of their inclusion would have been anti-dilutive.

Pro Forma Earnings Per Share

The pro forma earnings per share for the nine months ended September 30, 2011, gives effect to (i) the consummation of the corporate conversion, pursuant to which all outstanding common and preferred limited liability company units (including all accrued, but unpaid dividends thereon) and all principal and accrued interest outstanding under our promissory note in favor of IMPEX Enterprises, Ltd. were converted into 2,300,273 shares of our common stock; (ii) the issuance of 27,000 shares of common stock to two of our employees pursuant to the terms of each of their respective phantom stock agreements; and (iii) the issuance and conversion of a $30.0 million debenture into 1,272,727 shares of our common stock as if these events had been completed by January 2011.

Unaudited pro forma net income attributable to common stockholders per share is computed using the weighted-average number of common shares outstanding, including the pro forma effect of (i) to (iii) above, as if such conversion occurred at January 1, 2011. The pro forma net loss reflects a reduction of interest expense of $178,000, net of tax for the nine months ended September 30, 2011 due to the conversion of a promissory note in favor of IMPEX Enterprises, Ltd. into shares of our common stock, which occurred prior to the closing of our initial public offering, and the conversion of our promissory note in favor of Branch Office of Skarbonka Sp. z o.o into a $30.0 million debenture, and the conversion of that $30.0 million debenture into shares of our common stock, which occurred immediately prior to the closing of our public offering.

The following tables reconcile pro forma basic and diluted earnings per share for the nine months ended September 30, 2011 (in thousands except share and per share data).

	For the Nine Months
	Ended September 30,
	2011
Basic earnings (loss) per share:
Numerator:
Net loss available to common stockholders(1)(3)	$	(338	)
Denominator:
Weighted average common shares outstanding		18,728,435
Basic loss per share	$	(0.02	)
Diluted earnings per share:
Numerator:
Net loss available to common stockholders(1)(3)	$	(338	)
Denominator:
Diluted weighted average shares outstanding		18,728,435
Diluted loss per share(2)	$	(0.02	)

(1) Reflects a reduction of interest expense of $178,000, net of tax for the nine months ended September 30, 2011 due to the conversion of our promissory note in favor of IMPEX Enterprises, Ltd. into shares of our common stock, which occurred prior to the closing of our initial public offering, and the conversion of our promissory note in favor of Branch Office of Skarbonka Sp. z o.o into a $30.0 million debenture, and the conversion of that $30.0 million debenture into shares of our common stock, which occurred immediately prior to the closing of our initial public offering.

(2) The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

(3) For the pro forma period for the nine months ended September 30, 2011, the results of the Company being treated for the pro forma presentation as a “C” corporation resulted in no impact to the consolidated and combined balance sheet or statement of operations. The primary reasons for this are that the losses produce no current benefit and any net operating losses generated and other deferred assets (net of liabilities) at that time would have been fully reserved due to historical operating losses. The Company, therefore, has not recorded any pro forma tax provision.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies

(16) Commitments and Contingencies

In accordance with applicable accounting guidance, the Company establishes an accrued liability for litigation and regulatory matters when those matters present loss contingencies that are both probable and estimable. In such cases, there may be an exposure to loss in excess of any amounts accrued. When a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. As a litigation or regulatory matter develops, the Company, in conjunction with any outside counsel handling the matter, evaluates on an ongoing basis whether such matter presents a loss contingency that is probable and estimable. If, at the time of evaluation, the loss contingency related to a litigation or regulatory matter is not both probable and estimable, the matter will continue to be monitored for further developments that would make such loss contingency both probable and estimable. Once the loss contingency related to a litigation or regulatory matter is deemed to be both probable and estimable, the Company will establish an accrued liability with respect to such loss contingency and record a corresponding amount of litigation-related expense. The Company continues to monitor the matter for further developments that could affect the amount of the accrued liability that has been previously established. Excluding expenses of external legal service providers, litigation-related fees of $2.6 million and $12.8 million was recognized for the three months and nine months ended September 30, 2012, respectively. There were no comparable expenses in the respective periods during 2011.

Employment Agreements

In connection with our initial public offering, we entered into employment agreements with certain of our executive officers. The agreement for our chief executive officer provides for substantial payments in the event that the executive terminates his employment with us due to a material change in the geographic location where such officer performs his duties or upon a material diminution of his base salary or responsibilities, with or without cause. For our chief executive officer, payments are equal to three times the sum of base salary and the average of the three years’ annual cash bonus, unless the triggering event occurs during the first three years of his employment agreement, in which case the payments are equal to six times base salary. For our chief executive officer, the agreement provides for bonus incentives based on pre-tax income thresholds.

On April 26, 2012, the Company entered into a Separation Agreement and General Release of Claims (the “Separation Agreement”) with its chief operating officer, Jonathan Neuman. As part of the Separation Agreement, Mr. Neuman resigned as a member of the Company’s board of directors and as an employee of Company. Pursuant to the Separation Agreement, the Company paid Mr. Neuman a separation payment of $1.4 million. The Separation Agreement does not include a covenant by Mr. Neuman to refrain from competing with Imperial, but does contain customary non-disparagement and non-solicitation provisions. The Separation Agreement provides releases by each party and also obligates the Company to continue to indemnify Mr. Neuman for his legal expenses substantially in the same manner contemplated by his employment agreement with the Company.

On February 15, 2012, the Company entered into a retention arrangement with its Chief Financial Officer and Chief Credit Officer, Richard O’Connell, Jr. The arrangement provides that, in the event Mr. O’Connell’s employment is terminated without cause or Mr. O’Connell terminates his employment with the Company for good reason, in each case, prior to December 31, 2013, Mr. O’Connell will be entitled to 24 months’ base salary in addition to any accrued benefits. Additionally, unless Mr. O’Connell’s employment is terminated for cause, Mr. O’Connell will be entitled to a minimum bonus of $250,000 for each of 2012 and 2013, subject to the Company’s Board of Directors’ right to terminate the bonus payment in respect of 2013 prior to January 1, 2013. Except for the provisions relating to severance and other termination benefits, the terms of Mr. O’Connell’s Employment and Severance Agreement entered into with the Company as of November 4, 2010 remain in effect during the term of the retention arrangement and the provisions of the employment agreement relating to severance and other termination benefits will again be in effect following any termination of the retention arrangement if Mr. O’Connell is then employed by the Company.

During the first quarter of 2012, the Company also entered into severance and retention award agreements with certain of its executive officers (other than the CEO and CFO). The agreements generally provide for a minimum guaranteed bonus in each of 2012 and 2013 as well as severance payments equal to two years base salary in the event of termination by the Company without Cause (as defined in the respective agreement) provided the executive executes a general release of claims against the Company.

We do not have any general policies regarding the use of employment agreements, but may, from time to time, enter into such a written agreement to reflect the terms and conditions of employment of a particular named executive officer, whether at the time of hire or thereafter.

Subrogation Rights, net

Every credit facility entered into by subsidiaries of the Company between December 2007 and December 2010 to finance the premium finance lending business required lender protection insurance for each loan originated under such credit facility. Generally, when the Company exercises its right to foreclose on collateral, the Company’s lender protection insurer has the right to direct control or take beneficial ownership of the life insurance policy, subject to the terms and conditions of the lender protection insurance policy, including notice and timing requirements. Otherwise, the lender protection insurer maintains its salvage collection and subrogation rights. The lender protection insurer’s salvage collection and subrogation rights generally provide a remedy by which the insurer can seek to recover the amount of the lender protection claim paid plus premiums paid by it, expenses and interest thereon.

In those instances where the Company has foreclosed on the collateral, the lender protection insurer has maintained its salvage collection and subrogation rights and has been covering the cost of the ongoing premiums needed to maintain certain of these life insurance policies. However, the lender protection insurer may elect at any time to discontinue the payment of premiums which would result in lapse of the policies if the Company does not otherwise pay the premiums. The Company views these policies as having uncertain value because the lender protection insurer controls what happens to the policy from a payment of premium standpoint, and the amount of the lender protection insurer’s salvage collection and subrogation claim rights on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. For these reasons, these policies are considered contingent assets and are not included in the amount of life settlements on the accompanying consolidated and combined balance sheet.

The Company accounts for the maturities of life settlements with subrogation rights net of subrogation expenses as contingent gains in accordance with ASC 450, Contingencies and recognizes the revenue from the maturities of these policies when all contingencies are resolved.

The Class Action Litigation

On September 29, 2011, the Company, and certain of its officers and directors were named as defendants in a putative securities class action filed in the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entitled Martin J. Fuller v. Imperial Holdings, Inc. et al. Also named as defendants were the underwriters of the Company’s initial public offering. That complaint asserted claims under Sections 11 and 15 of the Securities Act of 1933, as amended, alleging that the Company should have but failed to disclose in the registration statement for its initial public offering purported wrongful conduct relating to its life finance business which gave rise to the government investigation described above. On October 21, 2011, an amended complaint was filed that asserts claims under Sections 11, 12 and 15 of the Securities Act of 1933, based on similar allegations. On October 25, 2011, defendants removed the case to the United States District Court for the Southern District of Florida.

On October 31, 2011, another putative class action case was filed in the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entitled City of Roseville Employees Retirement System v. Imperial Holdings, et al, naming the same defendants and also bringing claims under Sections 11,12 and 15 of the Securities Act of 1933 based on similar allegations. On November 28, 2011, defendants removed the case to the United States District Court for the Southern District of Florida. The plaintiffs in the Fuller and City of Roseville cases moved to remand their cases back to state court. Those motions were fully briefed and argued, and a decision is pending.

On November 18, 2011, a putative class action case was filed in the United States District Court for the Southern District of Florida, entitled Sauer v. Imperial Holdings, Inc., et al., naming the same defendants and bringing claims under Sections 11 and 15 of the Securities Act based on similar allegations.

On December 14, 2011, another putative class action case filed in United States District Court for the Southern District of Florida, entitled Pondick v. Imperial Holdings, Inc., et al., naming the same defendants and bringing claims under Sections 11, 12, and 15 of the Securities Act based on similar allegations.

On February 24, 2012, the four putative class actions were consolidated and designated: Fuller v. Imperial Holdings et al. in the United States District Court for the Southern District of Florida, and Lead Plaintiffs were appointed. In addition, the underwriters of the Company’s initial public offering have asserted that the Company is required by its Underwriting Agreement to indemnify the underwriters’ expenses and potential liabilities in connection with the litigation. See Note 18 — Subsequent Events.

The Insurance Coverage Declaratory Relief Complaint

On June 13, 2012, Catlin Insurance Company (UK) Ltd. (“Catlin”) filed a declaratory relief action against the Company in the United States District Court for the Southern District of Florida. The complaint seeks a determination that there is no coverage under Catlin’s primary Directors, Officers and Company Liability Policy (the “Policy”) issued to the Company for the period February 3, 2011 to February 3, 2012, based on a prior and pending litigation exclusion (the “Exclusion”). Catlin also seeks a determination that it is entitled to reimbursement of the approximately $0.8 million in defense costs and fees advanced to the Company in the first quarter of 2012 under the Policy if it is determined that the Exclusion precludes coverage. The Company recorded a reserve of $0.8 million for the recovery received during the nine months ended September 30, 2012 as other selling, general and administrative expense. $0.6 million of the amount reserved was recorded as other income due to this portion of the recovery relating to 2011 expenses and the remaining $0.2 million was recorded as a reduction of legal expenses for the nine months ended September 30, 2012. As of the filing of this Form 10-Q, the Company has not yet been served with the complaint. See Note 18 — Subsequent Events.

Derivative Claims

On November 16, 2011, the Company’s Board of Directors received a shareholder derivative demand from Harry Rothenberg (the “Rothenberg Demand”), which was referred to the Special Committee of the Company’s Board of Directors consisting of five outside Board Members (the “Special Committee”) for a thorough investigation of the issues, occurrences and facts relating to, connected to, and arising from the USAO Investigation referenced in the Rothenberg Demand. On May 8, 2012, the Company’s Board of Directors received a derivative demand made by another shareholder, Robert Andrzejczyk (the “Andrzejczyk Demand”). The Andrzejczyk Demand, like the Rothenberg Demand was referred to the Special Committee, which determined that it did not contain any allegations that differed materially from those alleged in the Rothenberg Demand. On July 20, 2012, the Company (as nominal defendant) and certain of the Company’s officers, directors, and a former director were named as defendants in a shareholder derivative action filed in the Circuit Court of the 15^th Judicial Circuit in and for Palm Beach County, Florida, entitled Robert Andrzejczyk v. Imperial Holdings, Inc. et al. The complaint alleges, among other things, that the Special Committee’s refusal of the Andrzejczyk Demand was improper. The defendants have not yet been required to respond to the complaint. See Note 18 — Subsequent Events.

SEC Investigation

On February 17, 2012, the Company received a subpoena issued by the staff of the SEC seeking documents from 2007 through the present, generally related to the Company’s premium finance business and corresponding financial reporting. The SEC is investigating whether any violations of federal securities laws have occurred and the Company has been cooperating with the SEC regarding this matter. The Company is unable to predict what action, if any, might be taken in the future by the SEC or its staff as a result of the matters that are the subject of the subpoena or what impact, if any, the cost of responding to the subpoena might have on the Company’s financial position, results of operations, or cash flows. The Company has not established any provision for losses in respect of this matter.

The Florida Litigation

On March 14, 2012, Opportunity Partners L.P. (“Opportunity”) served the Company with a complaint in the Circuit Court of the 15^th Judicial Circuit in and for Palm Beach County, Florida seeking to compel the Company to hold an annual meeting of shareholders as soon as possible and seeking recovery of all costs and expenses, including reasonable attorney’s fees and expenses of experts in connection with the complaint. On March 28, 2012, Opportunity filed a motion to compel an annual meeting of shareholders. The Company filed a motion to dismiss the complaint on April 3, 2012 and an opposition to the motion to compel on May 24, 2012. Following a hearing on June 1, 2012, the Court entered an Order dated June 15, 2012 granting Opportunity’s motion to compel an annual meeting of shareholders and denying the Company’s motion to dismiss. Pursuant to the Court’s Order, the Company was required to hold its annual meeting of shareholders on or before August 20, 2012. In addition, the Court ordered the Company to seek an exemption from the SEC pursuant to SEC Regulation 17 C.F.R. § 200.30-1(e)(18) on or before June 20, 2012 and to update the Court of any adverse response to its application on or before July 18, 2012.

On August 2, 2012, the Board of Directors of the Company appointed Andrew Dakos, Phillip Goldstein and Gerald Hellerman to serve as directors of the Company in connection with a settlement with Opportunity that resulted in Opportunity withdrawing its demand for a special meeting of shareholders, which it had submitted to the Company on May 23, 2012, and agreeing to dismiss its lawsuit to compel an annual meeting of shareholders. In connection with the Settlement, Walter Higgins and A. Penn Wyrough resigned from the Board of Directors. On August 14, 2012, Antony Mitchell, the Company’s chief executive officer, resigned as Chairman of the Board, though he continues to serve as the Company’s chief executive officer as well as a member of the Board of Directors, and Mr. Goldstein was elected Chairman. The committees of the Board of Directors were also reconstituted as follows: Audit: Messrs. Hellerman (chair), Buzen, Crow and Rosenberg; Compensation: Messrs. Dakos (chair), Crow, Goldstein and Hellerman; and Corporate Governance & Nominating Committee: Messrs. Goldstein (chair), Crow, Dakos and Hellerman.

Litigation

We are party to various other legal proceedings, which arise in the ordinary course of business. We believe that the resolution of these other proceedings will not, based on information currently available to us, have a material adverse effect on our financial position or results of operations. See Note 18 – Subsequent Events.

Guarantees

Under our Cedar Lane facility where we have guaranteed 5% of the applicable special purpose entity’s obligations, our chief executive officer and then chief operating officer made certain guaranties to lenders for the benefit of the special purpose entities for matters other than financial performance. These guaranties are not unconditional sources of credit support, but are intended to protect the lenders against acts of fraud, willful misconduct or a borrower commencing a bankruptcy filing. To the extent lenders sought recourse against our chief executive officer and former chief operating officer for such non-financial performance reasons, then our indemnification obligations to our chief executive officer and chief operating officer may require us to indemnify them for losses they may incur under these guaranties.

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Measurements

(12) Fair Value Measurements

The Company carries investments in life settlements (life insurance policies), certain structured settlements, and investment securities available for sale at estimated fair value in the consolidated and combined balance sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified based on the following fair value hierarchy:

Level 1 — Valuation is based on unadjusted quoted prices in active markets for identical assets and liabilities that are accessible at the reporting date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

Level 2 — Valuation is determined from pricing inputs that are other than quoted prices in active markets that are either directly or indirectly observable as of the reporting date. Observable inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 — Valuation is based on inputs that are both significant to the fair value measurement and unobservable. Level 3 inputs include situations where there is little, if any, market activity for the financial instrument. The inputs into the determination of fair value generally require significant management judgment or estimation. Accordingly, the actual exit price for any Level 3 asset, such as the Company’s investments in life insurance policies, may be substantially higher or lower than the reported valuation for such asset.

Assets and liabilities measured at fair value on a recurring basis

The balances of the Company’s assets measured at fair value on a recurring basis as of September 30, 2012, are as follows (in thousands):

							Total
	Level 1		Level 2		Level 3		Fair Value
Assets:
Investment in life settlements	$	—	$	—	$	102,328	$	102,328
Structured settlement receivables		—		—		2,496		2,496
Investment securities available for sale		—		24,173		—		24,173
	$	—	$	24,173	$	104,824	$	128,997

The balances of the Company’s assets measured at fair value on a recurring basis as of December 31, 2011, are as follows (in thousands):

	Level 1		Level 2		Level 3		Total Fair Value
Assets:
Investment in life settlements	$	—	$	—	$	90,917	$	90,917
Structured settlement receivables		—		—		12,376		12,376
Investment securities available for sale		—		57,242		—		57,242
	$	—	$	57,242	$	103,293	$	160,535

The Company values its investment in life settlement portfolio in two classes, non-premium financed and premium financed. In considering the categories, it is generally believed that market participants would require a lower risk premium for policies that were non-premium financed, while a higher risk premium would be required for policies that were premium financed.

($ in thousands)			Quantative Information about Level 3 Fair Value Measurements
	Fair Value at 9/30/12		Aggregate death benefit 9/30/12		Valuation Technique (s)	Unobservable Input	Range ( Weighted Average)
Non-premium financed	$	31,464	$	206,450	Discounted cash flow	Discount rate	18.05%
						Life expectancy evaluation	9.3 years
Premium financed		70,864		851,706	Discounted cash flow	Discount rate	20.05% - 30.65%
						Life expectancy evaluation	10.8 years
Investment in life settlements	$	102,328	$	1,058,156	Discounted cash flow	Discount rate	(24.61%)
						Life expectancy evaluation	(10.5 years)
Structured settlements receivables	$	2,496			Discounted cash flow	Facility sales discount rates	7.38% - 19.16%

Following is a description of the methodologies used to estimate the fair values of assets and liabilities measured at fair value on a recurring basis and within the fair value hierarchy.

Investment in life settlements— The Company has elected to account for the life settlement policies it acquires using the fair value method. Due to the inactive market for life settlements, the Company uses a present value technique to estimate the fair value of our investments in life settlements, which is a Level 3 fair value measurement as the significant inputs are unobservable and require significant management judgment or estimation. The Company currently uses a probabilistic method of valuing life insurance policies, which we believe to be the preferred valuation method in the industry. The most significant assumptions which we estimate are the life expectancy of the insured and the discount rate.

In determining the life expectancy estimate, we analyze medical reviews from independent secondary market life expectancy providers (each a “LE provider”). Additionally, the Company began procuring updated life expectancy reports and has applied updated life expectancy reports on 143 policies to its fair value model at September 30, 2012, including 79 reports that were produced after the valuation date. The Company recorded a non-cash charge of $20.1 million as unrealized loss on change in fair value of life settlements for the three months ended September 30, 2012. See Note 18 – Subsequent Events. An LE provider reviews the medical records and identifies all medical conditions it feels are relevant to the life expectancy of the insured. Debits and credits are then assigned by the LE provider to the individual’s health based on these medical conditions. The debit or credit that an LE provider assigns to a medical condition is derived from the experience of mortality attributed to this condition in the portfolio of lives that it monitors. The health of the insured is summarized by the LE provider into a life assessment of the individual’s life expectancy expressed both in terms of months and in mortality factor.

The resulting mortality factor represents an indication as to the degree to which the given life can be considered more or less impaired than a standard life having similar characteristics (e.g. gender, age, smoking, etc.). For example, a standard insured (the average life for the given mortality table) would carry a mortality rating of 100%. A similar but impaired life bearing a mortality rating of 200% would be considered to have twice the chance of dying earlier than the standard life. Historically, the Company has procured the majority of its life expectancy reports from two life expectancy report providers and only used AVS life expectancy reports for valuation purposes. Beginning in the quarter ended September 30, 2012, the Company began utilizing life expectancy reports from 21st Services for valuation purposes and began averaging or “blending,” the results of the two life expectancy reports to establish a composite mortality factor. However, when “blending” the AVS and 21st Services life expectancy reports, if the probability of mortality between the reports is greater than 150%, the Company will reduce the higher mortality factor until the difference is 150%.

The probability of mortality for an insured is then calculated by applying the blended life expectancy estimate to a mortality table. The mortality table is created based on the rates of death among groups categorized by gender, age, and smoking status. By measuring how many deaths occur before the start of each year, the table allows for a calculation of the probability of death in a given year for each category of insured people. The probability of mortality for an insured is found by applying the mortality rating from the life expectancy assessment to the probability found in the actuarial table for the insured’s age, sex and smoking status. The Company historically applied an actuarial table developed by a third party. However, as that party has ceased operations, in the quarter ended September 30, 2012, the Company transitioned to a table developed by the U.S. Society of Actuaries known as the 2008 Valuation Basic Table, or the 2008 VBT. However, because the 2008 VBT table does not account for anticipated improvements in mortality in the insured population, the table was modified by outside consultants to reflect these expected mortality improvements. The Company believes that the change in mortality table does not materially impact the valuation of its life insurance policies and that its adoption of a modified 2008 VBT table is consistent with modified tables used by market participants and third party medical underwriters. The Company believes that the change in mortality table does not materially impact the valuation of its life insurance policies and that its adoption of a modified 2008 VBT table is consistent with modified tables used by market participants and third party medical underwriters.

The mortality rating is used to create a range of possible outcomes for the given life and assign a probability that each of the possible outcomes might occur. This probability represents a mathematical curve known as a mortality curve. This curve is then used to generate a series of expected cash flows over the remaining expected lifespan of the insured and the corresponding policy. A discounted present value calculation is then used to determine the price of the policy. If the insured dies earlier than expected, the return will be higher than if the insured dies when expected or later than expected.

The calculation allows for the possibility that if the insured dies earlier than expected, the premiums needed to keep the policy in force will not have to be paid. Conversely, the calculation also considers the possibility that if the insured lives longer than expected, more premium payments will be necessary. Based on these considerations, each possible outcome is assigned a probability and the range of possible outcomes is then used to create a price for the policy.

The Company’s pricing department uses a premium optimizer to reverse engineer a projected payment stream for subsequent year premiums. This is determined based on inputs from the carrier such as the life insurance policy, the in force ledger or illustration and premium history.

The valuation of life insurance policies is performed by our pricing department at the end of each reporting period. During this process, management assesses and determines whether the valuation technique and inputs continues to be appropriate.

Life expectancy sensitivity analysis

As of September 30, 2012 the weighted average life expectancy calculated based on death benefit of the insured was 10.5 years. If all of the insured lives in the Company’s life settlement portfolio live six months shorter or longer than the blended life expectancies provided by these third parties, the change in fair market value would be as follows (dollars in thousands):

Life Expectancy Months Adjustment	Value		Change in Value
+6		85,305		(17,023	)
-		102,328		—
-6		120,596		18,268

As noted above, the Company takes an average, or blend, of the two life expectancy reports to derive a composite mortality factor, unless the probability of mortality between the reports is greater than 150%. In such instances and as reflected in the fair market value at September 30, 2012, the Company will cap the higher mortality factor at amount that is 150% above the lower mortality factor , which ultimately reduces the mortality factor inputted into the Company’s fair value model. At September 30, 2012, had the Company not implemented such a cap on affected policies, the fair value of the Company’s portfolio would have increased from the reported amount by $9.2 million.

Discount rate

The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require.

The Company believes that investors in esoteric assets such as life insurance policies typically target yields averaging between 12%—17% for investments of more than a 5 year duration, and had historically used a 15%—17% range of discount rates to value its life insurance policies. In the third quarter of 2011 and in the immediate aftermath of becoming aware of the USAO investigation, the Company substantially increased the discount rates inputted into its fair value model as it believed that the USAO Investigation along with certain unfavorable court decisions unrelated to the Company contributed to a contraction in the marketplace that has continued to reverberate. Since that time, the Company has been re-evaluating its discount rates at the end of every reporting period in order to reflect the estimated discount rates that could reasonably be used in a market transaction involving the Company’s portfolio of life insurance policies. In doing so, the Company relies on management insight, engages third party consultants to corroborate its assessment, engages in discussions with other market participants and potential financing sources and extrapolates the discount rate underlying actual sales of policies.

Although the Company believes that its entry into the Non-Prosecution Agreement had a positive effect on the market generally and for premium financed life insurance policies specifically, the Company believes that, when given the choice to invest in a policy that was associated with the Company’s premium finance business and a similar policy without such an association, all else being equal, an investor would have generally opted to invest in the policy that was not associated with the Company’s premium finance business. However, since entering into the Non-Prosecution Agreement, investors have required less of a risk premium to transact in these policies and the Company expects that, in time, investors will continue to require less of a risk premium to transact in policies associated with its premium finance business

Credit exposure of insurance company

The company considers the financial standing of the issuer of each policy typically, we seek to hold policies issued by insurance companies with investment-grade ratings of at least single-A. At September 30, 2012, the Company had six life insurance policies issued by one carrier that was rated non-investment grade by S&P at September 30, 2012. In order to compensate a market participant for the perceived credit and challenge risks associated with these policies, the Company applied an additional 300 basis point risk premium.

Estimated risk premium

As of September 30, 2012, the Company owned 212 policies with an aggregate investment in life settlements of $102.3 million. Of these 212 policies, 169 were premium financed and are valued using discount rates that range from 20.05% – 30.65%. The remaining 43 policies which are non-premium financed are valued using a discount rate of 18.05%. As of September 30, 2012, the weighted average discount rate calculated based on death benefit used in valuing the policies in our life settlement portfolio was 24.61%.

The extent to which the fair value could vary in the near term has been quantified by evaluating the effect of changes in the weighted average discount rate used to estimate the fair value. If the weighted average discount rate were increased or decreased by ¹/₂ of 1% and the other assumptions used to estimate fair value remained the same, the change in fair market value would be as follows (in thousands):

Market interest rate sensitivity analysis

Weighted Average Rate Calculated Based on Death Benefit	Rate Adjustment			Value		Change in Value
24.11%		-.50	%		104,992		2,663
24.61%		—			102,328		—
25.11%		+.50	%		99,769		(2,560	)

Future changes in the discount rates we use to value life insurance policies could have a material effect on our yield on life settlement transactions, which could have a material adverse effect on our business, financial condition and results of our operations.

Structured settlement receivables— All structured settlements that were acquired subsequent to July 1, 2010 were marked to fair value. Structured settlements that were acquired prior to July 1, 2010 were recorded at cost. We make this election because it is our intention to sell these assets within the next twelve months. Structured settlements are purchased at effective yields which are fixed. Purchase discounts are accreted into interest income using the effective-interest method for those structured settlements marked to fair value. As of September 30, 2012, the Company had 70 newly-acquired structured settlements with an estimated fair value of $2.5 million. The average sales discount rate for these newly-acquired structured settlements was 10.8%.

Changes in Fair Value

The following tables provide a roll-forward in the changes in fair value for the nine months ended September 30, 2012, for all assets for which the Company determines fair value using a material level of unobservable (Level 3) inputs (in thousands):

Life Settlements:
Balance, December 31, 2011	$	90,917
Purchase of policies		130
Acquired in foreclosure		5,050
Unrealized change in fair value		(8,401	)
Sale of policies		(5,334	)
Transfers into level 3		—
Transfers out of level 3		—
Premiums paid		20,106
Policies lapsed/written off		(140	)
Balance, September 30, 2012	$	102,328
Changes in fair value included in earnings for the period relating to assets held at September 30, 2012	$	(8,638	)

The Company recorded unrealized change in fair value loss of approximately $17.5 million and $14.1 million during the three months ended September 30, 2012 and 2011, respectively, and a loss in fair value of life settlements of approximately $8.4 million and a gain of approximately $14.8 million for the nine months ended September 30, 2012 and 2011, respectively.

Structured Settlements:
Balance, December 31, 2011	$	12,376
Purchase of contracts		17,115
Unrealized change in fair value		1,588
Sale of contracts		(28,396	)
Collections		(187	)
Transfers into level 3		—
Transfers out of level 3		—
Balance, September 30, 2012	$	2,496
Changes in fair value included in earnings for the period relating to assets held at September 30, 2012	$	429

The following tables provide a roll-forward in the changes in fair value for the nine months ended September 30, 2011, for all assets for which the Company determines fair value using a material level of unobservable (Level 3) inputs (in thousands).

Life Settlements:
Balance, December 31, 2010	$	17,138
Purchase of policies		48,057
Acquired in foreclosure		2,098
Unrealized change in fair value		14,811
Premiums paid		9,863
Transfers into Level 3		—
Transfers out of Level 3		—
Balance, September 30, 2011	$	91,967

Changes in fair value included in earnings for the period relating to assets held at September 30, 2011	$	14,811
Structured Settlements:
Balance, December 31, 2010	$	1,446
Purchase of contracts		21,469
Unrealized change in fair value		2,145
Sale of contracts		(20,789	)
Collections		(114	)
Transfers into Level 3		—
Transfers out of Level 3		—
Balance, September 30, 2011		4,157
Changes in fair value included in earnings for the period relating to assets held at September 30, 2011	$	1,151

There were no transfers of financial assets between levels of the fair value hierarchy during the nine months ended September 30, 2012 and 2011.

Assets and liabilities measured at fair value on a non-recurring basis

Following is a description of the methodologies used to estimate the fair values of assets and liabilities measured at fair value on a non-recurring basis, and the level within the fair value hierarchy in which those measurements are typically classified.

The Company’s impaired loans are measured at fair value on a non-recurring basis, as the carrying value is based on the fair value of the underlying collateral. The method used to estimate the fair value of impaired collateral-dependent loans depends on the nature of the collateral. For collateral that has lender protection insurance coverage, the fair value measurement is considered to be Level 2 as the insured value is an observable input and there are no material unobservable inputs. For collateral that does not have lender protection insurance coverage, the fair value measurement is considered to be Level 3 as the estimated fair value is based on a model whose significant inputs are the life expectancy of the insured and the discount rate, which are not observable inputs. As of September 30, 2012 and December 31, 2011, the Company had insured impaired loans with a net carrying value, which includes principal, accrued interest, and accreted origination fees, net of impairment, of approximately $1.4 million and $14.1 million, respectively. As of September 30, 2012 and December 31, 2011, the Company had uninsured impaired loans (Level 3) with a net carrying value of approximately $4.7 million and $10.2 million, respectively. The provision for losses on loans receivable related to impaired loans was approximately zero and $3.6 million for the three months ended September 30, 2012 and 2011, respectively and approximately $449,000 and $3.7 million for the nine months ended September 30, 2012 and 2011, respectively. See Notes 6 and 11.

XML

Origination Fees

9 Months Ended

Sep. 30, 2012

Origination Fees

(8) Origination Fees

A summary of the balance of origination fees that is included in loans receivable in the consolidated and combined balance sheet as of September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,			December 31,
	2012			2011
Loan origination fees gross	$	2,127		$	10,844
Un-accreted origination fees		(399	)		(2,666	)
Amortized loan origination costs		23			129
	$	1,751		$	8,307

Loan origination fees are fees payable to the Company on the date of loan maturity or repayment. Loan origination costs are deferred costs that are directly related to the creation of the loan receivable.

XML

Assumptions Used to Estimate Fair Values of Share Options Awarded (Detail)	9 Months Ended
	Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility, minimum	54.18%
Expected Volatility, maximum	54.23%
Expected Dividend	0.00%
Expected Term in Years	4 years 6 months
Risk Free Rate, minimum	2.16%
Risk Free Rate, maximum	2.29%

XML

Investment Securities Available for Sale

9 Months Ended

Sep. 30, 2012

Investment Securities Available for Sale

(6) Investment Securities Available for Sale

The amortized cost and estimated fair values of securities available for sale at September 30, 2012 are as follows (in thousands):

	September 30, 2012
	Amortized		Gross Unrealized		Gross Unrealized			Estimated
Description of Securities	Cost		Gains		Losses			Fair Value
Corporate bonds	$	19,118		39	$	(89	)	$	19,068
Government bonds		4,690		100		—			4,790
Other bonds		312		3		—			315
Total available for sale securities	$	24,120	$	142	$	(89	)	$	24,173

The amortized cost and estimated fair values of securities available for sale at December 31, 2011 are as follows (in thousands):

	December 31, 2011
Description of Securities	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate bonds	$	41,697	$	32	$	(127	)	$	41,602
Government bonds		14,789		39		(9	)		14,819
Other bonds		821		—		—			821
Total available for sale securities	$	57,307	$	71	$	(136	)	$	57,242

The scheduled maturities of securities (in thousands) at September 30 2012, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	September 30, 2012
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	14,628	$	14,655
Due after one year but less than five years		4,802		4,728
Due after five years but less than ten years		4,690		4,790
Total available for sale securities	$	24,120	$	24,173

The scheduled maturities of securities (in thousands) at December 31, 2011, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	December 31, 2011
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	25,904	$	25,892
Due after one year but less than five years		20,243		20,160
Due after five years but less than ten years		11,160		11,190
Total available for sale securities	$	57,307	$	57,242

Information pertaining to securities with gross unrealized losses (in thousands) at September 30, 2012, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position is as follows:

	September 30, 2012
	Less than 12 Months		12 Months or More							Total
	Estimated		Unrealized			Estimated		Unrealized		Estimated		Unrealized
Description of Securities	Fair Value		Loss			Fair Value		Loss		Fair Value		Loss
Corporate bonds		7,041		(89	)		—		—		7,041		(89	)
Total available for sale securities	$	7,041	$	(89	)	$	—	$	—	$	7,041	$	(89	)

Information pertaining to securities with gross unrealized losses (in thousands) at December 31, 2011, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position is as follows:

	December 31, 2011
	Less than 12 Months		12 Months or More							Total
Description of Securities	Estimated Fair Value		Unrealized Loss			Estimated Fair Value		Unrealized Loss		Estimated Fair Value		Unrealized Loss
Corporate bonds	$	26,051	$	(127	)	$	—	$	—	$	26,051	$	(127	)
Government bonds		5,927		(9	)		—		—		5,927		(9	)
Total available for sale securities	$	31,978	$	(136	)	$	—	$	—	$	31,978	$	(136	)

Proceeds from sale and prepayment of investment securities available for sale during the nine months ended September 30, 2012 amounted to approximately $67.9 million, resulting in gross realized gains of approximately $80,000.

The Company monitors its investment securities available for sale for other-than-temporary impairment, or OTTI, on an individual security basis considering numerous factors, including the Company’s intent to sell securities in an unrealized loss position, the likelihood that the Company will be required to sell these securities before an anticipated recovery in value, the length of time and extent to which fair value has been less than amortized cost, the historical and implied volatility of the fair value of the security, failure of the issuer of the security to make scheduled interest or principal payments, any changes to the rating of the security by a rating agency and recoveries or additional declines in fair value subsequent to the balance sheet date. The relative significance of each of these factors varies depending on the circumstances related to each security.

None of the securities in unrealized loss positions at September 30, 2012 were determined to be other-than-temporarily impaired. The Company does not intend to sell securities that are in unrealized loss positions and it is not more likely than not that the Company will be required to sell these securities before recovery of the amortized cost basis, which may be at maturity. At September 30, 2012, 6 securities were in unrealized loss positions. The amount of unrealized losses related to all of these securities was considered insignificant, totaling approximately $89,000. None of these securities were in a continuous unrealized loss position for 12 months or longer. No further analysis with respect to these securities was considered necessary.

XML

Loans Receivable

9 Months Ended

Sep. 30, 2012

Loans Receivable

(7) Loans Receivable

A summary of loans receivables at September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,			December 31,
	2012			2011
Loan principal balance	$	7,673		$	31,264
Loan origination fees, net		1,751			8,307
Loan impairment valuation		(4,030	)		(10,195	)
Loans receivable, net	$	5,394		$	29,376

The Company also had interest receivable, net which consisted of approximately $1.1 million and $5.3 million in accrued and unpaid interest at September 30, 2012 and December 31, 2011, respectively and a related impairment valuation of approximately $1.1 million and $1.9 million, respectively.

An analysis of the changes in loans receivable principal balance during the three months and nine months ended September 30, 2012 and 2011 is as follows (in thousands):

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2012			2011			2012			2011
Loan principal balance, beginning	$	12,935		$	51,092		$	31,264		$	76,939
Loan originations		—			2,549			—			18,385
Subsequent year premiums paid, net of reimbursement		—			34			—			326
Loan write-offs		—			(662	)		—			(2,950	)
Loan payoffs		(2,712	)		(8,809	)		(16,037	)		(47,867	)
Loans transferred to investments in life settlements		(2,550	)		(1,012	)		(7,554	)		(1,641	)
Loan principal balance, ending	$	7,673		$	43,192		$	7,673		$	43,192

Loan origination fees include origination fees, which are payable to the Company on the date the loan matures. The loan origination fees are reduced by any direct costs that are directly related to the creation of the loan receivable in accordance with ASC 310-20, Receivables — Nonrefundable Fees and Other Costs, and the net balance is accreted over the life of the loan using the effective interest method. Discounts include purchase discounts, net of accretion, which are attributable to loans that were acquired from affiliated companies under common ownership and control.

In accordance with ASC 310, Receivables, the Company specifically evaluates all loans for impairment based on the fair value of the underlying policies as foreclosure is considered probable. The loans are considered to be collateral dependent as the repayment of the loans is expected to be provided by the underlying policies.

An analysis of the loan impairment valuation for the three months ended September 30, 2012 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period	$	5,517		$	1,309		$	6,826
Charge-offs		(1,487	)		(252	)		(1,739	)
Balance at end of period	$	4,030		$	1,057		$	5,087

An analysis of the loan impairment valuation for the three months ended September 30, 2011 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period	$	5,201		$	1,189		$	6,390
Provision for loan losses		3,264			319			3,583
Charge-offs		(963	)		(118	)		(1,081	)
Balance at end of period	$	7,502		$	1,390		$	8,892

An analysis of the loan impairment valuation for the nine months ended September 30, 2012 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period		10,195			1,920			12,115
Provision for loan losses		360			81			441
Charge-offs		(6,525	)		(944	)		(7,469	)
Balance at end of period	$	4,030		$	1,057		$	5,087

An analysis of the loan impairment valuation for the nine months ended September 30, 2011 is as follows (in thousands):

	Loans			Interest
	Receivable			Receivable			Total
Balance at beginning of period		7,176			1,340			8,516
Provision for loan losses		3,337			375			3,712
Charge-offs		(3,011	)		(325	)		(3,336	)
Balance at end of period	$	7,502		$	1,390		$	8,892

An analysis of the allowance for loan losses and recorded investment in loans by loan type for the nine months ended September 30, 2012 is as follows (in thousands):

	Uninsured			Insured
	Loans			Loans			Total
Loan impairment valuation
Balance at beginning of period		7,103			3,092			10,195
Provision for losses	$	—		$	360		$	360
Charge-offs		(3,687	)		(2,838	)		(6,525	)
Ending balance	$	3,416		$	614		$	4,030
Ending balance: individually evaluated for impairment	$	3,416		$	614		$	4,030

All loans were individually evaluated for impairment as of September 30, 2012. There were no loans collectively evaluated for impairment and there were no loans acquired with deteriorated credit quality.

An analysis of the allowance for loan losses and recorded investment in loans by loan type for the nine months ended September 30, 2011 is as follows (in thousands):

	Uninsured			Insured
	Loans			Loans			Total
Loan impairment valuation
Balance at beginning of period	$	869		$	6,307		$	7,176
Provision for loan losses		3,318			19			3,337
Charge-offs		(407	)		(2,604	)		(3,011	)
Ending balance	$	3,780		$	3,722		$	7,502
Ending balance: individually evaluated for impairment	$	3,780		$	3,722		$	7,502

All loans were individually evaluated for impairment as of September 30, 2011. There were no loans collectively evaluated for impairment and there were no loans acquired with deteriorated credit quality. Notwithstanding the foregoing, the provision for losses on loans receivable for uninsured loans has increased for the nine months ended September 30, 2011 as a result of the decline in the estimated fair value of the collateral due to the higher discount rate applied in the fair value model. See Note 12.

An analysis of the credit ratings of life insurance carriers that issued life insurance policies that serve as our loan collateral by loan type at September 30, 2012 is presented in the following table (dollars in thousands):

	Uninsured					Insured(1)
S&P Designation	Unpaid Principal Balance		Percent			Unpaid Principal Balance		Percent
AAA	$	—		0.00	%	$	—		0.00	%
AA+		694		11.39	%		—		0.00	%
AA		—		0.00	%		—		0.00	%
AA-		3,550		58.25	%		696		44.10	%
A+		1,242		20.38	%		93		5.87	%
A1		—		0.00	%		—		0.00	%
A		543		8.91	%		101		6.40	%
A-		65		1.07	%		689		43.63	%
Total	$	6,094		100	%	$	1,579		100	%

(1) All of the Company’s insured loans have lender protection coverage with Lexington Insurance Company. As of September 30, 2012, Lexington had a financial strength rating of “A” with a stable outlook by Standard & Poor’s.

An analysis of the credit ratings of life insurance carriers that issued life insurance policies that serve as our loan collateral by loan type at December 31, 2011 is presented in the following table (dollars in thousands):

	Uninsured					Insured(1)
S&P Designation	Unpaid Principal Balance		Percent			Unpaid Principal Balance		Percent
AAA	$	—		0.00	%	$	—		0.00	%
AA+		694		5.08	%		222		1.26	%
AA		—		0.00	%		—		0.00	%
AA-		6,558		48.05	%		9,085		51.57	%
A+		3,060		22.42	%		1,287		7.31	%
A1		—		0.00	%		—		0.00	%
A		3,336		24.44	%		7,022		39.86	%
A-		—		0.00	%		—		0.00	%
Total	$	13,648		100	%	$	17,616		100	%

(1) All of the Company’s insured loans have lender protection coverage with Lexington Insurance Company. As of December 31, 2011, Lexington had a financial strength rating of “A” by Standard & Poor’s.

A summary of our investment in impaired loans at September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,		December 31,
	2012		2011
Loan receivable, net	$	5,063	$	17,424
Interest receivable, net		1,068		6,799
Investment in impaired loans	$	6,131	$	24,223

An analysis of impaired loans with and without a related allowance at September 30, 2012 is presented in the following table by loan type (in thousands):

			Unpaid				Average		Interest
	Recorded		Principal		Related		Recorded		Income
	Investment		Balance		Allowance		Investment		Recognized
With no related allowance recorded:
Uninsured Loans	$	—	$	—	$	—	$	—	$	—
Insured Loans		—		—		—		—		—
With an allowance recorded:
Uninsured Loans		4,722		6,074		3,991		7,437		1,612
Insured Loans		1,409		1,374		1,097		7,740		513
Total Impaired Loans	$	6,131	$	7,448	$	5,088	$	15,177	$	2,125

An analysis of impaired loans with and without a related allowance at December 31, 2011 is presented in the following table by loan type (in thousands):

			Unpaid				Average		Interest
	Recorded		Principal		Related		Recorded		Income
	Investment		Balance		Allowance		Investment		Recognized
With no related allowance recorded:
Uninsured Loans	$	—	$	—	$	—	$	—	$	—
Insured Loans		—		—		—		—		—
With an allowance recorded:
Uninsured Loans		10,153		13,628		6,894		6,764		1,684
Insured Loans		14,070		10,391		3,301		24,847		3,195
Total Impaired Loans	$	24,223	$	24,019	$	10,195	$	31,611	$	4,879

The amount of the investment in impaired loans that had an allowance as of September 30, 2012 and December 31, 2011 was $6.1 million and $24.2 million, respectively. The amount of the investment in impaired loans that did not have an allowance was $0 as of September 30, 2012 and December 31, 2011. The average aggregate investment in impaired loans during the periods ended September 30, 2012 and 2011 was approximately $15.2 million and $34.1 million, respectively. The interest recognized on the impaired loans was approximately $166,000 and $1.1 million for the nine months ended September 30, 2012 and 2011, respectively.

An analysis of the unpaid principal balance of past due loans at September 30, 2012 is presented in the following table by loan type (in thousands):

					Greater Than
	30-59 Days		60-89 Days		90 Days		Total
	Past Due		Past Due		Past Due		Past Due
Uninsured Loans	$	—	$	—	$	599	$	599
Insured Loans		—		43		272		315
Total	$	—	$	43	$	871	$	914

An analysis of the unpaid principal balance of past due loans at December 31, 2011 is presented in the following table by loan type (in thousands):

	30-59 Days Past Due		60-89 Days Past Due		Greater Than 90 Days Past Due		Total Past Due
Uninsured Loans	$	—	$	—	$	599	$	599
Insured Loans		1,570		—		—		1,570
Total	$	1,570	$	—	$	599	$	2,169

During the nine months ended September 30, 2012 and the year-ended December 31, 2011, the Company originated 0 and 58 loans receivable with a principal balance of approximately $0 and $18.3 million, respectively. Loan interest receivable at September 30, 2012 and December 31, 2011 was approximately $1.1 million and $5.3 million net of impairment of approximately $1.1 million, and $1.9 million, respectively. As of September 30, 2012, there were 31 loans with the average loan balance of approximately $233,000.

The allowance for interest receivable represents interest that is not expected to be collected. At the time the interest income was recognized and at the end of the reporting period in which the interest income was recognized, the interest income was believed to be collectible. The Company continually reassesses whether interest income is collectible in conjunction with its loan impairment analysis. The allowance for interest receivable represents interest that was determined to be uncollectible during a reporting period subsequent to the initial recognition of the interest income. As of September 30, 2012, the loan portfolio consisted of loans with original maturities of 2 to 4 years and variable interest rates at an average interest rate of 12.9%. During the nine months ended September 30, 2012 and 2011, 79 and 131 of our loans were paid off with proceeds of lender protection insurance totaling approximately $24.0 million and $26.3 million, respectively, of which approximately $15.6 million, and $16.8 million was for the principal of the loans and approximately $6.0 million and $4.3 million was for accrued interest, respectively, and accreted origination fees of approximately $6.6 million and $6.7 million, respectively. The Company had an impairment associated with these loans of approximately $4.6 million and $2.3 million, respectively. We recognized a loss of approximately $14,000 and a gain of approximately $736,000 on these transactions, respectively.

During the nine months ended September 30, 2012 and 2011, the Company wrote off 0 and 8 loans, respectively related to the Acorn facility. The principal amount written off was approximately $0 and $2.4 million with accrued interest of approximately $0 and $545,000, and origination receivable of approximately $0 and $381,000, respectively. The Company had an impairment associated with these loans of approximately $0 and $72,000, and incurred a loss on these loans of approximately $0 and $3.3 million, respectively.

XML

Stock-Based Compensation

9 Months Ended

Sep. 30, 2012

Stock-Based Compensation

(9) Stock-Based Compensation

In connection with the Company’s initial public offering, the Company established the Imperial Holdings 2010 Omnibus Incentive Plan (the “Omnibus Plan”). The purpose of the Omnibus Plan is to attract, retain and motivate participating employees and to attract and retain well-qualified individuals to serve as members of the board of directors, consultants and advisors through the use of incentives based upon the value of our common stock. Awards under the Omnibus Plan may consist of incentive awards, stock options, stock appreciation rights, performance shares, performance units, and shares of common stock, restricted stock, restricted stock units or other stock-based awards as determined by the compensation committee. The Omnibus Plan provides that an aggregate of 1,200,000 shares of common stock are reserved for issuance under the Omnibus Plan, subject to adjustment as provided in the Omnibus Plan. The Company recognized approximately $105,000 and $423,000 in stock-based compensation expense relating to stock options it granted under the Omnibus Plan during the three months ended September 30, 2012 and 2011, respectively and $201,000 and $1.2 million during the nine months ended September 30, 2012 and 2011, respectively. The Company incurred additional stock-based compensation expense of approximately $290,000 related to the conversion of two phantom stock agreements it had with two employees into 27,000 shares of common stock in connection with its corporate conversion in the first quarter of 2011 and approximately $0 and $9,500 in stock-based compensation relating to restricted stock granted to its board of directors during the three months ended September 30, 2012 and 2011, respectively and $4,000 and $24,000 during the nine months ended September 30, 2012 and 2011, respectively. Prior to our initial public offering, the Company had no equity compensation plan.

Options

As of September 30, 2012, options to purchase 488,499 shares of common stock were outstanding and unexercised under the Omnibus Plan at a weighted average exercise price of $10.75 per share. All of the outstanding options expire seven years after the date of grant and were granted with a strike price at $10.75 which was the offering price of our initial public offering or fair market value (closing price) of the stock on the date of grant and vest over three years.

The Company has used the Black-Scholes model to calculate fair values of options awarded. This model requires assumptions as to expected volatility, dividends, terms, and risk free rates. Assumptions used for the periods covered herein, are outlined in the table below:

	Nine Months Ended September 30, 2011
Expected Volatility	54.18% — 54.23%
Expected Dividend	0%
Expected Term in Years	4.5
Risk Free Rate	2.16% — 2.29%

There were no options granted in the nine months ended September 30, 2012.

The Company commenced its initial public offering of common stock in February 2011. Accordingly, there was no public market for the Company’s common stock prior to this date. Therefore, the Company identified comparable public entities and used the average volatility of those entities to reasonably estimate its expected volatility. The Company does not expect to pay dividends on its common stock for the foreseeable future. Expected term is the period of time over which the options granted are expected to remain outstanding and is based on the simplified method as outlined in the SEC Staff Accounting Bulletin 110. The Company will continue to estimate expected lives based on the simplified method until reliable historical data becomes available. The risk free rate is based on the U.S Treasury yield curve in effect at the time of grant for the appropriate life of each of each option.

The following table presents the activity of the Company’s outstanding stock options of common stock for the nine-month period ended September 30, 2012:

Common Stock Options	Number of Shares			Weighted Average Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Options outstanding, December 31, 2011		627,419		$	10.75		6.11	$	—
Options granted		—			—		—		—
Options exercised		—			—		—		—
Options forfeited		(138,920	)		10.75		—		—
Options expired		—					—		—
Options outstanding, September 30, 2012		488,499		$	10.75			$	—
Exercisable at September 30, 2012		287,988			10.74		5.36	$	—
Unvested at September 30, 2012		200,511		$	10.75		5.36	$	—

As of September 30, 2012, all outstanding stock options had an exercise price above the fair market value of the common stock on that date.

The remaining unamortized amounts of approximately $105,000, $336,000 and $21,000 will be expensed during 2012, 2013 and 2014, respectively.

Restricted Stock

3,507 shares of restricted stock granted to our directors under the Omnibus Plan subject to a one year vesting schedule commencing on the date of grant vested during the nine months ended September 30, 2012. The fair value of the vested restricted stock was valued at $38,016 based on the closing price of the Company’s shares on the grant date.

The following table presents the activity of the Company’s unvested restricted common shares for the nine-month period ended September 30, 2012:

Common Unvested Shares	Number of Shares
Outstanding December 31, 2011		3,507
Granted		—
Vested		(3,507	)
Forfeited		—
Outstanding September 30, 2012		—

There were no restricted stock awards granted during the nine months ended September 30, 2012.

XML

Structured Settlements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended			9 Months Ended							12 Months Ended				9 Months Ended					9 Months Ended		6 Months Ended	12 Months Ended		3 Months Ended	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012 Structured settlements	Sep. 30, 2011 Structured settlements	Dec. 31, 2011 Structured settlements	Sep. 30, 2012 Unrelated Parties	Sep. 30, 2011 Unrelated Parties	Sep. 30, 2012 SPV Contract	Sep. 30, 2012 Structured Settlements Intended for Sale to ISF	Sep. 30, 2011 Structured Settlements Intended for Sale to ISF	Sep. 30, 2012 8.39% Fixed Rate Asset Backed Variable Funding Notes	Sep. 30, 2011 8.39% Fixed Rate Asset Backed Variable Funding Notes	Dec. 31, 2011 8.39% Fixed Rate Asset Backed Variable Funding Notes	Dec. 31, 2010 8.39% Fixed Rate Asset Backed Variable Funding Notes	Sep. 30, 2012 8.39% Fixed Rate Asset Backed Variable Funding Notes Guaranteed Insurance Contracts Contract	Sep. 30, 2011 8.39% Fixed Rate Asset Backed Variable Funding Notes Guaranteed Insurance Contracts Contract	Sep. 30, 2012 Scenario, Previously Reported Unrelated Parties	Sep. 30, 2012 ISF 2010 Contract	Sep. 30, 2012 ISF 2010 8.39% Fixed Rate Asset Backed Variable Funding Notes	Dec. 31, 2011 ISF 2010 8.39% Fixed Rate Asset Backed Variable Funding Notes	Sep. 24, 2010 ISF 2010 8.39% Fixed Rate Asset Backed Variable Funding Notes	Sep. 30, 2012 ISF 2010 Maximum 8.39% Fixed Rate Asset Backed Variable Funding Notes	Sep. 30, 2012 Life Contingent Structured Settlement Facility Contract	Jun. 30, 2012 Life Contingent Structured Settlement Facility Scenario, Previously Reported Contract	Dec. 31, 2011 Life Contingent Structured Settlement Facility Scenario, Previously Reported	Sep. 30, 2012 Life Contingent Structured Settlement Facility Scenario, Previously Reported Contract	Sep. 30, 2012 Life Contingent Structured Settlement Facility Compass	Dec. 31, 2011 Life Contingent Structured Settlement Facility Compass	Dec. 31, 2011 Life Contingent Structured Settlement Facility Compass Maximum	Dec. 31, 2011 Life Contingent Structured Settlement Facility WSF Maximum
Securities Financing Transaction [Line Items]
Proceeds from sale of investments in life settlements			$ 5,626,000						$ 2,500,000																								$ 40,000,000
Purchases of investments in life settlements																															5,000,000	40,000,000
Number of structured settlement contracts											38							319	307		131					311	55		107
Gain on sale of structured settlements	2,187,000	2,240,000	7,796,000	5,457,000					1,800,000					4,200,000	3,800,000						64,000					1,800,000
Unrealized change in fair value of life settlements	(17,530,000)	(14,074,000)	(8,401,000)	14,811,000								548,000	582,000														565,000	1,100,000		147,000
Credit facility, maximum borrowing																								50,000,000
Debt instrument maturity date																						Jan. 01, 2057
Percent of credit facility limit																						15.00%			5.00%
Credit facility outstanding																						40,400,000	20,600,000
Total funds held amount																						2,100,000	1,000,000
Number of policies sold														500	485
Number of policies originated														181	12
Unrealized change in fair value of structured settlements	409,000	928,000	1,587,000	2,145,000					188,000	107,000	32,000					129,000	3,200,000			134,000
Acquisition purchase price percentage	95.00%		95.00%
Ownership interest																					5.00%
Percentage contributed to cash reserve held by Wimington Trust	1.00%		1.00%
Number of policies sold									169
Interest income	252,000	2,289,000	1,856,000	7,031,000		243,000	318,000
Other receivable	2,062,000		2,062,000		1,043,000	4,300,000		13,900,000
Discount on receivables						11,100,000		27,800,000
Gain on sale of holdback funds				$ 223,000
Payments due by holder period				90 days

XML

Investments in Life settlement (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012 Contract	Dec. 31, 2011 Contract
Number of Life Settlement Contracts
0 - 1
1 - 2		1
2 - 3	1	2
3 - 4	4	4
4 - 5	8	3
Thereafter	199	180
Total	212	190
Fair Value
0 - 1
1 - 2		3,033
2 - 3	1,021	2,484
3 - 4	2,901	7,084
4 - 5	10,655	2,357
Thereafter	87,751	75,959
Total	102,328	90,917
Face Value
0 - 1
1 - 2		5,000
2 - 3	2,500	4,500
3 - 4	11,450	20,200
4 - 5	33,050	7,950
Thereafter	1,011,156	897,816
Total	$ 1,058,156	$ 935,466

XML

Structural Settlements (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Long-Duration Contracts, Assumptions by Product and Guarantee [Line Items]
Structured settlements - at cost	$ 1,783	$ 1,553
Structured settlements-at fair value	2,496	12,376
Structured settlements receivable, net	$ 4,279	$ 13,929

XML

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2012

Assets Measured at Fair Value on Recurring Basis

The balances of the Company’s assets measured at fair value on a recurring basis as of September 30, 2012, are as follows (in thousands):

							Total
	Level 1		Level 2		Level 3		Fair Value
Assets:
Investment in life settlements	$	—	$	—	$	102,328	$	102,328
Structured settlement receivables		—		—		2,496		2,496
Investment securities available for sale		—		24,173		—		24,173
	$	—	$	24,173	$	104,824	$	128,997

The balances of the Company’s assets measured at fair value on a recurring basis as of December 31, 2011, are as follows (in thousands):

	Level 1		Level 2		Level 3		Total Fair Value
Assets:
Investment in life settlements	$	—	$	—	$	90,917	$	90,917
Structured settlement receivables		—		—		12,376		12,376
Investment securities available for sale		—		57,242		—		57,242
	$	—	$	57,242	$	103,293	$	160,535

Quantative Information About Level 3 Fair Value Measurements

($ in thousands)			Quantative Information about Level 3 Fair Value Measurements
	Fair Value at 9/30/12		Aggregate death benefit 9/30/12		Valuation Technique (s)	Unobservable Input	Range ( Weighted Average)
Non-premium financed	$	31,464	$	206,450	Discounted cash flow	Discount rate	18.05%
						Life expectancy evaluation	9.3 years
Premium financed		70,864		851,706	Discounted cash flow	Discount rate	20.05% - 30.65%
						Life expectancy evaluation	10.8 years
Investment in life settlements	$	102,328	$	1,058,156	Discounted cash flow	Discount rate	(24.61%)
						Life expectancy evaluation	(10.5 years)
Structured settlements receivables	$	2,496			Discounted cash flow	Facility sales discount rates	7.38% - 19.16%

Life Expectancies

Life Expectancy Months Adjustment	Value		Change in Value
+6		85,305		(17,023	)
-		102,328		—
-6		120,596		18,268

Market Interest Rate Sensitivity Analysis

Market interest rate sensitivity analysis

Weighted Average Rate Calculated Based on Death Benefit	Rate Adjustment			Value		Change in Value
24.11%		-.50	%		104,992		2,663
24.61%		—			102,328		—
25.11%		+.50	%		99,769		(2,560	)

Changes in Fair value for All Assets using Material Level of Unobservable (Level 3) Inputs

The following tables provide a roll-forward in the changes in fair value for the nine months ended September 30, 2012, for all assets for which the Company determines fair value using a material level of unobservable (Level 3) inputs (in thousands):

Life Settlements:
Balance, December 31, 2011	$	90,917
Purchase of policies		130
Acquired in foreclosure		5,050
Unrealized change in fair value		(8,401	)
Sale of policies		(5,334	)
Transfers into level 3		—
Transfers out of level 3		—
Premiums paid		20,106
Policies lapsed/written off		(140	)
Balance, September 30, 2012	$	102,328
Changes in fair value included in earnings for the period relating to assets held at September 30, 2012	$	(8,638	)

Structured Settlements:
Balance, December 31, 2011	$	12,376
Purchase of contracts		17,115
Unrealized change in fair value		1,588
Sale of contracts		(28,396	)
Collections		(187	)
Transfers into level 3		—
Transfers out of level 3		—
Balance, September 30, 2012	$	2,496
Changes in fair value included in earnings for the period relating to assets held at September 30, 2012	$	429

The following tables provide a roll-forward in the changes in fair value for the nine months ended September 30, 2011, for all assets for which the Company determines fair value using a material level of unobservable (Level 3) inputs (in thousands).

Life Settlements:
Balance, December 31, 2010	$	17,138
Purchase of policies		48,057
Acquired in foreclosure		2,098
Unrealized change in fair value		14,811
Premiums paid		9,863
Transfers into Level 3		—
Transfers out of Level 3		—
Balance, September 30, 2011	$	91,967

Changes in fair value included in earnings for the period relating to assets held at September 30, 2011	$	14,811
Structured Settlements:
Balance, December 31, 2010	$	1,446
Purchase of contracts		21,469
Unrealized change in fair value		2,145
Sale of contracts		(20,789	)
Collections		(114	)
Transfers into Level 3		—
Transfers out of Level 3		—
Balance, September 30, 2011		4,157
Changes in fair value included in earnings for the period relating to assets held at September 30, 2011	$	1,151

XML

Analysis of Changes in Loans Receivable Principal Balance (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan principal balance, beginning	$ 12,935	$ 51,092	$ 31,264	$ 76,939
Loan originations		2,549		18,385
Subsequent year premiums paid, net of reimbursement		34		326
Loan write-offs		(662)		(2,950)
Loan payoffs	(2,712)	(8,809)	(16,037)	(47,867)
Loans transferred to investments in life settlements	(2,550)	(1,012)	(7,554)	(1,641)
Loan principal balance, ending	$ 7,673	$ 43,192	$ 7,673	$ 43,192

XML

Segment Information

9 Months Ended

Sep. 30, 2012

Segment Information

(14) Segment Information

The Company operates in two segments: life finance and structured settlements. The life finance segment provided financing in the form of loans to trusts and individuals for the payment of premiums of life insurance policies until the end of the third quarter of 2011. Beginning in 2011, in this segment, the Company also acquired life insurance policies through policy purchases in the secondary and tertiary markets. The structured settlements segment purchases structured settlements from individuals.

Recipients of structured settlements are permitted to sell their deferred payment streams to a structured settlement purchaser pursuant to state statutes that require certain disclosures, notice to the obligors and state court approval. Through such sales, the Company purchases a certain number of fixed, scheduled future settlement payments on a discounted basis in exchange for a single lump sum payment.

The performance of the segments is evaluated on the segment level by members of the Company’s senior management team. Cash and income taxes generally are managed centrally. Performance of the segments is based on revenue and cost control.

Segment results and reconciliation to consolidated net income were as follows (in thousands):

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Life finance
Income
Agency fee income	$	—		$	937		$	—		$	6,564
Interest income		180			2,145			1,613			6,712
Origination income		45			1,753			483			5,858
Realized gain on sale of life settlements		—			—			291			5
Gain on forgiveness of debt		—			198			—			4,880
Unrealized change in fair value of life settlements		(17,530	)		(14,074	)		(8,401	)		14,811
Servicing fee income		271			376			955			1,447
Gain on maturities of life settlements with subrogation rights, net		—			3,188			6,090			3,188
Other		16			8			175			182
		(17,018	)		(5,469	)		1,206			43,647
Direct segment expenses
Interest expense		140			1,660			1,215			7,135
Provision for losses on loan receivables		—			3,583			441			3,712
(Gain) loss on loans payoffs and settlements, net		(139	)		261			14			3,927
Loss on life settlements write off		140			—			140			—
Amortization of deferred costs		255			1,409			1,752			4,913
Personnel costs		1,099			2,192			4,663			5,121
Marketing		—			—			—			16
Legal fees		1,116			803			2,622			1,456
Professional fees		315			460			1,180			1,359
Insurance		313			—			806			133
Other selling, general and administrative expenses		443			863			1,205			1,390
		3,682			11,231			14,038			29,162
Segment operating (loss) income	$	(20,700	)	$	(16,700	)	$	(12,832	)	$	14,485

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Structured settlements
Income
Realized gain on sale of structured settlements	$	2,187		$	2,240		$	7,796		$	5,457
Interest income		72			144			243			319
Unrealized change in fair value of structured settlements		409			928			1,587			2,145
Other income		101			50			354			195
		2,769			3,362			9,980			8,116
Direct segment expenses
Personnel costs		2,443			2,959			7,033			6,544
Marketing		1,034			1,754			4,481			4,169
Legal fees		527			455			1,671			1,803
Professional fees		615			199			1,527			930
Insurance		313			67			799			216
Other selling, general and administrative expenses		328			1,467			1,362			1,573
		5,260			6,901			16,873			15,235
Segment operating loss	$	(2,491	)	$	(3,539	)	$	(6,893	)	$	(7,119	)
Consolidated
Segment operating (loss) income		(23,191	)		(20,239	)		(19,725	)		7,366
Unallocated income
Other income		78			344			969			545
Unallocated expenses
Interest expense		—			—			3			296
Personnel costs		53			(315	)		621			2,498
Legal fees		7,685			563			18,625			928
Professional fees		629			793			2,565			2,157
Insurance		—			119			107			199
Other selling, general and administrative expenses		—			(678	)		340			997
		8,367			482			22,261			7,075
(Loss) income before income taxes		(31,480	)		(20,377	)		(41,017	)		836
(Benefit) provision for income taxes		(5	)		(7,827	)		(46	)		1,352
Net loss	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)

Segment assets and reconciliation to consolidated total assets were as follows (in thousands):

	September 30,		December 31,
	2012		2011
Direct segment assets
Life finance	$	122,395	$	138,520
Structured settlements		6,876		17,155
		129,271		155,675
Other unallocated assets		45,048		66,924
	$	174,319	$	222,599

XML

Principles of Consolidation and Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2012

Gain on Maturities of Life Settlements with Subrogation Rights, net

Gain on Maturities of Life Settlements with Subrogation Rights, net

Every credit facility entered into by subsidiaries of the Company between December 2007 and December 2010 to finance the premium finance lending business required lender protection insurance for each loan originated under such credit facility. Generally, when the Company exercises its right to foreclose on collateral the Company’s lender protection insurer has the right to direct control or take beneficial ownership of the life insurance policy, subject to the terms and conditions of the lender protection insurance policy, including notice and timing requirements. Otherwise, the lender protection insurer maintains its salvage collection and subrogation rights. The lender protection insurer’s salvage collection and subrogation rights generally provide a remedy by which the insurer can seek to recover an amount equal to but not greater than the amount of the lender protection claim paid plus premiums paid by it, expenses and interest thereon.

In those instances where the Company has foreclosed on the collateral, the lender protection insurer has maintained its salvage collection and subrogation rights, and has been covering the cost of the ongoing premiums needed to maintain these life insurance policies. However, the lender protection insurer may elect at any time to discontinue the payment of premiums which would result in lapse of the policies if the Company does not otherwise pay the premiums. The Company views these policies as having uncertain value because the lender protection insurer controls what happens to the policy from a payment of premium standpoint, and the amount of the lender protection insurer’s salvage collection and subrogation claim rights on any individual life insurance policy could equal the cash flow received by the Company with respect to any such policy. For these reasons, these policies are considered contingent assets and not included in the amount of life settlements on the accompanying consolidated and combined balance sheet.

The Company accounts for the maturities of life settlements with subrogation rights, net of subrogation expenses as contingent gains in accordance with Accounting Standards Codification (ASC) 450, Contingencies and recognizes the revenue from the maturities of these policies when all contingencies are resolved.

Use of Estimates

Use of Estimates

The preparation of these consolidated and combined financial statements, in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and such differences could be material. Significant estimates made by management include the loan impairment valuation, allowance for doubtful accounts, income taxes, valuation of securities available for sale, valuation of structured settlements and the valuation of investments in life settlements.

Change in Accounting Estimate

Change in Accounting Estimate

The Company has elected to account for the life settlement policies it acquired using the fair value method. The fair value of life settlement policies is determined on a discounted cash flow basis, incorporating current life expectancy, expected premiums and discount rate assumptions (see Note 12). During the first quarter of 2011, the Company made revisions to the application of its valuation technique and assumptions used to measure fair value of the life settlement policies it acquired. The Company accounted for this change in accounting estimate prospectively in accordance with ASC 250-10-45-17, Change in Accounting Estimate, resulting in recognition of a pretax gain of $3.0 million recorded in unrealized change in fair value of life settlements in the accompanying consolidated and combined statement of operations for the nine months ended September 30, 2011.

The Company’s decision to revise its fair value calculations used to value all life insurance policies on hand at December 31, 2010 was driven by two factors. Firstly, with consideration to the wind-down of the lender protection insurance coverage (LPIC) program, which ended on December 31, 2010, the value of the collateral serving the Company’s new lending activity is no longer determined primarily by the limit of liability provided by the LPIC coverage. Instead, the value of the collateral was based solely on the Company’s valuation model. Secondly, as a result of the Company’s initial public offering in February, 2011 and the new capital structure provided by it, the Company planned to build and retain a large and diversified pool of life policies.

As discussed above, the Company uses a discounted cash flow model to calculate the fair value of its life insurance policy portfolio. That model is based on three principal factors: life expectancy, expected premiums and the discount rate. As discussed in Note 12, the Company began receiving updated life expectancy reports on the insureds represented in the Company’s portfolio of life insurance policies. As a result, the calculation of the life expectancy and discount rate inputs have changed. While the Company is endeavoring to obtain updated life expectancy reports for all of its policies, at September 30, 2012, the Company had only received updated life expectancies for 64 of the 212 policies in its portfolio. Since September 30, 2012, however, the Company received additional updated life expectancies on 79 more policies. All updated reports that were obtained have been blended and inputted in the Company’s fair value model at September 30, 2012, which drove a decline of $30.3 million in the fair market value of the Company’s portfolio of life insurance policies. This decline was partially offset by premium payments, accretion due to the passage of time, and other changes to the Company’s fair value model, which resulted in a net unrealized change in fair value of approximately $17.5 million during the quarter ended September 30, 2012. See Note 18 – Subsequent Event

XML

Summary of Loans Receivables (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Dec. 31, 2010
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan principal balance	$ 7,673	$ 12,935	$ 31,264	$ 43,192	$ 51,092	$ 76,939
Loan origination fees, net	1,751		8,307
Loan impairment valuation	(4,030)		(10,195)	(7,502)		(7,176)
Loans receivable, net	$ 5,394		$ 29,376

XML

Reconciliation of Actual Basic and Diluted Earnings Per Share (Parenthetical) (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Stock Options
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	488,499	665,956	488,499	665,956
Warrant
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	4,240,521	4,240,521	4,240,521	4,240,521

XML

Consolidated And Combined Statements Of Comprehensive Loss (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net loss	$ (31,475)	$ (12,550)	$ (40,971)	$ (516)
Other comprehensive loss, net of tax:
Unrealized gains (loss) on investment securities available for sale	9	(44)	73	(44)
Comprehensive loss	$ (31,466)	$ (12,594)	$ (40,898)	$ (560)

XML

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2012

Recent Accounting Pronouncements

(3) Recent Accounting Pronouncements

There are no recent accounting pronouncements issued by the Financial Accounting Standards Board (FAS) (including its Emerging Issues Task Force), and the SEC that are believed to have a material impact on the Company’s present or future financial statements.

XML

Summary of Origination Fees in Loans Receivable (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan origination fees gross	$ 2,127	$ 10,844
Un-accreted origination fees	(399)	(2,666)
Amortized loan origination costs	23	129
Loan origination fees, net	$ 1,751	$ 8,307

XML

Subsequent Events - Additional Information (Detail) (USD $) Share data in Millions, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended		9 Months Ended			9 Months Ended
	Sep. 30, 2012 Contract	Sep. 30, 2011	Sep. 30, 2012 Contract	Sep. 30, 2011	Dec. 31, 2011 Contract	Sep. 30, 2012 Pending Litigation	Sep. 30, 2011 Pending Litigation	Sep. 30, 2012 Pending Litigation	Sep. 30, 2011 Pending Litigation	Sep. 30, 2012 Life Expectancy Update Received Contract	Sep. 30, 2012 Subsequent Event Contract	Dec. 31, 2012 Subsequent Event	Sep. 30, 2012 Subsequent Event Directors And Officers Insurance Policy [Member]	Sep. 30, 2012 Subsequent Event Pending Litigation	Sep. 30, 2012 Subsequent Event Pending Litigation	Dec. 31, 2012 Subsequent Event 2012	Dec. 31, 2012 Subsequent Event 2013	Sep. 30, 2012 Subsequent Event Derivative Actions [Member]	Dec. 17, 2012 Subsequent Event Life Expectancy Update Received Contract	Sep. 30, 2012 Subsequent Event Life Expectancy Update Received Contract	Sep. 30, 2012 Subsequent Event Carrier Contracts Pending Litigation
Subsequent Event [Line Items]
Class action settlement															$ 12,000,000						$ 11,000,000
Issue of warrant														2	2
Common stock warrant issued															3,100,000
Amount of common stock warrant issued															$ 10.75
Litigation reserve					8,000,000									15,100,000	15,100,000
Prepaid and other asset	14,634,000		14,634,000		3,277,000						1,500,000			11,000,000	11,000,000
Legal fee	9,328,000	1,821,000	22,918,000	4,187,000		2,600,000	0	12,800,000	0		1,000,000			4,100,000				1,500,000
Derivative actions and the contribution settlement																		500,000
Contribution amount of claims													500,000
Insurance trust reserve											2,500,000
Number of life settlement contracts	212		212		190					143	212								79	64
Unrealized change in fair value of life settlements	(17,530,000)	(14,074,000)	(8,401,000)	14,811,000							20,100,000
Life insurance policies premium payment																6,900,000	27,800,000
Cash and cash equivalent												20,300,000
Restricted cash	1,148,000		1,148,000		691,000							1,100,000
Litigation settlement agreed to pay			$ 1,000,000

XML

Fair Value Measured on Recurring Basis Unobservable Input Reconciliation (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investment in life settlements	$ 102,328	$ 90,917
Structured settlements receivables	2,496	12,376
Investment in life settlements	1,058,156	935,466
Weighted average discount rate	24.61%
Fair Value, Inputs, Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investment in life settlements	102,328	90,917
Structured settlements receivables	2,496	12,376
Investment in life settlements	1,058,156
Fair Value, Inputs, Level 3 | Non Premium Financed
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investment in life settlements	31,464
Investment in life settlements	206,450
Fair Value, Inputs, Level 3 | Premium Financed
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investment in life settlements	70,864
Investment in life settlements	$ 851,706
Fair Value, Inputs, Level 3 | Life Finance
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Valuation Technique (s)	Discounted cash flow
Weighted average life expectancy valuation period	10 years 6 months
Weighted average discount rate	(24.61%)
Fair Value, Inputs, Level 3 | Life Finance | Non Premium Financed
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Valuation Technique (s)	Discounted cash flow
Weighted average life expectancy valuation period	9 years 3 months 18 days
Weighted average discount rate	18.05%
Fair Value, Inputs, Level 3 | Life Finance | Premium Financed
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Valuation Technique (s)	Discounted cash flow
Weighted average life expectancy valuation period	10 years 9 months 18 days
Fair Value, Inputs, Level 3 | Structured settlements
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Valuation Technique (s)	Discounted cash flow
Minimum | Fair Value, Inputs, Level 3 | Life Finance | Premium Financed
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	20.05%
Minimum | Fair Value, Inputs, Level 3 | Structured settlements
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	7.38%
Maximum | Fair Value, Inputs, Level 3 | Life Finance | Premium Financed
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	30.65%
Maximum | Fair Value, Inputs, Level 3 | Structured settlements
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	19.16%

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Reconciliation of Actual Basic and Diluted Earnings Per Share

The following tables reconcile actual basic and diluted earnings per share for the three months and nine months ended September 30, 2012 and 2011 (in thousands except share and per share data).

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2012			2011			2012			2011
Basic (loss) earnings per share:
Numerator:
Net loss available to common stockholders	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Denominator:
Weighted average common shares outstanding		21,206,121			21,202,614			21,205,622			18,728,435
Basic loss per share	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)
Diluted earnings per share:
Numerator:
Net loss available to common stockholders	$	(31,475	)	$	(12,550	)	$	(40,971	)	$	(516	)
Denominator:
Diluted weighted average shares outstanding		21,206,121			21,202,614			21,205,622			18,728,435
Diluted loss per share(1)(2)	$	(1.48	)	$	(0.59	)	$	(1.93	)	$	(0.03	)

(1) The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the three months and nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

(2) The computation of diluted EPS did not include 488,499 options and 4,240,521 warrants for the three months and nine months ended September 30, 2012, as the effect of their inclusion would have been anti-dilutive.

Reconciliation of Pro Forma Basic and Diluted Earnings Per Share

The following tables reconcile pro forma basic and diluted earnings per share for the nine months ended September 30, 2011 (in thousands except share and per share data).

	For the Nine Months
	Ended September 30,
	2011
Basic earnings (loss) per share:
Numerator:
Net loss available to common stockholders(1)(3)	$	(338	)
Denominator:
Weighted average common shares outstanding		18,728,435
Basic loss per share	$	(0.02	)
Diluted earnings per share:
Numerator:
Net loss available to common stockholders(1)(3)	$	(338	)
Denominator:
Diluted weighted average shares outstanding		18,728,435
Diluted loss per share(2)	$	(0.02	)

(1) Reflects a reduction of interest expense of $178,000, net of tax for the nine months ended September 30, 2011 due to the conversion of our promissory note in favor of IMPEX Enterprises, Ltd. into shares of our common stock, which occurred prior to the closing of our initial public offering, and the conversion of our promissory note in favor of Branch Office of Skarbonka Sp. z o.o into a $30.0 million debenture, and the conversion of that $30.0 million debenture into shares of our common stock, which occurred immediately prior to the closing of our initial public offering.

(2) The computation of diluted EPS did not include 665,956 options and 4,240,521 warrants for the nine months ended September 30, 2011, as the effect of their inclusion would have been anti-dilutive.

(3) For the pro forma period for the nine months ended September 30, 2011, the results of the Company being treated for the pro forma presentation as a “C” corporation resulted in no impact to the consolidated and combined balance sheet or statement of operations. The primary reasons for this are that the losses produce no current benefit and any net operating losses generated and other deferred assets (net of liabilities) at that time would have been fully reserved due to historical operating losses. The Company, therefore, has not recorded any pro forma tax provision.

XML

Summary of Principal Balances of Notes Payable (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Notes payable and debenture payable, net of discount	$ 1,222	$ 19,277
Cedar Lane
Debt Instrument [Line Items]
Notes payable and debenture payable, net of discount	1,222	19,104
White Oak, Inc.
Debt Instrument [Line Items]
Notes payable and debenture payable, net of discount		$ 173

XML

Principles of Consolidation and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012 Shareholder	Sep. 30, 2011	Sep. 30, 2012 Shareholder	Sep. 30, 2011
Organization And Basis Of Presentation [Line Items]
Number of stockholders of company owned	2		2
Unrealized change in fair value of life settlements	$ (17,530,000)	$ (14,074,000)	$ (8,401,000)	$ 14,811,000
Decline in the fair market value of the Company's portfolio of life insurance policies	(30,300,000)
Change in Accounting Estimate
Organization And Basis Of Presentation [Line Items]
Unrealized change in fair value of life settlements				$ 3,000,000

XML

Notes and Debenture Payable

9 Months Ended

Sep. 30, 2012

Notes and Debenture Payable

(13) Notes and Debenture Payable

A summary of the principal balances of notes payable included in the consolidated and combined balance sheet as of September 30, 2012 and December 31, 2011 is as follows (in thousands):

	September 30,		December 31,
	2012		2011
Cedar Lane	$	1,222	$	19,104
White Oak, Inc.		—		173
Total	$	1,222	$	19,277

Cedar Lane

On December 2, 2009, Imperial PFC Financing II, LLC was formed to enter into a financing agreement with Cedar Lane Capital, LLC, so that Imperial PFC Financing II, LLC could purchase Imperial Premium Finance notes for cash or a participation interest in the notes. The financing agreement is for a minimum of $5 million to a maximum of $250 million. The agreement is for a term of 28 months from the time of borrowing and the borrowings bear an annual interest rate of 14%, 15% or 16%, depending on the class of lender and are compounded monthly. All of the assets of Imperial PFC Financing II, LLC serve as collateral under this credit facility. The Company is subject to several restrictive covenants under the facility. The restrictive covenants include items such as restrictions on the ability to pay dividends or incur additional indebtedness by Imperial PFC Financing II, LLC. The Company believes it is in compliance at September 30, 2012. The outstanding principal at September 30, 2012 and December 31, 2011 was approximately $1.2 million and $19.1 million, respectively, and accrued interest was approximately $358,000 and $5.4 million, respectively. The Company is required to retain 2% of the principal amount of each loan made to the borrower, for purposes of indemnifying the facility for any breaches of representations, warranties or covenants of the borrower, as well as to fund collection efforts, if required. As of September 30, 2012 and December 31, 2011 the Company’s consolidated financial statements reflected balances of approximately $1.1 million and $691,000 included in restricted cash, respectively. Our lender protection insurer ceased providing us with lender protection insurance under this credit facility on December 31, 2010.

White Oak, Inc.

On February 5, 2009, Imperial Life Financing II, LLC, was formed to enter into a loan agreement with White Oak Global Advisors, LLC, so that Imperial Life Financing II, LLC could purchase Imperial Premium Finance notes in exchange for cash or a participation interest in the notes.

In September 2009, the Imperial Life Financing II, LLC loan agreement was amended to increase the commitment by $12 million to a total commitment of $27 million. All of the assets of Imperial Life Financing II, LLC serve as collateral under this facility. The notes are payable 6-26 months from issuance and the facility matured on March 11, 2012. The outstanding principal at September 30, 2012 and December 31, 2011, was approximately $0 and $172,000, respectively, and accrued interest was approximately $0 and $104,000, respectively. After December 31, 2010, we ceased originating premium finance loans with lender protection insurance. All remaining amounts under this facility were repaid during the three months ended March 31, 2012.